The	O
correlation	O
between	O
oxidative	O
measures	O
and	O
myeloperoxidase	B-ENZY
concentrations	O
in	O
the	O
lung	O
indicates	O
that	O
neutrophil	O
oxidants	O
could	O
be	O
responsible	O
for	O
the	O
injury	O
.	O

BALF	O
levels	O
of	O
urokinase	B-ENZY
-	O
type	O
plasminogen	O
activator	O
were	O
significantly	O
reduced	O
throughout	O
,	O
whereas	O
the	O
lavage	O
concentrations	O
of	O
tissue	B-ENZY
-	I-ENZY
type	I-ENZY
plasminogen	I-ENZY
activator	I-ENZY
did	O
not	O
differ	O
from	O
those	O
in	O
control	O
subjects	O
.	O

Serologic	O
(	O
viral	O
neutralization	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
[	O
ELISA	O
])	O
assays	O
and	O
a	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
were	O
used	O
.	O

TITLE	O
:	O
The	O
viral	O
nucleocapsid	O
protein	O
of	O
transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
)	O
is	O
cleaved	O
by	O
caspase	B-ENZY
-	I-ENZY
6	I-ENZY
and	O
-	O
7	O
during	O
TGEV	O
-	O
induced	O
apoptosis	O
.	O

The	O
trends	O
in	O
results	O
were	O
similar	O
with	O
surfactant	O
to	O
those	O
for	O
the	O
HVS	B-ENZY
subgroup	O
analysis	O
.	O

A	O
clinicopathologic	O
study	O
using	O
immunohistochemical	O
staining	O
and	O
viral	O
genome	O
detection	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
was	O
performed	O
with	O
this	O
autopsied	O
case	O
.	O

With	O
ECMO	O
support	O
,	O
gas	B-ENZY
exchange	O
was	O
well	O
maintained	O
with	O
a	O
lower	O
ventilator	O
setting	O
,	O
and	O
ventilator	O
-	O
induced	O
lung	O
injuries	O
were	O
avoided	O
.	O

The	O
DACS	B-ENZY
procedure	O
provided	O
high	O
-	O
quality	O
and	O
reproducible	O
S	O
-	O
1	O
sequence	O
for	O
all	O
IBV	O
serotypes	O
tested	O
,	O
including	O
variant	O
serotypes	O
that	O
had	O
not	O
been	O
sequenced	O
previously	O
.	O

The	O
putative	O
functional	O
site	O
for	O
acetylesterase	B-ENZY
activity	O
was	O
present	O
in	O
the	O
HE	O
protein	O
as	O
Phe	O
-	O
Gly	O
-	O
Asp	O
-	O
Ser	O
(	O
FGDS	O
),	O
suggesting	O
that	O
the	O
SDAV	O
HE	O
protein	O
might	O
have	O
retained	O
the	O
esterase	O
activity	O
.	O

ABSTRACT	O
:	O
Conventional	O
mechanical	O
ventilatory	O
support	O
(	O
CV	O
)	O
contributes	O
to	O
lung	O
injury	O
in	O
premature	O
lambs	O
with	O
respiratory	O
distress	O
syndrome	O
,	O
a	O
disease	O
that	O
is	O
characterized	O
by	O
progressive	O
deterioration	O
of	O
gas	B-ENZY
exchange	O
and	O
increased	O
lung	O
inflammation	O
.	O

Mice	O
received	O
pancreatic	B-ENZY
elastase	I-ENZY
,	O
amylase	O
,	O
lipase	B-ENZY
,	O
or	O
trypsin	B-ENZY
intraperitoneally	O
.	O

Twenty	O
-	O
five	O
of	O
the	O
26	O
lung	O
samples	O
were	O
positive	O
for	O
Pasteurella	O
spp	B-ENZY
.,	O
and	O
their	O
CFU	O
ranged	O
between	O
4	O
.	O
0	O
x	O
10	O
(	O
5	O
)	O
and	O
2	O
.	O
3	O
x	O
10	O
(	O
9	O
)	O
per	O
g	O
.	O
Acute	O
and	O
subacute	O
exudative	O
,	O
necrotizing	O
lobar	O
pneumonia	O
characterized	O
the	O
lung	O
lesions	O
of	O
these	O
cattle	O
with	O
a	O
majority	O
of	O
pneumonic	O
lung	O
lobes	O
exhibiting	O
fibronecrotic	O
and	O
exudative	O
changes	O
typical	O
of	O
pneumonic	O
pasteurellosis	O
,	O
but	O
other	O
lung	O
lobules	O
had	O
histological	O
changes	O
consisting	O
of	O
bronchiolitis	O
and	O
alveolitis	O
typical	O
of	O
virus	O
-	O
induced	O
changes	O
.	O

Results	O
of	O
this	O
study	O
suggest	O
a	O
close	O
functional	O
relationship	O
between	O
the	O
arterivirus	O
nsp10	O
and	O
the	O
coronavirus	O
helicase	O
,	O
for	O
which	O
NTPase	B-ENZY
and	O
duplex	O
-	O
unwinding	O
activities	O
were	O
recently	O
demonstrated	O
.	O

Among	O
the	O
researches	O
developed	O
,	O
the	O
use	O
of	O
inhalation	O
of	O
NO	O
gas	B-ENZY
allowed	O
us	O
to	O
propose	O
this	O
therapy	O
in	O
lung	O
diseases	O
with	O
promising	O
results	O
.	O

We	O
hypothesized	O
that	O
(	O
1	O
)	O
PCEB	O
-	O
ACE	B-ENZY
alterations	O
can	O
be	O
found	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
(	O
2	O
)	O
PCEB	O
-	O
ACE	B-ENZY
activity	O
correlates	O
with	O
the	O
severity	O
of	O
lung	O
injury	O
and	O
may	O
be	O
used	O
as	O
a	O
quantifiable	O
marker	O
of	O
the	O
underlying	O
pulmonary	O
capillary	O
endothelial	O
dysfunction	O
.	O

Both	O
parameters	O
decreased	O
early	O
during	O
the	O
ALI	O
continuum	O
and	O
were	O
inversely	O
related	O
to	O
APACHE	O
II	O
score	O
and	O
LIS	B-ENZY
.	O

The	O
LIS	B-ENZY
at	O
time	O
of	O
recruitment	O
into	O
the	O
study	O
was	O
2	O
.	O
2	O
(+/-	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
effects	O
of	O
high	O
-	O
dose	O
almitrine	O
infusion	O
on	O
gas	B-ENZY
exchange	O
and	O
right	O
ventricular	O
function	O
in	O
patients	O
with	O
severe	O
hypoxemia	O
related	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Gas	B-ENZY
exchange	O
and	O
hemodynamic	O
parameters	O
were	O
recorded	O
before	O
and	O
after	O
almitrine	O
infusion	O
.	O

The	O
absence	O
of	O
PMN	O
in	O
the	O
peritoneum	O
was	O
due	O
in	O
part	O
to	O
lysis	O
of	O
intraperitoneal	O
PMN	O
,	O
because	O
the	O
peritoneal	O
fluids	O
contained	O
free	O
myeloperoxidase	B-ENZY
and	O
induced	O
rapid	O
death	O
of	O
normal	O
rabbit	O
PMN	O
in	O
vitro	O
.	O

These	O
results	O
are	O
particularly	O
interesting	O
in	O
terms	O
of	O
identification	O
of	O
an	O
RNA	O
target	O
for	O
mitochondrial	O
aconitase	B-ENZY
,	O
which	O
has	O
a	O
cytoplasmic	O
homolog	O
,	O
cytoplasmic	O
aconitase	B-ENZY
,	O
also	O
known	O
as	O
iron	O
regulatory	O
protein	O
1	O
,	O
a	O
well	O
-	O
recognized	O
RNA	O
-	O
binding	O
protein	O
.	O

To	O
determine	O
the	O
involvement	O
of	O
individual	O
MMPs	O
in	O
the	O
development	O
of	O
lung	O
injury	O
,	O
mice	O
genetically	O
deficient	O
in	O
gelatinase	B-ENZY
B	I-ENZY
(	O
MMP	O
-	O
9	O
)	O
and	O
stromelysin	B-ENZY
1	I-ENZY
(	O
MMP	O
-	O
3	O
)	O
were	O
acutely	O
injured	O
with	O
immunoglobulin	O
G	O
immune	O
complexes	O
and	O
the	O
intensity	O
of	O
the	O
lung	O
injury	O
was	O
compared	O
with	O
genetically	O
identical	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	O
with	O
normal	O
MMP	O
activities	O
.	O

Arterial	O
blood	O
gas	B-ENZY
tensions	O
,	O
hemodynamic	O
variables	O
,	O
and	O
the	O
oxygenation	O
index	O
were	O
recorded	O
after	O
each	O
dose	O
of	O
5	O
mL	O
/	O
kg	O
.	O

Then	O
,	O
it	O
was	O
used	O
during	O
acute	O
respiratory	O
failure	O
to	O
improve	O
gas	B-ENZY
exchange	O
.	O

They	O
underwent	O
ventilation	O
with	O
a	O
fixed	O
pattern	O
and	O
hyperoxic	O
gas	B-ENZY
mixtures	O
with	O
different	O
fractions	O
of	O
inspired	O
carbon	O
dioxide	O
(	O
FICO2	O
)	O
to	O
produce	O
a	O
partial	O
pressures	O
of	O
arterial	O
carbon	O
dioxide	O
(	O
PaCO2	O
)	O
of	O
24	O
.	O
4	O
+/-	O

Pre	O
-	O
operatively	O
,	O
predicted	O
mean	O
of	O
PaO	B-ENZY
(	O
2	O
),	O
PaCO	O
(	O
2	O
)	O
and	O
%	O
FEV1	O
were	O
72	O
mmHg	O
(	O
57	O
--	O
86	O
),	O
37	O
mmHg	O
(	O
33	O
--	O
42	O
)	O
and	O
80	O
%	O
(	O
37	O
--	O
114	O
),	O
respectively	O
.	O

Intravenous	O
administration	O
of	O
recombinant	O
tissue	B-ENZY
plasminogen	I-ENZY
activator	I-ENZY
was	O
carried	O
on	O
for	O
36	O
hours	O
and	O
followed	O
by	O
heparin	O
and	O
antithrombin	O
III	O
administration	O
.	O

CONCLUSIONS	O
:	O
The	O
inhalation	O
of	O
a	O
PFC	O
aerosol	O
led	O
to	O
a	O
significant	O
improvement	O
in	O
pulmonary	O
mechanics	O
and	O
gas	B-ENZY
exchange	O
,	O
which	O
was	O
not	O
observed	O
in	O
the	O
other	O
two	O
groups	O
.	O

Blood	O
gas	B-ENZY
values	O
,	O
dynamic	O
lung	O
compliance	O
(	O
Cdyn	O
),	O
and	O
airway	O
resistance	O
(	O
Raw	O
)	O
were	O
measured	O
during	O
the	O
2	O
-	O
hour	O
treatment	O
.	O

Estrogen	O
and	O
ACE	B-ENZY
inhibitors	O
should	O
be	O
avoided	O
in	O
a	O
patient	O
with	O
congenital	O
or	O
acquired	O
C1	O
-	O
INH	O
deficiency	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
whether	O
rapid	O
or	O
slowly	O
infused	O
intravenous	O
fat	O
emulsions	O
affect	O
the	O
ratio	O
of	O
prostaglandin	O
I2	O
/	O
thromboxane	O
A2	O
in	O
arterial	O
blood	O
,	O
pulmonary	O
hemodynamics	O
,	O
and	O
gas	B-ENZY
exchange	O
.	O

The	O
inhibition	O
of	O
acetylcholinesterase	B-ENZY
causes	O
accumulation	O
of	O
acetylcholine	O
at	O
synapses	O
,	O
and	O
overstimulation	O
of	O
neurotransmission	O
occurs	O
as	O
a	O
result	O
of	O
this	O
accumulation	O
.	O

When	O
edema	O
was	O
profuse	O
,	O
PV	O
curves	O
displayed	O
a	O
marked	O
lower	O
inflection	O
point	O
(	O
LIP	B-ENZY
),	O
the	O
UIP	O
at	O
low	O
pressure	O
disappeared	O
but	O
another	O
was	O
seen	O
at	O
high	O
volume	O
above	O
the	O
LIP	B-ENZY
,	O
and	O
the	O
correlation	O
between	O
Vuip	O
changes	O
and	O
edema	O
severity	O
was	O
lost	O
.	O

A	O
significant	O
correlation	O
for	O
PCT	O
serum	O
and	O
BAL	B-ENZY
levels	O
was	O
found	O
on	O
day	O
2	O
(	O
p	O
=.	O
0063	O
).	O

TITLE	O
:	O
[	O
Tracheal	O
gas	B-ENZY
insufflation	O
avoids	O
hypercapnia	O
in	O
patients	O
with	O
severe	O
head	O
trauma	O
and	O
acute	O
lung	O
injury	O
].	O

Patients	O
with	O
major	O
trauma	O
underwent	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
and	O
IL	O
-	O
8	O
levels	O
were	O
measured	O
in	O
BAL	B-ENZY
fluid	O
by	O
ELISA	O
.	O

The	O
expression	O
of	O
a	O
reporter	O
gene	O
(	O
beta	B-ENZY
-	I-ENZY
glucuronidase	I-ENZY
)	O
by	O
using	O
the	O
selected	O
TRS	O
led	O
to	O
the	O
production	O
of	O
2	O
to	O
8	O
microg	O
of	O
protein	O
per	O
10	O
(	O
6	O
)	O
cells	O
.	O

Mp	O
-	O
associated	O
HPS	B-ENZY
was	O
diagnosed	O
in	O
this	O
case	O
by	O
clinical	O
and	O
laboratory	O
findings	O
,	O
including	O
a	O
bone	O
marrow	O
aspiration	O
specimen	O
and	O
serum	O
Mp	O
antibody	O
titer	O
.	O

Pharmacodynamics	O
of	O
iNO	O
in	O
this	O
model	O
was	O
related	O
to	O
improvement	O
in	O
gas	B-ENZY
exchange	O
,	O
Cdyn	O
,	O
PVRI	O
,	O
and	O
suppression	O
of	O
proinflammatory	O
cytokine	O
expression	O
in	O
the	O
lungs	O
,	O
and	O
its	O
adverse	O
effect	O
was	O
mainly	O
confined	O
to	O
MetHb	O
at	O
higher	O
NO	O
dose	O
.	O

The	O
difference	O
of	O
PaO	B-ENZY
(	O
2	O
)	O
before	O
and	O
during	O
SI	O
were	O
(	O
65	O
+/-	O
40	O
)	O
mm	O
Hg	O
and	O
(	O
52	O
+/-	O
25	O
)	O
mm	O
Hg	O
respectively	O
in	O
the	O
5P	O
(	O
m	O
)	O
and	O
6P	O
(	O
m	O
)	O
group	O
,	O
being	O
significantly	O
higher	O
than	O
that	O
in	O
the	O
1P	O
(	O
m	O
)	O
group	O
[(-	O
5	O
+/-	O

In	O
this	O
study	O
,	O
the	O
molecular	O
basis	O
of	O
fgl2	O
prothrombinase	B-ENZY
activity	O
was	O
examined	O
in	O
detail	O
.	O

TITLE	O
:	O
Murine	O
coronavirus	O
replication	O
-	O
induced	O
p38	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
activation	O
promotes	O
interleukin	O
-	O
6	O
production	O
and	O
virus	O
replication	O
in	O
cultured	O
cells	O
.	O

Experiments	O
with	O
a	O
specific	O
inhibitor	O
of	O
p38	O
MAPK	B-ENZY
,	O
SB	O
203580	O
,	O
demonstrated	O
that	O
MHV	O
-	O
induced	O
p38	O
MAPK	B-ENZY
activation	O
resulted	O
in	O
the	O
accumulation	O
of	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
mRNAs	O
and	O
an	O
increase	O
in	O
the	O
production	O
of	O
IL	O
-	O
6	O
,	O
regardless	O
of	O
MHV	O
-	O
induced	O
general	O
host	O
protein	O
synthesis	O
inhibition	O
.	O

Furthermore	O
,	O
MHV	O
production	O
was	O
suppressed	O
in	O
SB	O
203580	O
-	O
treated	O
cells	O
,	O
demonstrating	O
that	O
activated	O
p38	O
MAPK	B-ENZY
played	O
a	O
role	O
in	O
MHV	O
replication	O
.	O

Interestingly	O
,	O
there	O
was	O
a	O
transient	O
increase	O
in	O
the	O
amount	O
of	O
phosphorylation	O
of	O
the	O
translation	O
initiation	O
factor	O
4E	O
(	O
eIF4E	O
)	O
in	O
infected	O
cells	O
,	O
and	O
this	O
eIF4E	O
phosphorylation	O
was	O
p38	O
MAPK	B-ENZY
dependent	O
;	O
it	O
is	O
known	O
that	O
phosphorylated	O
eIF4E	O
enhances	O
translation	O
rates	O
of	O
cap	O
-	O
containing	O
mRNAs	O
.	O

MHV	O
utilized	O
this	O
p38	O
MAPK	B-ENZY
-	O
dependent	O
increase	O
in	O
eIF4E	O
phosphorylation	O
to	O
promote	O
virus	O
-	O
specific	O
protein	O
synthesis	O
and	O
subsequent	O
progeny	O
virus	O
production	O
.	O

ABSTRACT	O
:	O
Abdominal	O
Compartment	O
Syndrome	O
(	O
ACS	B-ENZY
)	O
has	O
multiple	O
causes	O
,	O
and	O
decompressive	O
laparotomy	O
has	O
been	O
the	O
most	O
frequent	O
modality	O
to	O
prevent	O
worsening	O
cardiovascular	O
,	O
respiratory	O
,	O
and	O
renal	O
function	O
.	O

Five	O
patients	O
underwent	O
PD	O
successfully	O
,	O
and	O
their	O
IAH	O
did	O
not	O
progress	O
to	O
ACS	B-ENZY
.	O

The	O
individual	O
SNAP	O
items	O
that	O
contributed	O
most	O
to	O
SNAP	O
moderate	O
and	O
severe	O
categories	O
were	O
blood	O
gas	B-ENZY
items	O
,	O
creatinine	O
,	O
urine	O
output	O
,	O
blood	O
glucose	O
,	O
and	O
seizures	O
.	O

The	O
proper	O
diagnosis	O
was	O
made	O
after	O
repeating	O
the	O
screening	O
test	O
followed	O
by	O
specific	O
tests	O
of	O
porphobilinogen	B-ENZY
deaminase	I-ENZY
.	O

We	O
discuss	O
his	O
case	O
and	O
review	O
the	O
etiology	O
,	O
pathophysiology	O
,	O
clinical	O
presentation	O
,	O
laboratory	O
findings	O
,	O
treatment	O
and	O
possible	O
long	O
-	O
term	O
sequelae	O
of	O
chlorine	O
gas	B-ENZY
toxicity	O
.	O

rTGEV	O
-	O
Delta3abDeltaE	O
reached	O
high	O
titers	O
(	O
10	O
(	O
7	O
)	O
PFU	O
/	O
ml	O
)	O
in	O
baby	O
hamster	O
kidney	O
cells	O
expressing	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
BHK	O
-	O
pAPN	O
),	O
the	O
cellular	O
receptor	O
for	O
TGEV	O
,	O
using	O
Sindbis	O
replicon	O
and	O
reached	O
titers	O
up	O
to	O
5	O
x	O
10	O
(	O
5	O
)	O
PFU	O
/	O
ml	O
in	O
cells	O
stably	O
expressing	O
E	O
protein	O
under	O
the	O
control	O
of	O
the	O
CMV	O
promoter	O
.	O

All	O
patients	O
developed	O
neurologic	O
complications	O
resulting	O
from	O
ACS	B-ENZY
episodes	O
,	O
including	O
seizures	O
(	O
n	O
=	O
2	O
),	O
silent	O
cerebral	O
infarcts	O
(	O
n	O
=	O
3	O
),	O
cerebral	O
hemorrhage	O
(	O
n	O
=	O
2	O
),	O
and	O
reversible	O
posterior	O
leukoencephalopathy	O
syndrome	O
(	O
n	O
=	O
3	O
).	O

ABSTRACT	O
:	O
Feline	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
fAPN	O
)	O
has	O
been	O
shown	O
to	O
serve	O
as	O
a	O
receptor	O
for	O
feline	O
,	O
canine	O
,	O
porcine	O
and	O
human	O
coronaviruses	O
.	O

The	O
properties	O
of	O
the	O
GAV	O
3CL	O
(	O
pro	O
)	O
define	O
a	O
novel	O
RNA	O
virus	O
proteinase	O
variant	O
that	O
bridges	O
the	O
gap	O
between	O
the	O
distantly	O
related	O
chymotrypsin	B-ENZY
-	O
like	O
cysteine	O
proteinases	O
of	O
coronaviruses	O
and	O
potyviruses	O
.	O

Neutrophil	B-ENZY
elastase	I-ENZY
and	O
sThrombomodulin	O
levels	O
in	O
the	O
DIC	O
patients	O
persistently	O
increased	O
during	O
the	O
study	O
period	O
compared	O
to	O
those	O
in	O
the	O
non	O
-	O
DIC	O
patients	O
.	O

(	O
5	O
.	O
4	O
%),	O
Cryptosporidium	O
parvum	O
(	O
3	O
.	O
8	O
%),	O
Toxocara	O
canis	O
(	O
3	O
.	O
1	O
%),	O
Salmonella	O
spp	B-ENZY
.	O

Administration	O
of	O
100	O
mg	O
/	O
kg	O
bovine	O
surfactant	O
intratracheally	O
under	O
continuous	O
ventilation	O
and	O
PEEP	O
,	O
as	O
soon	O
as	O
the	O
PaO	B-ENZY
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
ratio	O
dropped	O
to	O
less	O
than	O
100	O
for	O
2	O
h	O
(	O
in	O
the	O
pilot	O
study	O
increments	O
of	O
50	O
mg	O
/	O
kg	O
as	O
long	O
as	O
the	O
PaO	B-ENZY
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
did	O
not	O
increase	O
by	O
20	O
%).	O

In	O
the	O
pilot	O
study	O
the	O
PaO	B-ENZY
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
increased	O
by	O
a	O
mean	O
of	O
100	O
at	O
48	O
h	O
(	O
n	O
=	O
19	O
).	O

In	O
the	O
high	O
PEEP	O
group	O
the	O
PaO	B-ENZY
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
ratio	O
was	O
lower	O
(	O
243	O
+/-	O
90	O
vs	O
285	O
+/-	O
78	O
mmHg	O
)	O
and	O
PaCO	O
(	O
2	O
)	O
higher	O
(	O
45	O
+/-	O
9	O
.	O
4	O
vs	O
39	O
+/-	O
7	O
.	O
1	O
mmHg	O
)	O
when	O
compared	O
to	O
the	O
low	O
PEEP	O
group	O
.	O

Furthermore	O
,	O
oxygenation	O
did	O
not	O
deteriorate	O
with	O
PDT	O
even	O
in	O
patients	O
with	O
gravely	O
impaired	O
gas	B-ENZY
exchange	O
(	O
lowest	O
quartile	O
)	O
with	O
a	O
PaO	B-ENZY
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
averaging	O
130	O
+/-	O
42	O
mmHg	O
(	O
range	O
45	O
-	O
192	O
mmHg	O
)	O
at	O
a	O
PEEP	O
of	O
17	O
+/-	O
4	O
mbar	O
.	O

In	O
group	O
D	O
,	O
however	O
,	O
blood	O
gas	B-ENZY
dynamics	O
,	O
blood	O
gas	B-ENZY
acid	O
-	O
base	O
status	O
and	O
electrolytes	O
changed	O
little	O
after	O
seawater	O
perfusion	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

CONCLUSIONS	O
:	O
Although	O
the	O
data	O
support	O
a	O
key	O
role	O
for	O
neutrophil	B-ENZY
elastase	I-ENZY
in	O
the	O
pathogenesis	O
of	O
ARDS	O
,	O
further	O
study	O
is	O
needed	O
to	O
fully	O
define	O
the	O
actions	O
of	O
neutrophil	B-ENZY
elastase	I-ENZY
,	O
and	O
how	O
these	O
actions	O
affect	O
host	O
functions	O
,	O
before	O
we	O
can	O
exploit	O
this	O
knowledge	O
for	O
therapeutic	O
benefit	O
.	O

The	O
mechanisms	O
that	O
contribute	O
to	O
this	O
fibrin	O
deposition	O
are	O
bronchoalveolar	O
tissue	O
factor	O
-	O
mediated	O
thrombin	B-ENZY
generation	O
and	O
localized	O
depression	O
of	O
urokinase	B-ENZY
plasminogen	O
activator	O
-	O
mediated	O
fibrinolysis	O
,	O
caused	O
by	O
the	O
increase	O
of	O
plasminogen	O
activator	O
inhibitors	O
.	O

Fecal	O
samples	O
were	O
also	O
screened	O
for	O
other	O
enteric	O
pathogens	O
,	O
including	O
rotavirus	O
,	O
coronavirus	O
,	O
and	O
Cryptosporidium	O
spp	B-ENZY
.	O

Leukemic	O
blasts	O
with	O
positive	O
peroxidase	B-ENZY
stain	O
,	O
but	O
negative	O
periodic	O
acid	O
-	O
Schiff	O
stain	O
comprised	O
91	O
.	O
6	O
%	O
on	O
bone	O
marrow	O
specimen	O
.	O

As	O
this	O
patient	O
was	O
considered	O
to	O
have	O
a	O
high	O
risk	O
of	O
relapse	O
,	O
we	O
selected	O
allogeneic	O
BMT	B-ENZY
from	O
URD	O
.	O

We	O
tested	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
samples	O
obtained	O
from	O
HSCT	O
recipients	O
with	O
acute	O
pulmonary	O
infiltrates	O
for	O
HRV	O
(	O
n	O
=	O
122	O
)	O
and	O
coronavirus	O
(	O
n	O
=	O
46	O
)	O
by	O
reverse	O
-	O
transcriptase	O
polymerase	O
chain	O
reaction	O
.	O

Gas	B-ENZY
flow	O
with	O
a	O
FiO2	O
of	O
1	O
.	O
0	O
was	O
set	O
to	O
equal	O
blood	O
flow	O
.	O

In	O
animals	O
with	O
ALI	O
,	O
hemodynamics	O
remained	O
stable	O
and	O
gas	B-ENZY
transfer	O
across	O
the	O
extracorporeal	O
oxygenators	O
was	O
optimal	O
,	O
but	O
only	O
in	O
2	O
animals	O
was	O
a	O
marked	O
increase	O
in	O
PaO2	O
observed	O
.	O

ABSTRACT	O
:	O
Mustard	O
gas	B-ENZY
exposure	O
causes	O
adult	O
respiratory	O
distress	O
syndrome	O
associated	O
with	O
lung	O
injury	O
.	O

To	O
confirm	O
that	O
this	O
was	O
the	O
case	O
,	O
a	O
set	O
of	O
minigenomes	O
was	O
expressed	O
that	O
included	O
an	O
expression	O
cassette	O
for	O
an	O
mRNA	O
including	O
the	O
beta	B-ENZY
-	I-ENZY
glucuronidase	I-ENZY
gene	O
(	O
GUS	O
)	O
plus	O
variable	O
sequence	O
fragments	O
from	O
the	O
5	O
'	O
end	O
of	O
the	O
virus	O
genome	O
potentially	O
including	O
Psi	O
.	O

Six	O
out	O
of	O
the	O
21	O
patients	O
developed	O
one	O
episode	O
of	O
ACS	B-ENZY
(	O
two	O
patients	O
had	O
positive	O
blood	O
cultures	O
,	O
for	O
Mycoplasma	O
pneumoniae	O
and	O
Haemophilus	O
influenzae	O
respectively	O
).	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
the	O
therapeutic	O
efficacy	O
of	O
red	O
cell	O
-	O
exchange	O
during	O
ACS	B-ENZY
.	O

MCT	B-ENZY
/	O
LCT	O
as	O
fat	O
resource	O
shared	O
50	O
%	O
calories	O
intake	O
.	O

We	O
provide	O
the	O
first	O
quantitative	O
analysis	O
of	O
the	O
polynucleic	O
acid	O
binding	O
and	O
NTPase	B-ENZY
activities	O
of	O
a	O
Nidovirus	O
helicase	O
,	O
using	O
a	O
high	O
throughput	O
phosphate	O
release	O
assay	O
that	O
will	O
be	O
readily	O
adaptable	O
to	O
the	O
future	O
testing	O
of	O
helicase	O
inhibitors	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
ALT	O
/	O
AST	B-ENZY
elevation	O
rates	O
between	O
severe	O
and	O
mild	O
clinical	O
type	O
(	O
chi2	O
=	O
19	O
.	O
28	O
,	O
P	O
<	O
0	O
.	O
05	O
).	O

RESULTS	O
:	O
When	O
being	O
admitted	O
to	O
hospital	O
,	O
serum	O
ALT	O
and	O
(	O
or	O
)	O
AST	B-ENZY
levels	O
were	O
elevated	O
in	O
37	O
.	O
7	O
%	O
SARS	O
patients	O
.	O

In	O
conclusion	O
,	O
combined	O
use	O
of	O
aerosolised	O
iloprost	O
and	O
subthreshold	O
systemic	O
phosphodiesterase	B-ENZY
-	O
3	O
/	O
4	O
inhibitor	O
may	O
result	O
in	O
selective	O
intrapulmonary	O
vasodilation	O
,	O
a	O
reduction	O
in	O
oedema	O
formation	O
and	O
an	O
improvement	O
in	O
ventilation	O
-	O
perfusion	O
matching	O
in	O
acute	O
respiratory	O
failure	O
.	O

TITLE	O
:	O
[	O
Relationship	O
between	O
acid	O
-	O
base	O
disturbance	O
in	O
blood	O
gas	B-ENZY
analysis	O
and	O
prognosis	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
].	O

Artery	O
blood	O
gas	B-ENZY
analysis	O
indexes	O
were	O
determined	O
in	O
38	O
of	O
103	O
cases	O
of	O
SARS	O
patients	O
during	O
acute	O
stage	O
,	O
the	O
relationship	O
between	O
the	O
change	O
of	O
blood	O
gas	B-ENZY
analysis	O
index	O
and	O
prognosis	O
of	O
patients	O
with	O
SARS	O
was	O
analyzed	O
.	O

The	O
artery	O
blood	O
gas	B-ENZY
analysis	O
is	O
useful	O
for	O
judging	O
the	O
conditions	O
and	O
prognosis	O
of	O
patients	O
with	O
SARS	O
,	O
and	O
is	O
beneficial	O
for	O
clinical	O
treatment	O
.	O

CONCLUSIONS	O
:	O
The	O
artery	O
blood	O
gas	B-ENZY
analysis	O
is	O
useful	O
for	O
judging	O
the	O
conditions	O
and	O
prognosis	O
of	O
patients	O
with	O
SARS	O
,	O
and	O
is	O
beneficial	O
for	O
clinical	O
treatment	O
.	O

Heart	O
rate	O
,	O
oxygen	O
saturation	O
,	O
temperature	O
,	O
and	O
alanine	B-ENZY
aminotransferase	I-ENZY
(	O
ALT	O
)	O
and	O
aspartate	B-ENZY
aminotransferase	I-ENZY
(	O
AST	B-ENZY
)	O
levels	O
were	O
recorded	O
daily	O
.	O

Hemogram	O
and	O
blood	O
gas	B-ENZY
analysis	O
showed	O
that	O
blood	O
sugar	O
and	O
white	O
blood	O
cell	O
(	O
WBC	O
)	O
increased	O
(	O
P	O
<	O
0	O
.	O
001	O
);	O
lymphocyte	O
decreased	O
significantly	O
(	O
P	O
<	O
0	O
.	O
005	O
)	O
and	O
PaO	B-ENZY
(	O
2	O
),	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
decreased	O
Progressively	O
(	O
P	O
<	O
0	O
.	O
005	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
late	O
stage	O
of	O
SARS	O
versus	O
just	O
entering	O
the	O
hospital	O
.	O

TITLE	O
:	O
Detection	O
of	O
infectious	O
bronchitis	O
virus	O
by	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
and	O
identification	O
of	O
a	O
quasispecies	O
in	O
the	O
Beaudette	O
strain	O
.	O

The	O
cleavage	O
sites	O
of	O
the	O
3C	O
-	O
like	O
proteinase	O
and	O
papain	B-ENZY
-	O
like	O
proteinase	O
are	O
highly	O
conserved	O
.	O

Based	O
on	O
the	O
method	O
of	O
traditional	O
positional	O
weight	O
matrix	O
trained	O
by	O
the	O
peptides	O
around	O
cleavage	O
sites	O
,	O
the	O
present	O
method	O
also	O
sufficiently	O
considers	O
the	O
length	O
conservation	O
of	O
non	O
-	O
structural	O
proteins	O
cleaved	O
by	O
the	O
3C	O
-	O
like	O
proteinase	O
and	O
papain	B-ENZY
-	O
like	O
proteinase	O
to	O
reduce	O
the	O
false	O
positive	O
prediction	O
rate	O
.	O

ABSTRACT	O
:	O
To	O
discuss	O
the	O
false	O
-	O
positive	O
of	O
serological	O
diagnostic	O
testing	O
for	O
coronavirus	O
antibody	O
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
),	O
66	O
normal	O
individual	O
and	O
31	O
SLE	O
with	O
non	O
-	O
SARS	O
patients	O
were	O
detected	O
for	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
antibody	O
and	O
RNA	O
by	O
enzymelinked	O
immunosorbent	O
assays	O
(	O
ELISA	O
)	O
and	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

Prior	O
treatment	O
of	O
cells	O
with	O
the	O
lysosomotropic	O
agents	O
NH	O
(	O
4	O
)	O
Cl	O
and	O
chloroquine	O
as	O
well	O
as	O
the	O
vacuolar	O
proton	B-ENZY
pump	I-ENZY
-	O
ATPase	B-ENZY
inhibitor	O
bafilomycin	O
A1	O
,	O
all	O
of	O
which	O
block	O
the	O
acidification	O
of	O
the	O
endosome	O
,	O
prevented	O
oligodendrocytes	O
from	O
succumbing	O
to	O
apoptosis	O
induced	O
by	O
MHV	O
mutant	O
OBLV60	O
,	O
which	O
enters	O
cells	O
via	O
endocytosis	O
,	O
indicating	O
that	O
fusion	O
between	O
the	O
viral	O
envelope	O
and	O
cell	O
membranes	O
triggers	O
the	O
apoptotic	O
cascade	O
.	O

134	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
samples	O
were	O
obtained	O
from	O
32	O
infants	O
requiring	O
mechanical	O
ventilation	O
for	O
respiratory	O
distress	O
syndrome	O
(	O
RDS	O
):	O
13	O
infants	O
(	O
median	O
gestation	O
26	O
weeks	O
,	O
range	O
23	O
to	O
28	O
)	O
subsequently	O
developed	O
CLD	O
(	O
CLD	O
group	O
),	O
and	O
19	O
infants	O
(	O
gestation	O
31	O
weeks	O
,	O
range	O
25	O
to	O
39	O
)	O
recovered	O
fully	O
(	O
RDS	O
group	O
).	O

RESULTS	O
:	O
Neutrophil	O
apoptosis	O
was	O
increased	O
in	O
the	O
RDS	O
group	O
(	O
mean	O
(	O
SEM	O
)	O
neutrophil	O
apoptosis	O
on	O
day	O
7	O
BAL	B-ENZY
:	O
RDS	O
17	O
.	O
0	O
(	O
8	O
.	O
6	O
)%	O
v	O
CLD	O
0	O
.	O
7	O
(	O
0	O
.	O
2	O
)%	O
(	O
p	O
<	O
0	O
.	O
05	O
)).	O

TITLE	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
in	O
long	O
-	O
chain	O
3	B-ENZY
-	I-ENZY
hydroxyacyl	I-ENZY
-	I-ENZY
CoA	I-ENZY
dehydrogenase	I-ENZY
and	O
mitochondrial	O
trifunctional	O
protein	O
deficiencies	O
.	O

Three	O
of	O
the	O
patients	O
were	O
homozygous	O
for	O
the	O
'	O
common	O
'	O
1528G	O
>	O
C	O
mutation	O
in	O
the	O
alpha	O
-	O
subunit	O
of	O
the	O
MTP	O
,	O
giving	O
rise	O
to	O
long	O
-	O
chain	O
3	B-ENZY
-	I-ENZY
hydroxyacyl	I-ENZY
-	I-ENZY
CoA	I-ENZY
dehydrogenase	I-ENZY
deficiency	O
.	O

Oxygenation	O
was	O
assessed	O
by	O
means	O
of	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
in	O
the	O
supine	O
position	O
(	O
one	O
hour	O
before	O
prone	O
positioning	O
),	O
one	O
hour	O
after	O
prone	O
positioning	O
,	O
and	O
one	O
hour	O
after	O
returning	O
to	O
the	O
supine	O
position	O
.	O

TITLE	O
:	O
A	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
assay	O
for	O
the	O
diagnosis	O
of	O
turkey	O
coronavirus	O
infection	O
.	O

TITLE	O
:	O
A	O
new	O
millennium	O
conundrum	O
:	O
how	O
to	O
use	O
a	O
powerful	O
class	O
of	O
influenza	O
anti	O
-	O
neuraminidase	B-ENZY
drugs	O
(	O
NAIs	O
)	O
in	O
the	O
community	O
.	O

A	O
total	O
of	O
39	O
potential	O
pathogens	O
were	O
obtained	O
,	O
including	O
coronavirus	O
(	O
n	O
=	O
19	O
crias	O
;	O
42	O
%),	O
Giardia	O
spp	B-ENZY
(	O
8	O
;	O
18	O
%),	O
Eimeria	O
spp	B-ENZY
(	O
6	O
;	O
13	O
%),	O
Cryptosporidium	O
spp	B-ENZY
(	O
4	O
;	O
9	O
%),	O
rotavirus	O
(	O
1	O
;	O
2	O
%),	O
and	O
nematode	O
ova	O
(	O
1	O
;	O
2	O
%).	O

The	O
interferon	O
alfacon	O
-	O
1	O
treatment	O
group	O
had	O
a	O
shorter	O
time	O
to	O
50	O
%	O
resolution	O
of	O
lung	O
radiographic	O
abnormalities	O
(	O
median	O
time	O
,	O
4	O
days	O
vs	O
9	O
days	O
;	O
P	O
=.	O
001	O
),	O
had	O
better	O
oxygen	O
saturation	O
(	O
P	O
=.	O
02	O
),	O
resolved	O
their	O
need	O
for	O
supplemental	O
oxygen	O
more	O
rapidly	O
(	O
median	O
,	O
10	O
days	O
vs	O
16	O
days	O
;	O
P	O
=.	O
02	O
),	O
had	O
less	O
of	O
an	O
increase	O
in	O
creatine	B-ENZY
kinase	I-ENZY
levels	O
(	O
P	O
=.	O
03	O
),	O
and	O
showed	O
a	O
trend	O
toward	O
more	O
rapid	O
resolution	O
of	O
lactate	O
dehydrogenase	O
levels	O
compared	O
with	O
the	O
group	O
receiving	O
corticosteroids	O
alone	O
.	O

Early	O
diagnosis	O
can	O
be	O
made	O
with	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
of	O
nasopharyngeal	O
aspirate	O
samples	O
.	O

In	O
the	O
SNO	O
,	O
values	O
for	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
were	O
improved	O
from	O
(	O
185	O
+/-	O
39	O
)	O
mmHg	O
at	O
baseline	O
to	O
(	O
301	O
+/-	O

RESULTS	O
:	O
(	O
1	O
)	O
Meconium	O
aspiration	O
induced	O
ALI	O
and	O
severe	O
HRF	O
(	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
<	O
200	O
mmHg	O
)	O
and	O
depressed	O
dynamic	O
compliance	O
of	O
respiratory	O
system	O
(	O
Cdyn	O
)	O
and	O
airway	O
resistance	O
(	O
Raw	O
).	O

CAT	O
protein	O
was	O
detected	O
from	O
T7	O
-	O
derived	O
IBV	O
D	O
-	O
RNA	O
transcripts	O
in	O
a	O
cell	O
-	O
free	O
protein	O
synthesis	O
system	O
and	O
in	O
situ	O
in	O
avian	O
chick	O
kidney	O
(	O
CK	O
)	O
cells	O
following	O
T7	O
-	O
derived	O
D	O
-	O
RNA	O
synthesis	O
from	O
a	O
recombinant	O
fowlpox	O
virus	O
expressing	O
the	O
bacteriophage	O
T7	O
DNA	B-ENZY
-	I-ENZY
dependent	I-ENZY
RNA	I-ENZY
polymerase	I-ENZY
.	O

The	O
S1	O
glycoprotein	O
gene	O
of	O
IBV	O
isolates	O
were	O
amplified	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
analyzed	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analysis	O
.	O

Although	O
proteolysis	O
did	O
not	O
enhance	O
the	O
infectivity	O
of	O
cell	O
-	O
free	O
pseudovirions	O
,	O
trypsin	B-ENZY
activation	O
is	O
required	O
for	O
cell	O
-	O
cell	O
fusion	O
.	O

Second	O
generation	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
assays	O
are	O
able	O
to	O
detect	O
SARS	O
-	O
CoV	O
in	O
nasopharyngeal	O
aspirates	O
of	O
approximately	O
80	O
%	O
of	O
patients	O
with	O
SARS	O
within	O
the	O
first	O
3	O
days	O
of	O
illness	O
.	O

Neuraminidase	B-ENZY
inhibitors	O
have	O
produced	O
notable	O
progress	O
in	O
the	O
therapeutic	O
approaches	O
to	O
influenza	O
-	O
associated	O
pulmonary	O
infections	O
and	O
are	O
at	O
least	O
able	O
to	O
shorten	O
the	O
duration	O
of	O
symptoms	O
in	O
selected	O
patients	O
.	O

This	O
effect	O
was	O
attenuated	O
by	O
treatment	O
with	O
N	O
-	O
acetylcysteine	O
(	O
MPO	O
43	O
-	O
9	O
microg	O
/	O
mL	O
,	O
BAL	B-ENZY
protein	O
605	O
-	O
198	O
microg	O
/	O
mL	O
).	O

The	O
results	O
lead	O
to	O
several	O
findings	O
;	O
1	O
)	O
although	O
two	O
dissected	O
parts	O
folded	O
into	O
the	O
native	O
-	O
like	O
structures	O
,	O
the	O
chymotrypsin	B-ENZY
fold	O
only	O
had	O
weak	O
activity	O
as	O
compared	O
with	O
the	O
entire	O
enzyme	O
,	O
and	O
2	O
)	O
although	O
the	O
chymotrypsin	B-ENZY
fold	O
remained	O
a	O
monomer	O
within	O
a	O
wide	O
range	O
of	O
protein	O
concentrations	O
,	O
the	O
extra	O
domain	O
existed	O
as	O
a	O
stable	O
dimer	O
even	O
at	O
a	O
very	O
low	O
concentration	O
.	O

Alanine	B-ENZY
aminotransferase	I-ENZY
(	O
ALT	O
),	O
aspartate	B-ENZY
aminotransferase	I-ENZY
(	O
AST	B-ENZY
),	O
lactate	O
dehydrogenase	O
(	O
LDH	O
),	O
total	O
bilirubin	O
(	O
TBil	O
)	O
of	O
patients	O
with	O
SARS	O
were	O
higher	O
than	O
those	O
of	O
controls	O
,	O
they	O
were	O
(	O
91	O
.	O
61	O
+/-	O
50	O
.	O
53	O
)	O
U	O
/	O
L	O
vs	O
.	O
(	O
32	O
.	O
91	O
+/-	O
10	O
.	O
56	O
)	O
U	O
/	O
L	O
,	O
(	O
78	O
.	O
68	O
+/-	O
33	O
.	O
32	O
)	O
U	O
/	O
L	O
vs	O
.	O
(	O
29	O
.	O
43	O
+/-	O
8	O
.	O
89	O
)	O
U	O
/	O
L	O
,	O
(	O
429	O
.	O
95	O
+/-	O
188	O
.	O
94	O
)	O
U	O
/	O
L	O
vs	O
.	O
(	O
200	O
.	O
83	O
+/-	O
44	O
.	O
86	O
)	O
U	O
/	O
L	O
,	O
(	O
11	O
.	O
67	O
+/-	O
4	O
.	O
26	O
)	O
micromol	O
/	O
L	O
vs	O
.	O
(	O
8	O
.	O
44	O
+/-	O
3	O
.	O
86	O
)	O
micromol	O
/	O
L	O
,	O
all	O
P	O
<	O
0	O
.	O
001	O
.	O

The	O
average	O
of	O
LDH	O
,	O
ALT	O
,	O
and	O
AST	B-ENZY
of	O
dead	O
patients	O
were	O
higher	O
than	O
those	O
of	O
the	O
survivors	O
.	O

Specific	O
antisense	O
activity	O
designed	O
to	O
block	O
translation	O
of	O
the	O
viral	O
replicase	O
polyprotein	O
was	O
first	O
confirmed	O
by	O
reduction	O
of	O
luciferase	B-ENZY
expression	O
from	O
a	O
target	O
sequence	O
-	O
containing	O
reporter	O
construct	O
in	O
both	O
cell	O
-	O
free	O
and	O
transfected	O
cell	O
culture	O
assays	O
.	O

TITLE	O
:	O
Cleavage	O
inhibition	O
of	O
the	O
murine	O
coronavirus	O
spike	O
protein	O
by	O
a	O
furin	B-ENZY
-	O
like	O
enzyme	O
affects	O
cell	O
-	O
cell	O
but	O
not	O
virus	O
-	O
cell	O
fusion	O
.	O

ABSTRACT	O
:	O
We	O
have	O
generated	O
a	O
mouse	O
strain	O
carrying	O
a	O
transgene	O
driven	O
by	O
a	O
strong	O
and	O
ubiquitous	O
promoter	O
(	O
human	O
cytomegalovirus	O
hCMV	O
/	O
beta	O
-	O
actin	O
)	O
and	O
containing	O
an	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
eGFP	O
)	O
coding	O
sequence	O
upstream	O
of	O
the	O
3	O
'	O
untranslated	O
region	O
(	O
3	O
'	O
UTR	O
)	O
of	O
tissue	B-ENZY
-	I-ENZY
type	I-ENZY
plasminogen	I-ENZY
activator	I-ENZY
(	O
t	O
-	O
PA	O
)	O
mRNA	O
.	O

Hantaviruses	O
(	O
Puumala	O
,	O
Hantaan	O
,	O
Sin	O
Nombre	O
and	O
others	O
)	O
infecting	O
field	O
rodents	O
may	O
be	O
a	O
cause	O
of	O
hemorrhagic	O
fever	O
with	O
renal	O
syndrome	O
(	O
HFRS	O
)	O
or	O
pulmonary	O
syndrome	O
(	O
HPS	B-ENZY
)	O
in	O
farmers	O
and	O
laboratory	O
workers	O
.	O

Of	O
the	O
182	O
patients	O
,	O
128	O
(	O
70	O
.	O
3	O
%)	O
had	O
abnormal	O
ALT	O
activity	O
,	O
57	O
(	O
31	O
.	O
3	O
%)	O
had	O
abnormal	O
AST	B-ENZY
activity	O
and	O
87	O
(	O
47	O
.	O
8	O
%)	O
had	O
abnormal	O
LDH	O
activity	O
.	O

ABSTRACT	O
:	O
The	O
zinc	O
metallopeptidase	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
is	O
the	O
only	O
known	O
human	O
homologue	O
of	O
the	O
key	O
regulator	O
of	O
blood	O
pressure	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	B-ENZY
).	O

In	O
a	O
murine	O
model	O
we	O
measured	O
NF	O
-	O
kappaB	O
activation	O
,	O
expression	O
of	O
intercellular	O
adhesion	O
molecule	O
(	O
ICAM	O
)	O
1	O
,	O
nitrotyrosine	O
,	O
inducible	O
nitric	O
oxide	O
synthase	O
(	O
iNOS	O
),	O
nuclear	O
enzyme	O
poly	B-ENZY
(	I-ENZY
ADP	I-ENZY
-	I-ENZY
ribose	I-ENZY
)	I-ENZY
synthetase	I-ENZY
(	O
PARS	O
),	O
myeloperoxidase	B-ENZY
,	O
malondialdehyde	O
,	O
amylase	O
and	O
lipase	B-ENZY
and	O
determined	O
histological	O
evidence	O
of	O
lung	O
and	O
pancreas	O
injury	O
in	O
four	O
groups	O
:	O
control	O
(	O
saline	O
only	O
),	O
cerulein	O
,	O
calpain	O
I	O
inhibitor	O
plus	O
cerulein	O
and	O
calpain	O
I	O
inhibitor	O
plus	O
saline	O
.	O

Thus	O
,	O
besides	O
basic	O
treatment	O
of	O
the	O
underlying	O
disease	O
the	O
use	O
of	O
vasodilators	O
is	O
a	O
valuable	O
therapeutic	O
option	O
to	O
decrease	O
right	O
ventricular	O
afterload	O
,	O
but	O
intravenous	O
vasodilators	O
may	O
provoke	O
systemic	O
arterial	O
hypotension	O
and	O
impair	O
gas	B-ENZY
exchange	O
due	O
to	O
vasodilation	O
of	O
pulmonary	O
shunt	O
areas	O
.	O

However	O
,	O
most	O
of	O
the	O
diagnostic	O
methods	O
available	O
today	O
,	O
such	O
as	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
require	O
a	O
second	O
detection	O
method	O
for	O
confirmation	O
because	O
they	O
detect	O
a	O
single	O
sequence	O
region	O
of	O
the	O
SARS	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

ABSTRACT	O
:	O
Human	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
APN	O
/	O
CD13	O
/	O
ANPEP	O
)	O
has	O
been	O
identified	O
as	O
the	O
receptor	O
for	O
human	O
coronavirus	O
(	O
HCoV	O
)	O
229E	O
.	O

ABSTRACT	O
:	O
This	O
study	O
established	O
a	O
modified	O
alkaline	B-ENZY
phosphatase	I-ENZY
-	O
labelled	O
avidin	O
-	O
biotin	O
-	O
complex	O
(	O
ABC	O
-	O
AP	O
)	O
method	O
for	O
diagnosis	O
of	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
and	O
Mycoplasma	O
pulmonis	O
infection	O
from	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
wax	O
-	O
embedded	O
sections	O
,	O
murine	O
antibody	O
-	O
positive	O
serum	O
being	O
used	O
as	O
the	O
primary	O
reagent	O
.	O

Furthermore	O
,	O
activation	O
of	O
the	O
p38	O
MAPK	B-ENZY
pathway	O
was	O
found	O
to	O
induce	O
actin	O
reorganization	O
in	O
cells	O
devoid	O
of	O
growth	O
factors	O
.	O

The	O
data	O
extracted	O
included	O
patient	O
demographics	O
,	O
etiology	O
of	O
respiratory	O
failure	O
,	O
ventilator	O
settings	O
,	O
and	O
gas	B-ENZY
exchange	O
and	O
cardiovascular	O
data	O
from	O
baseline	O
to	O
72	O
h	O
of	O
treatment	O
,	O
as	O
well	O
as	O
at	O
the	O
transition	O
from	O
HFOV	O
to	O
conventional	O
ventilation	O
(	O
CV	O
).	O

APC	O
inhibits	O
ET	O
-	O
induced	O
TNF	O
-	O
alpha	O
production	O
in	O
vitro	O
in	O
human	O
monocytes	O
by	O
inhibiting	O
activation	O
of	O
NFkappaB	O
and	O
AP	O
-	O
1	O
by	O
inhibiting	O
degradation	O
of	O
IkappaB	O
and	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
pathways	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
we	O
also	O
demonstrated	O
angiotensin	O
1	O
converting	O
enzyme	O
(	O
ACE	B-ENZY
)-	O
the	O
homologue	O
of	O
ACE2	O
could	O
not	O
function	O
as	O
a	O
receptor	O
for	O
SARS	O
-	O
CoV	O
.	O

In	O
patients	O
with	O
severe	O
head	O
trauma	O
and	O
ALI	O
receiving	O
mechanical	O
ventilation	O
,	O
expiratory	O
tracheal	O
gas	B-ENZY
insufflation	O
allowed	O
the	O
targeted	O
arterial	O
PCO	O
(	O
2	O
)	O
level	O
to	O
be	O
maintained	O
together	O
with	O
a	O
substantial	O
reduction	O
in	O
tidal	O
volume	O
.	O

Extracorporeal	O
life	O
support	O
(	O
ECLS	O
)	O
during	O
severe	O
ARDS	O
maintains	O
oxygen	O
and	O
carbon	O
dioxide	O
gas	B-ENZY
exchange	O
while	O
providing	O
an	O
optimal	O
environment	O
for	O
recovery	O
of	O
pulmonary	O
function	O
.	O

For	O
instance	O
,	O
one	O
evident	O
trend	O
is	O
high	O
sequence	O
conservation	O
in	O
the	O
V	O
(	O
H	O
)	O
chains	O
of	O
the	O
neutralizing	O
mAbs	O
,	O
particularly	O
in	O
CDR	B-ENZY
-	O
1	O
and	O
CDR	B-ENZY
-	O
2	O
.	O

p38	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
(	O
MAPK	B-ENZY
)	O
and	O
its	O
downstream	O
targets	O
are	O
activated	O
in	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)-	O
infected	O
Vero	O
E6	O
cells	O
and	O
activation	O
of	O
p38	O
MAPK	B-ENZY
enhances	O
the	O
cytopathic	O
effects	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

RESULTS	O
:	O
Compared	O
with	O
healthy	O
person	O
,	O
the	O
levels	O
of	O
serum	O
TC	O
,	O
Fe	O
,	O
Ca	O
,	O
Alb	O
were	O
significantly	O
lowered	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
),	O
while	O
the	O
activity	O
of	O
LDH	O
,	O
CK	O
,	O
ALT	O
,	O
AST	B-ENZY
were	O
elevated	O
,	O
the	O
increase	O
of	O
CK	O
and	O
the	O
decrease	O
of	O
Fe	O
were	O
the	O
most	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
),	O
the	O
changes	O
of	O
TP	O
and	O
TG	O
were	O
not	O
obvious	O
.	O

In	O
convalescent	O
stage	O
,	O
all	O
the	O
tests	O
were	O
returned	O
to	O
normal	O
ranges	O
except	O
ALT	O
,	O
AST	B-ENZY
were	O
still	O
elevated	O
in	O
SARS	O
patients	O
.	O

Specifically	O
,	O
a	O
dual	O
luciferase	B-ENZY
reporter	O
assay	O
was	O
employed	O
to	O
measure	O
the	O
efficiency	O
of	O
four	O
programmed	O
-	O
1	O
frameshift	O
signals	O
.	O

In	O
the	O
presence	O
of	O
MG132	O
,	O
the	O
entering	O
viruses	O
accumulated	O
in	O
both	O
the	O
endosome	O
and	O
denser	O
lysosome	O
,	O
suggesting	O
that	O
the	O
ubiquitin	O
-	O
proteasome	B-ENZY
system	O
is	O
involved	O
in	O
the	O
release	O
of	O
virus	O
from	O
the	O
endosome	O
to	O
the	O
cytosol	O
during	O
the	O
virus	O
entry	O
step	O
.	O

nsp10	O
ATPase	B-ENZY
/	O
helicase	O
deficiency	O
resulting	O
from	O
single	O
-	O
residue	O
substitutions	O
in	O
the	O
ZBD	O
or	O
deletion	O
of	O
the	O
entire	O
domain	O
could	O
not	O
be	O
complemented	O
in	O
trans	O
by	O
wild	O
-	O
type	O
ZBD	O
,	O
suggesting	O
a	O
critical	O
function	O
of	O
the	O
ZBD	O
in	O
cis	O
.	O

Consistently	O
,	O
no	O
viral	O
RNA	O
synthesis	O
was	O
detected	O
after	O
transfection	O
of	O
EAV	O
full	O
-	O
length	O
RNAs	O
encoding	O
ATPase	B-ENZY
/	O
helicase	O
-	O
deficient	O
nsp10	O
into	O
susceptible	O
cells	O
.	O

ABSTRACT	O
:	O
A	O
few	O
members	O
of	O
coronavirus	O
group	O
I	O
which	O
includes	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
use	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
pAPN	O
)	O
as	O
a	O
cellular	O
receptor	O
.	O

In	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
the	O
debate	O
concerning	O
the	O
use	O
of	O
long	O
-	O
chain	O
fatty	O
acids	O
as	O
opposed	O
to	O
physical	O
mixtures	O
of	O
medium	O
-	O
and	O
long	O
-	O
chain	O
fatty	O
acids	O
,	O
specifically	O
regarding	O
their	O
effects	O
on	O
gas	B-ENZY
exchange	O
and	O
pulmonary	O
hemodynamics	O
,	O
still	O
remains	O
unresolved	O
.	O

TITLE	O
:	O
[	O
Application	O
of	O
fluorescent	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
in	O
detecting	O
influenza	O
viruses	O
].	O

By	O
allowing	O
patients	O
with	O
acute	O
lung	O
injury	O
to	O
breathe	O
spontaneously	O
,	O
one	O
can	O
expect	O
improvement	O
in	O
gas	B-ENZY
exchange	O
and	O
in	O
systemic	O
blood	O
flow	O
,	O
on	O
the	O
basis	O
of	O
both	O
experimental	O
and	O
clinical	O
trials	O
.	O

ABSTRACT	O
:	O
A	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
for	O
the	O
detection	O
of	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
messenger	O
RNA	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
is	O
described	O
.	O

The	O
immunological	O
fragment	O
of	O
the	O
S	O
protein	O
(	O
Ala251	O
-	O
His641	O
,	O
SARS_S1b	O
)	O
is	O
believed	O
to	O
be	O
essential	O
for	O
SARS_CoV	O
entering	O
the	O
host	O
cell	O
through	O
S	O
protein	O
-	O
ACE	B-ENZY
-	O
2	O
interaction	O
.	O

ABSTRACT	O
:	O
To	O
identify	O
the	O
function	O
of	O
HAb18G	O
/	O
CD147	O
in	O
invasion	O
of	O
host	O
cells	O
by	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
),	O
we	O
analyzed	O
the	O
protein	O
-	O
protein	O
interaction	O
among	O
HAb18G	O
/	O
CD147	O
,	O
cyclophilin	B-ENZY
A	O
(	O
CyPA	O
),	O
and	O
SARS	O
-	O
CoV	O
structural	O
proteins	O
by	O
coimmunoprecipitation	O
and	O
surface	O
plasmon	O
resonance	O
analysis	O
.	O

But	O
in	O
ARDSexp	O
,	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
was	O
significantly	O
increased	O
after	O
0	O
.	O
5	O
h	O
and	O
2	O
h	O
in	O
the	O
prone	O
position	O
(	O
116	O
.	O
5	O
+/-	O
55	O
.	O
0	O
to	O
163	O
.	O
2	O
+/-	O

The	O
abnormalities	O
of	O
serum	O
alanine	B-ENZY
aminotransferase	I-ENZY
(	O
ALT	O
)	O
were	O
52	O
.	O
5	O
%,	O
71	O
.	O
8	O
%,	O
85	O
.	O
7	O
%	O
and	O
85	O
.	O
2	O
%.	O

Increasing	O
the	O
sensitivity	O
for	O
SARS	O
-	O
CoV	O
and	O
GAPDH	B-ENZY
mRNA	O
detection	O
was	O
investigated	O
in	O
follow	O
up	O
specimens	O
in	O
which	O
SARS	O
-	O
CoV	O
and	O
GAPDH	B-ENZY
mRNA	O
were	O
not	O
detected	O
initially	O
.	O

Patients	O
with	O
,	O
versus	O
those	O
without	O
,	O
ARDS	O
also	O
tended	O
to	O
present	O
with	O
more	O
severe	O
lymphopenia	O
and	O
leukocytosis	O
,	O
and	O
with	O
higher	O
levels	O
of	O
LDH	O
and	O
aspartate	B-ENZY
aminotransferase	I-ENZY
.	O

Serum	O
myeloperoxidase	B-ENZY
(	O
MPO	B-ENZY
)	O
activity	O
,	O
malondialdehyde	O
(	O
MDA	O
)	O
levels	O
and	O
total	O
antioxidant	O
capacity	O
(	O
TAC	O
)	O
and	O
lung	O
tissue	O
MPO	B-ENZY
activity	O
,	O
MDA	O
levels	O
and	O
Na	O
+-	O
K	O
+	O
ATPase	B-ENZY
activity	O
were	O
measured	O
and	O
light	O
microscopic	O
analyses	O
of	O
lung	O
specimens	O
were	O
performed	O
.	O

ABSTRACT	O
:	O
Elevation	O
of	O
alanine	B-ENZY
aminotransferase	I-ENZY
(	O
ALT	O
)	O
level	O
is	O
commonly	O
seen	O
among	O
patients	O
suffering	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

We	O
report	O
about	O
two	O
cases	O
of	O
pulmonary	O
zygomycosis	O
,	O
caused	O
by	O
Rhizopus	O
spp	B-ENZY
.:	O
patient	O
1	O
,	O
female	O
73	O
years	O
old	O
:	O
Delayed	O
clinical	O
course	O
according	O
to	O
hip	O
arthroplasty	O
infection	O
and	O
infection	O
of	O
a	O
femoropopliteal	O
bypass	O
of	O
the	O
right	O
leg	O
,	O
eventually	O
exarticulation	O
of	O
the	O
right	O
hip	O
joint	O
,	O
Pseudomonas	O
pneumonia	O
,	O
severe	O
sepsis	O
caused	O
by	O
staphylococci	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDs	O
),	O
acute	O
renal	O
failure	O
and	O
multiple	O
use	O
of	O
antibiotics	O
.	O

In	O
contrast	O
,	O
oleic	O
acid	O
caused	O
severe	O
alveolar	O
damage	O
with	O
the	O
development	O
of	O
alveolar	O
edema	O
of	O
the	O
increased	O
-	O
permeability	O
type	O
with	O
associated	O
abnormalities	O
in	O
gas	B-ENZY
exchange	O
.	O

Bioactivity	O
assay	O
results	O
(	O
in	O
vitro	O
tests	O
)	O
demonstrated	O
that	O
some	O
of	O
these	O
compounds	O
are	O
potent	O
and	O
selective	O
inhibitors	O
against	O
SARS	O
coronavirus	O
3CL	O
protease	O
with	O
IC50	O
values	O
ranging	O
from	O
0	O
.	O
95	O
to	O
17	O
.	O
50	O
microM	O
.	O
Additionally	O
,	O
isatin	O
4o	O
exhibited	O
more	O
potent	O
inhibition	O
for	O
SARS	O
coronavirus	O
protease	O
than	O
for	O
other	O
proteases	O
including	O
papain	B-ENZY
,	O
chymotrypsin	B-ENZY
,	O
and	O
trypsin	B-ENZY
.	O

Interestingly	O
,	O
a	O
viral	O
receptor	O
,	O
angiotensin	O
converting	O
enzyme	O
(	O
ACE	B-ENZY
)-	O
2	O
,	O
was	O
down	O
-	O
regulated	O
in	O
persistently	O
infected	O
cells	O
.	O

However	O
,	O
compared	O
with	O
the	O
high	O
avidity	O
of	O
SSp	O
-	O
1	O
-	O
specific	O
CTLs	O
derived	O
from	O
memory	O
T	O
cells	O
of	O
recovered	O
SARS	O
patients	O
,	O
SSp	O
-	O
1	O
-	O
specific	O
CTLs	O
from	O
the	O
five	O
exceptional	O
healthy	O
donors	O
were	O
of	O
low	O
avidity	O
,	O
as	O
determined	O
by	O
their	O
rapid	O
tetramer	O
dissociation	O
kinetics	O
and	O
reduced	O
cytotoxic	O
reactivity	O
,	O
IFN	O
-	O
gamma	O
secretion	O
,	O
and	O
intracellular	O
production	O
of	O
IFN	O
-	O
gamma	O
,	O
TNF	O
-	O
alpha	O
,	O
perforin	O
,	O
and	O
granzyme	B-ENZY
A	I-ENZY
.	O
These	O
results	O
indicate	O
that	O
SARS	O
-	O
CoV	O
infection	O
induces	O
strong	O
and	O
long	O
-	O
lasting	O
CTL	O
-	O
mediated	O
immunity	O
in	O
surviving	O
SARS	O
patients	O
,	O
and	O
that	O
cross	O
-	O
reactive	O
memory	O
T	O
cells	O
to	O
SARS	O
-	O
CoV	O
may	O
exist	O
in	O
the	O
T	O
cell	O
repertoire	O
of	O
a	O
small	O
subset	O
of	O
healthy	O
individuals	O
and	O
can	O
be	O
reactivated	O
by	O
SARS	O
-	O
CoV	O
infection	O
.	O

In	O
all	O
sheep	O
,	O
the	O
EVW	O
maintained	O
gas	B-ENZY
exchange	O
during	O
and	O
after	O
bronchoconstriction	O
,	O
as	O
well	O
as	O
during	O
OA	O
injury	O
.	O

S	O
-	O
peptide	O
,	O
mice	O
primed	O
with	O
oral	O
live	O
-	O
attenuated	O
S	O
.	O
typhimurium	O
that	O
contained	O
tPA	B-ENZY
-	O
optimize800	O
DNA	O
vaccine	O
(	O
Salmonella	O
-	O
tPA	B-ENZY
-	O
S	O
-	O
DNA	O
)	O
and	O
boosted	O
with	O
i	O
.	O
p	O
.	O

tPA	B-ENZY
-	O
S	O
-	O
DNA	O
boosted	O
with	O
i	O
.	O
p	O
.	O

Contrast	O
echocardiography	O
was	O
performed	O
in	O
any	O
case	O
of	O
suspicion	O
of	O
hepatopulmonary	O
syndrome	O
(	O
HPS	B-ENZY
).	O

Indirect	O
immunofluorescence	O
studies	O
revealed	O
a	O
preferential	O
expression	O
of	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE	B-ENZY
-	O
2	O
),	O
the	O
functional	O
receptor	O
of	O
SARS	O
-	O
CoV	O
,	O
on	O
the	O
apical	O
surface	O
.	O

TITLE	O
:	O
Hematopoietic	O
prostaglandin	B-ENZY
D2	I-ENZY
synthase	I-ENZY
in	O
the	O
chicken	O
Harderian	O
gland	O
.	O

To	O
this	O
end	O
,	O
ACE2	O
may	O
counterbalance	O
the	O
effects	O
of	O
ACE	B-ENZY
within	O
the	O
renin	B-ENZY
-	O
angiotensin	O
system	O
(	O
RAS	O
).	O

In	O
addition	O
,	O
SARS	O
-	O
CoV	O
infection	O
was	O
blocked	O
by	O
specific	O
inhibitors	O
of	O
the	O
pH	O
-	O
sensitive	O
endosomal	O
protease	O
cathepsin	B-ENZY
L	I-ENZY
.	O
A	O
cell	O
-	O
free	O
membrane	O
-	O
fusion	O
system	O
demonstrates	O
that	O
engagement	O
of	O
receptor	O
followed	O
by	O
proteolysis	O
is	O
required	O
for	O
SARS	O
-	O
CoV	O
membrane	O
fusion	O
and	O
indicates	O
that	O
cathepsin	B-ENZY
L	I-ENZY
is	O
sufficient	O
to	O
activate	O
membrane	O
fusion	O
by	O
SARS	O
-	O
CoV	O
S	O
.	O
These	O
results	O
suggest	O
that	O
SARS	O
-	O
CoV	O
infection	O
results	O
from	O
a	O
unique	O
,	O
three	O
-	O
step	O
process	O
:	O
receptor	O
binding	O
and	O
induced	O
conformational	O
changes	O
in	O
S	O
glycoprotein	O
followed	O
by	O
cathepsin	B-ENZY
L	I-ENZY
proteolysis	O
within	O
endosomes	O
.	O

Four	O
of	O
the	O
eleven	O
bananins	O
(	O
BN	O
,	O
IBNCA	O
,	O
VANBA	O
,	O
euBN	O
)	O
were	O
already	O
demonstrated	O
to	O
constitute	O
effective	O
inhibitors	O
of	O
SARS	O
-	O
CoV	O
NSP10	O
/	O
nsp13	O
RNA	O
/	O
DNA	O
helicase	O
/	O
NTPase	B-ENZY
protein	O
ATPase	B-ENZY
enzymatic	O
function	O
.	O

Also	O
,	O
using	O
specific	O
inhibitors	O
of	O
phosphorylation	O
and	O
an	O
in	O
vitro	O
phosphorylation	O
assay	O
,	O
we	O
show	O
that	O
the	O
nucleocapsid	O
protein	O
is	O
a	O
substrate	O
of	O
cyclin	B-ENZY
-	I-ENZY
dependent	I-ENZY
kinase	I-ENZY
(	O
CDK	O
),	O
glycogen	B-ENZY
synthase	I-ENZY
kinase	O
,	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
,	O
and	O
casein	O
kinase	O
II	O
.	O

ABSTRACT	O
:	O
Although	O
the	O
finding	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
in	O
caged	O
palm	O
civets	O
from	O
live	O
animal	O
markets	O
in	O
China	O
has	O
provided	O
evidence	O
for	O
interspecies	O
transmission	O
in	O
the	O
genesis	O
of	O
the	O
SARS	O
epidemic	O
,	O
subsequent	O
studies	O
suggested	O
that	O
the	O
civet	O
may	O
have	O
served	O
only	O
as	O
an	O
amplification	O
host	O
for	O
SARS	O
-	O
CoV	O
.	O
In	O
a	O
surveillance	O
study	O
for	O
CoV	O
in	O
noncaged	O
animals	O
from	O
the	O
wild	O
areas	O
of	O
the	O
Hong	O
Kong	O
Special	O
Administration	O
Region	O
,	O
we	O
identified	O
a	O
CoV	O
closely	O
related	O
to	O
SARS	O
-	O
CoV	O
(	O
bat	B-ENZY
-	O
SARS	O
-	O
CoV	O
)	O
from	O
23	O
(	O
39	O
%)	O
of	O
59	O
anal	O
swabs	O
of	O
wild	O
Chinese	O
horseshoe	O
bats	O
(	O
Rhinolophus	O
sinicus	O
)	O
by	O
using	O
RT	O
-	O
PCR	O
.	O

The	O
DNA	O
/	O
RNA	O
hybrid	O
formed	O
by	O
a	O
modified	O
oligodeoxynucleotide	O
and	O
its	O
target	O
RNA	O
could	O
activate	O
RNase	B-ENZY
H	I-ENZY
.	O
The	O
3	O
'-	O
end	O
-	O
modified	O
antisense	O
oligodeoxynucelotides	O
inhibited	O
S	O
-	O
glycoprotein	O
expression	O
of	O
SARS	O
-	O
CoV	O
at	O
the	O
mRNA	O
levels	O
in	O
insect	O
Sf9	O
cells	O
.	O

In	O
this	O
study	O
,	O
the	O
Renilla	O
and	O
the	O
firefly	B-ENZY
luciferase	I-ENZY
genes	O
were	O
systematically	O
analyzed	O
for	O
their	O
stability	O
after	O
insertion	O
at	O
various	O
genomic	O
positions	O
in	O
the	O
group	O
1	O
coronavirus	O
feline	O
infectious	O
peritonitis	O
virus	O
and	O
in	O
the	O
group	O
2	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
.	O

In	O
contrast	O
,	O
supine	O
-	O
HFOV	O
did	O
not	O
improve	O
gas	B-ENZY
exchange	O
and	O
was	O
associated	O
with	O
enhanced	O
lung	O
inflammation	O
.	O

The	O
vacuolar	O
-	O
H	O
+	O
ATPase	B-ENZY
(	O
V	O
-	O
ATPase	B-ENZY
)	O
G1	O
subunit	O
that	O
contained	O
a	O
3CL	O
(	O
pro	O
)	O
cleavage	O
site	O
-	O
like	O
motif	O
was	O
identified	O
as	O
a	O
3CL	O
(	O
pro	O
)-	O
interacting	O
protein	O
,	O
as	O
confirmed	O
using	O
the	O
co	O
-	O
immunoprecipitation	O
assay	O
and	O
the	O
relative	O
affinity	O
assay	O
.	O

Scalable	O
transcriptional	O
analysis	O
routine	O
(	O
STAR	O
)	O
represents	O
a	O
novel	O
integration	O
of	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
and	O
capillary	O
electrophoresis	O
that	O
allows	O
detection	O
of	O
dozens	O
of	O
gene	O
transcripts	O
in	O
a	O
multiplexed	O
format	O
using	O
amplicon	O
size	O
as	O
an	O
identifier	O
for	O
each	O
target	O
.	O

Classic	O
plasma	O
markers	O
of	O
endothelial	O
injury	O
,	O
tPA	B-ENZY
and	O
sTM	O
significantly	O
elevated	O
in	O
SARS	O
patients	O
in	O
comparison	O
to	O
controls	O
[	O
t	O
-	O
PA	O
:	O
1	O
.	O
48	O
+/-	O

ABSTRACT	O
:	O
Pyrrolobenzoxazepinones	O
(	O
PBOs	O
)	O
represent	O
a	O
new	O
class	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
nonnucleoside	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
)	O
inhibitors	O
(	O
NNRTIs	O
)	O
whose	O
prototype	O
is	O
5	O
.	O

The	O
rise	O
in	O
cefotaxime	O
-	O
resistant	O
or	O
ciprofloxacin	O
-	O
resistant	O
E	O
.	O
coli	O
and	O
meropenem	O
-	O
resistant	O
P	O
.	O
aeruginosa	O
was	O
significantly	O
correlated	O
with	O
increased	O
consumption	O
of	O
extended	O
-	O
spectrum	O
cephalosporins	O
,	O
beta	O
-	O
lactam	O
-	O
beta	B-ENZY
-	I-ENZY
lactamase	I-ENZY
inhibitor	O
combinations	O
,	O
carbapenems	O
,	O
fluoroquinolones	O
and	O
aminoglycosides	O
(	O
for	O
ciprofloxacin	O
-	O
resistant	O
E	O
.	O
coli	O
and	O
meropenem	O
-	O
resistant	O
P	O
.	O
aeruginosa	O
only	O
)	O
in	O
the	O
hospital	O
(	O
Pearson	O
'	O
s	O
correlation	O
coefficient	O
,	O
r	O
>	O
0	O
.	O
72	O
(	O
or	O
<	O
-	O
0	O
.	O
72	O
)	O
and	O
P	O
-	O
value	O
<	O
0	O
.	O
05	O
).	O

Using	O
gel	O
mobility	O
shift	O
RNase	B-ENZY
T1	O
protection	O
assays	O
and	O
secondary	O
structure	O
modeling	O
,	O
we	O
have	O
characterized	O
a	O
possible	O
role	O
for	O
RNA	O
secondary	O
structure	O
in	O
host	O
protein	O
binding	O
to	O
the	O
3	O
'-	O
terminal	O
42	O
-	O
nucleotide	O
element	O
.	O

ABSTRACT	O
:	O
Replication	O
of	O
the	O
genomic	O
RNA	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
mediated	O
by	O
replicase	O
polyproteins	O
that	O
are	O
processed	O
by	O
two	O
viral	O
proteases	O
,	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
and	O
3C	O
-	O
like	O
protease	O
(	O
3CLpro	O
).	O

We	O
performed	O
bioinformatics	O
analysis	O
on	O
16	O
papain	B-ENZY
-	O
like	O
protease	O
domains	O
from	O
nine	O
different	O
coronaviruses	O
and	O
identified	O
a	O
putative	O
catalytic	O
triad	O
(	O
Cys1651	O
-	O
His1812	O
-	O
Asp1826	O
)	O
and	O
zinc	O
-	O
binding	O
site	O
.	O

TITLE	O
:	O
The	O
papain	B-ENZY
-	O
like	O
protease	O
from	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
is	O
a	O
deubiquitinating	O
enzyme	O
.	O

Here	O
we	O
show	O
that	O
SARS	O
-	O
CoV	O
,	O
but	O
not	O
HCoV	O
-	O
NL63	O
,	O
utilizes	O
the	O
enzymatic	O
activity	O
of	O
the	O
cysteine	O
protease	O
cathepsin	B-ENZY
L	I-ENZY
to	O
infect	O
ACE2	O
-	O
expressing	O
cells	O
.	O

ABSTRACT	O
:	O
A	O
subgroup	O
of	O
patients	O
infected	O
with	O
the	O
Hantavirus	O
develops	O
a	O
pulmonary	O
syndrome	O
(	O
HPS	B-ENZY
)	O
characterized	O
by	O
severe	O
acute	O
respiratory	O
failure	O
and	O
myocardial	O
depression	O
,	O
that	O
has	O
a	O
high	O
mortality	O
rate	O
.	O

However	O
,	O
treatment	O
with	O
a	O
caspase	B-ENZY
-	I-ENZY
8	I-ENZY
inhibitor	O
only	O
slightly	O
blocked	O
cytochrome	O
c	O
release	O
from	O
the	O
mitochondria	O
.	O

Western	O
blot	O
analysis	O
using	O
phosphospecific	O
antibodies	O
indicated	O
that	O
7a	O
protein	O
activated	O
p38	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
(	O
MAPK	B-ENZY
),	O
but	O
not	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
protein	B-ENZY
kinase	I-ENZY
/	O
stress	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
.	O

ABSTRACT	O
:	O
Late	O
infantile	O
neuronal	O
ceroid	O
lipofuscinosis	O
(	O
LINCL	O
),	O
a	O
pediatric	O
autosomal	O
recessive	O
neurodegenerative	O
lysosomal	O
storage	O
disorder	O
,	O
results	O
from	O
mutations	O
in	O
the	O
CLN2	O
gene	O
and	O
consequent	O
deficiency	O
in	O
tripeptidyl	B-ENZY
-	I-ENZY
peptidase	I-ENZY
I	I-ENZY
(	O
TPP	B-ENZY
-	O
I	O
)	O
and	O
progressive	O
destruction	O
of	O
neurons	O
.	O

HPS	B-ENZY
has	O
a	O
mortality	O
rate	O
of	O
40	O
%	O
and	O
,	O
unlike	O
many	O
other	O
severe	O
respiratory	O
diseases	O
,	O
often	O
occurs	O
in	O
young	O
,	O
healthy	O
adults	O
.	O

In	O
addition	O
,	O
the	O
cell	O
-	O
cell	O
fusion	O
activity	O
of	O
S	O
was	O
monitored	O
by	O
a	O
Renilla	O
luciferase	B-ENZY
-	O
based	O
cell	O
-	O
cell	O
fusion	O
assay	O
.	O

PCA	O
significantly	O
increased	O
in	O
PBMC	O
in	O
patients	O
with	O
severe	O
AOC	O
hepatitis	O
B	O
.	O
The	O
molecular	O
and	O
cellular	O
results	O
reported	O
here	O
in	O
both	O
mice	O
and	O
patients	O
with	O
severe	O
viral	O
hepatitis	O
suggest	O
that	O
virus	O
-	O
induced	O
hfgl2	O
prothrombinase	B-ENZY
/	O
fibroleukin	O
expression	O
and	O
the	O
coagulation	O
activity	O
associated	O
with	O
the	O
encoded	O
fgl2	O
protein	O
play	O
a	O
pivotal	O
role	O
in	O
initiating	O
severe	O
hepatitis	O
.	O

We	O
assessed	O
the	O
changes	O
in	O
respiratory	O
mechanics	O
and	O
gas	B-ENZY
exchange	O
during	O
ARDS	O
.	O

Heart	O
rate	O
,	O
systemic	O
arterial	O
pressure	O
,	O
arterial	O
pH	O
,	O
blood	O
gas	B-ENZY
values	O
,	O
and	O
lung	O
mechanics	O
were	O
recorded	O
for	O
12	O
hours	O
.	O

Erysipelas	O
is	O
infrequently	O
associated	O
with	O
GGS	O
but	O
,	O
much	O
more	O
often	O
,	O
with	O
group	O
A	O
streptococci	O
(	O
GAS	B-ENZY
).	O

Ranked	O
by	O
the	O
luciferase	B-ENZY
activity	O
from	O
the	O
highest	O
to	O
the	O
lowest	O
,	O
the	O
order	O
is	O
A549	O
,	O
HepG2	O
,	O
ECV304	O
,	O
HeLa	O
and	O
Vero	O
E6	O
.	O

It	O
was	O
shown	O
,	O
by	O
in	O
vitro	O
translation	O
experiments	O
and	O
protein	O
sequencing	O
,	O
that	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
1	O
,	O
PL1	O
(	O
pro	O
),	O
but	O
not	O
a	O
mutant	O
derivative	O
containing	O
a	O
substitution	O
of	O
the	O
presumed	O
active	O
-	O
site	O
nucleophile	O
,	O
Cys	O
(	O
1093	O
),	O
cleaves	O
the	O
nsp2	O
|	O
nsp3	O
site	O
at	O
(	O
879	O
)	O
Gly	O
|	O
Gly	O
(	O
880	O
).	O

Of	O
22	O
samples	O
that	O
tested	O
positive	O
by	O
conventional	O
methods	O
,	O
15	O
tested	O
positive	O
for	O
the	O
same	O
pathogen	O
by	O
NAT	B-ENZY
,	O
1	O
tested	O
positive	O
for	O
a	O
different	O
pathogen	O
,	O
2	O
had	O
co	O
-	O
infections	O
identified	O
only	O
by	O
NAT	B-ENZY
,	O
and	O
4	O
tested	O
negative	O
by	O
NAT	B-ENZY
.	O

NAT	B-ENZY
improves	O
detection	O
of	O
potential	O
pathogens	O
from	O
ETT	O
and	O
BAL	B-ENZY
samples	O
.	O

These	O
viruses	O
resemble	O
influenza	O
C	O
viruses	O
because	O
they	O
share	O
not	O
only	O
the	O
receptor	O
determinant	O
,	O
but	O
also	O
the	O
presence	O
of	O
an	O
acetylesterase	B-ENZY
that	O
releases	O
the	O
9	O
-	O
O	O
-	O
acetyl	O
group	O
from	O
sialic	O
acid	O
and	O
thus	O
abolishes	O
the	O
ability	O
of	O
the	O
respective	O
sialoglycoconjugate	O
to	O
function	O
as	O
a	O
receptor	O
for	O
BCoV	O
.	O
As	O
in	O
the	O
case	O
of	O
influenza	O
viruses	O
,	O
the	O
receptor	O
-	O
destroying	O
enzyme	O
of	O
BCoV	O
is	O
believed	O
to	O
facilitate	O
the	O
spread	O
of	O
virus	O
infection	O
by	O
removing	O
receptor	O
determinants	O
from	O
the	O
surface	O
of	O
infected	O
cells	O
and	O
by	O
preventing	O
the	O
formation	O
of	O
virus	O
aggregates	O
.	O

Pulmonary	O
and	O
systemic	O
blood	O
pressures	O
,	O
heart	O
rate	O
,	O
and	O
lung	O
gas	B-ENZY
exchange	O
improved	O
in	O
all	O
the	O
patients	O
within	O
minutes	O
after	O
the	O
initiation	O
of	O
NO	O
administration	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
prevalence	O
of	O
pulmonary	O
hypertension	O
associated	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
to	O
asses	O
the	O
value	O
of	O
pulmonary	O
artery	O
trunk	O
diameter	O
(	O
PAT	B-ENZY
)	O
to	O
predict	O
pulmonary	O
hypertension	O
.	O

Gas	B-ENZY
exchange	O
,	O
respiratory	O
effort	O
,	O
and	O
hemodynamic	O
function	O
were	O
measured	O
,	O
and	O
ventilation	O
-	O
perfusion	O
distributions	O
were	O
calculated	O
by	O
multiple	O
inert	O
-	O
gas	B-ENZY
-	O
elimination	O
techniques	O
.	O

Among	O
these	O
proteins	O
,	O
the	O
alterations	O
of	O
fetuin	O
and	O
anti	O
-	O
chymotrypsin	B-ENZY
were	O
further	O
confirmed	O
by	O
Western	O
blotting	O
.	O

This	O
study	O
aims	O
to	O
characterize	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
caused	O
by	O
chlorine	O
gas	B-ENZY
(	O
Cl2	O
)	O
inhalation	O
in	O
a	O
large	O
-	O
animal	O
model	O
.	O

Fiberoptic	O
bronchoscopy	O
with	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
is	O
the	O
cornerstone	O
of	O
the	O
causal	O
diagnosis	O
.	O

Inhibitors	O
of	O
the	O
endosomal	O
cysteine	O
proteases	O
cathepsin	B-ENZY
B	I-ENZY
and	O
cathepsin	B-ENZY
L	I-ENZY
greatly	O
reduce	O
MHV	O
-	O
2	O
spike	O
-	O
mediated	O
entry	O
,	O
while	O
they	O
have	O
little	O
effect	O
on	O
A59	O
entry	O
,	O
suggesting	O
that	O
there	O
is	O
a	O
proteolytic	O
step	O
in	O
MHV	O
-	O
2	O
entry	O
.	O

Factors	O
significantly	O
associated	O
with	O
initial	O
CRP	O
concentration	O
>	O
47	O
.	O
5	O
mg	O
/	O
L	O
included	O
dyspnea	O
(	O
OR	O
=	O
4	O
.	O
3	O
),	O
red	O
blood	O
cell	O
count	O
<	O
4	O
.	O
1	O
x	O
106	O
/	O
microL	O
(	O
OR	O
=	O
4	O
.	O
3	O
)	O
and	O
serum	O
aspartate	B-ENZY
aminotransferase	I-ENZY
>	O
57	O
IU	O
/	O
L	O
(	O
OR	O
=	O
3	O
.	O
1	O
).	O

In	O
this	O
study	O
,	O
we	O
sampled	O
bat	B-ENZY
populations	O
in	O
15	O
provinces	O
of	O
China	O
and	O
reveal	O
that	O
approximately	O
6	O
.	O
5	O
%	O
of	O
the	O
bats	O
,	O
from	O
diverse	O
species	O
distributed	O
throughout	O
the	O
region	O
,	O
harbor	O
coronaviruses	O
.	O

The	O
cases	O
were	O
classified	O
as	O
dry	O
-	O
bite	O
(	O
n	O
=	O
1	O
,	O
caused	O
by	O
M	O
.	O
lemniscatus	O
;	O
did	O
not	O
receive	O
antivenom	O
),	O
mild	O
(	O
n	O
=	O
2	O
,	O
local	O
manifestations	O
with	O
no	O
acute	O
myasthenic	O
syndrome	O
;	O
M	O
.	O
frontalis	O
and	O
Micrurus	O
spp	B-ENZY
.),	O
moderate	O
(	O
n	O
=	O
5	O
,	O
mild	O
myasthenia	O
)	O
or	O
severe	O
(	O
n	O
=	O
3	O
,	O
important	O
myasthenia	O
;	O
one	O
of	O
them	O
caused	O
by	O
M	O
.	O
frontalis	O
).	O

In	O
contrast	O
,	O
AR	O
calves	O
had	O
low	O
antibody	O
titers	O
against	O
BCV	O
at	O
arrival	O
(	O
GMT	B-ENZY
,	O
102	O
)	O
and	O
64	O
%	O
shed	O
BCV	O
in	O
nasal	O
secretions	O
and	O
65	O
%	O
in	O
feces	O
.	O

Genetic	O
analysis	O
of	O
these	O
viruses	O
indicates	O
that	O
there	O
are	O
at	O
least	O
four	O
different	O
,	O
but	O
closely	O
related	O
,	O
group	O
1	O
coronaviruses	O
(	O
bat	B-ENZY
-	O
CoV	O
1A	O
,	O
1B	O
,	O
HKU7	O
and	O
HKU8	O
)	O
circulating	O
in	O
bent	O
-	O
winged	O
bats	O
.	O

Arterial	O
blood	O
gas	B-ENZY
,	O
white	O
blood	O
cell	O
count	O
in	O
bronchial	O
alveolar	O
lavage	O
fluid	O
,	O
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
and	O
interleukin	O
-	O
6	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
and	O
serum	O
were	O
measured	O
at	O
the	O
indicated	O
time	O
points	O
.	O

We	O
identified	O
19	O
CEAs	B-ENZY
published	O
through	O
2003	O
with	O
48	O
cost	O
-	O
effectiveness	O
ratios	O
pertaining	O
to	O
treatment	O
of	O
severe	O
sepsis	O
,	O
acute	O
respiratory	O
failure	O
,	O
and	O
general	O
critical	O
care	O
interventions	O
.	O

Middle	O
ear	O
fluid	O
(	O
MEF	O
)	O
was	O
tested	O
for	O
viral	O
pathogens	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
for	O
bacteria	O
by	O
gram	O
-	O
staining	O
and	O
culture	O
.	O

In	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
nsps	O
1	O
,	O
2	O
,	O
and	O
3	O
are	O
processed	O
by	O
two	O
papain	B-ENZY
-	O
like	O
proteinase	O
activities	O
within	O
nsp3	O
(	O
PLP1	O
and	O
PLP2	O
)	O
to	O
yield	O
nsp1	O
,	O
an	O
nsp2	O
-	O
3	O
intermediate	O
,	O
and	O
mature	O
nsp2	O
and	O
nsp3	O
.	O

This	O
model	O
was	O
further	O
utilized	O
to	O
design	O
small	O
molecules	O
that	O
are	O
expected	O
to	O
block	O
an	O
ATPase	B-ENZY
catalytic	O
pocket	O
thus	O
inhibit	O
the	O
enzymatic	O
activity	O
.	O

ORF1a	O
encodes	O
several	O
membrane	O
domains	O
,	O
a	O
putative	O
ADP	O
-	O
ribose	O
1	O
"""-"	O
phosphatase	O
,	O
and	O
a	O
chymotrypsin	B-ENZY
-	O
like	O
serine	O
protease	O
whose	O
activity	O
was	O
established	O
in	O
this	O
study	O
.	O

In	O
this	O
study	O
,	O
complete	O
genome	O
sequences	O
of	O
two	O
additional	O
group	O
2b	O
coronaviruses	O
(	O
G2b	O
-	O
CoVs	O
)	O
were	O
determined	O
from	O
horseshoe	O
bat	B-ENZY
Rhinolophus	O
ferrumequinum	O
(	O
G2b	O
-	O
CoV	O
Rf1	O
)	O
and	O
Rhinolophus	O
macrotis	O
(	O
G2b	O
-	O
CoV	O
Rm1	O
).	O

Although	O
a	O
SARS	O
-	O
like	O
coronavirus	O
isolated	O
from	O
a	O
bat	B-ENZY
is	O
thought	O
to	O
be	O
the	O
progenitor	O
of	O
SARS	O
-	O
CoV	O
,	O
a	O
lack	O
of	O
genomic	O
sequences	O
for	O
the	O
animal	O
coronaviruses	O
has	O
prevented	O
elucidation	O
of	O
the	O
true	O
origin	O
of	O
SARS	O
-	O
CoV	O
.	O
Sequence	O
analysis	O
of	O
SARS	O
-	O
CoV	O
shows	O
that	O
the	O
5	O
'	O
polymerase	O
gene	O
has	O
a	O
mammalian	O
ancestry	O
;	O
whereas	O
the	O
3	O
'	O
end	O
structural	O
genes	O
(	O
excluding	O
the	O
spike	O
glycoprotein	O
)	O
have	O
an	O
avian	O
origin	O
.	O

TITLE	O
:	O
Suppression	O
of	O
coronavirus	O
replication	O
by	O
inhibition	O
of	O
the	O
MEK	B-ENZY
signaling	O
pathway	O
.	O

Six	O
deaths	O
of	O
refractory	O
shock	O
included	O
4	O
who	O
had	O
ARDS	O
and	O
DIC	O
and	O
2	O
who	O
had	O
shock	O
with	O
DIC	O
3	O
patients	O
had	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-ENZY
)	O
has	O
not	O
been	O
previously	O
described	O
in	O
children	O
with	O
DSS	O
and	O
may	O
lead	O
to	O
fluid	O
refractory	O
shock	O
if	O
not	O
corrected	O
.	O

ABSTRACT	O
:	O
Feline	O
coronavirus	O
(	O
FCoV	O
),	O
porcine	O
transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
),	O
canine	O
coronavirus	O
(	O
CCoV	O
),	O
and	O
human	O
coronavirus	O
HCoV	O
-	O
229E	O
,	O
which	O
belong	O
to	O
the	O
group	O
1	O
coronavirus	O
,	O
use	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
APN	B-ENZY
)	O
of	O
their	O
natural	O
host	O
and	O
feline	O
APN	B-ENZY
(	O
fAPN	O
)	O
as	O
receptors	O
.	O

Phylogenetic	O
trees	O
constructed	O
using	O
chymotrypsin	B-ENZY
-	O
like	O
protease	O
,	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
,	O
helicase	O
,	O
spike	O
,	O
and	O
nucleocapsid	O
all	O
showed	O
that	O
the	O
group	O
2a	O
and	O
2b	O
and	O
putative	O
group	O
2c	O
and	O
2d	O
coronaviruses	O
are	O
more	O
closely	O
related	O
to	O
each	O
other	O
than	O
to	O
group	O
1	O
and	O
3	O
coronaviruses	O
.	O

Here	O
,	O
we	O
demonstrated	O
that	O
,	O
among	O
five	O
accessory	O
proteins	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
tested	O
,	O
3a	O
/	O
X1	O
and	O
7a	O
/	O
X4	O
were	O
capable	O
of	O
activating	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
and	O
c	B-ENZY
-	I-ENZY
Jun	I-ENZY
N	I-ENZY
-	I-ENZY
terminal	I-ENZY
kinase	I-ENZY
(	O
JNK	B-ENZY
),	O
and	O
significantly	O
enhanced	O
interleukin	O
8	O
(	O
IL	O
-	O
8	O
)	O
promoter	O
activity	O
.	O

The	O
RNase	B-ENZY
L	O
activity	O
associated	O
with	O
2	O
',	O
5	O
'-	O
oligoadenylate	O
synthetase	O
is	O
not	O
activated	O
or	O
is	O
blocked	O
,	O
since	O
cellular	O
RNA	O
is	O
not	O
degraded	O
.	O

In	O
Europe	O
,	O
primary	O
efforts	O
should	O
be	O
focussed	O
on	O
the	O
implementation	O
of	O
effective	O
passive	O
and	O
active	O
surveillance	O
systems	O
for	O
EBLVs	O
in	O
the	O
Serotine	O
bat	B-ENZY
,	O
Eptesicus	O
serotinus	O
,	O
and	O
Myotis	O
species	O
(	O
i	O
.	O
e	O
.,	O
M	O
.	O
daubentonii	O
and	O
M	O
.	O
dasycneme	O
).	O

TITLE	O
:	O
The	O
contribution	O
of	O
arterio	O
-	O
venous	O
extracorporeal	O
lung	O
assist	O
to	O
gas	B-ENZY
exchange	O
in	O
a	O
porcine	O
model	O
of	O
lavage	O
-	O
induced	O
acute	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
This	O
prospective	O
large	O
-	O
animal	O
study	O
was	O
performed	O
to	O
evaluate	O
the	O
contribution	O
of	O
arterio	O
-	O
venous	O
extracorporeal	O
lung	O
assist	O
(	O
AV	O
-	O
ECLA	O
)	O
to	O
pulmonary	O
gas	B-ENZY
exchange	O
in	O
a	O
porcine	O
lavage	O
-	O
induced	O
acute	O
lung	O
injury	O
model	O
.	O

This	O
result	O
suggests	O
that	O
not	O
only	O
E	O
.	O
R	O
.-	O
association	O
but	O
also	O
specific	O
protein	O
sequence	O
is	O
important	O
for	O
the	O
HCV	O
core	O
protein	O
signal	O
peptide	O
cleavage	O
by	O
SPP	B-ENZY
.	O

Commonly	O
to	O
other	O
animal	O
coronavirus	O
infection	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
is	O
likely	O
to	O
contribute	O
to	O
the	O
execution	O
phase	O
of	O
apoptosis	O
induced	O
by	O
CCoV	O
in	O
A	O
-	O
72	O
cells	O
since	O
we	O
found	O
activation	O
of	O
enzymatic	O
activity	O
as	O
well	O
as	O
procaspase	O
-	O
3	O
activating	O
cleavage	O
.	O

CONCLUSIONS	O
:	O
Caspase	B-ENZY
-	I-ENZY
1	I-ENZY
activation	O
,	O
and	O
overproduction	O
of	O
IL	O
-	O
1beta	O
and	O
IL	O
-	O
18	O
play	O
an	O
important	O
role	O
in	O
the	O
course	O
of	O
ALI	O
,	O
and	O
Caspase	B-ENZY
-	I-ENZY
1	I-ENZY
inhibition	O
is	O
effective	O
for	O
the	O
treatment	O
of	O
ALI	O
in	O
experimental	O
SAP	O
.	O

Both	O
PDK	B-ENZY
-	O
1	O
and	O
Akt	O
kinases	O
play	O
essential	O
roles	O
in	O
the	O
cell	O
survival	O
signaling	O
pathway	O
.	O

RESULTS	O
:	O
In	O
univariate	O
analyses	O
,	O
daily	O
average	O
temperature	O
(	O
DAT	B-ENZY
),	O
daily	O
average	O
air	O
pressure	O
(	O
DAAP	O
),	O
and	O
daily	O
average	O
relative	O
humidity	O
(	O
DARH	O
)	O
were	O
inversely	O
associated	O
with	O
secondary	O
attack	O
rate	O
(	O
P	O
<	O
0	O
.	O
001	O
);	O
a	O
significant	O
positive	O
association	O
was	O
found	O
for	O
daily	O
hours	O
of	O
sunshine	O
(	O
DHS	O
)	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

Results	O
from	O
this	O
study	O
show	O
that	O
free	O
-	O
ranging	O
maned	O
wolves	O
in	O
a	O
remote	O
area	O
of	O
Bolivia	O
have	O
been	O
exposed	O
to	O
multiple	O
infectious	O
and	O
parasitic	O
agents	O
of	O
domestic	O
carnivores	O
,	O
including	O
CAV	O
,	O
CDV	O
,	O
CPV	O
,	O
canine	O
coronavirus	O
,	O
rabies	O
virus	O
,	O
Leptospira	O
interrogans	O
spp	B-ENZY
.,	O
Toxoplasma	O
gondii	O
,	O
and	O
Dirofilaria	O
immitis	O
,	O
and	O
may	O
be	O
at	O
increased	O
risk	O
for	O
disease	O
due	O
to	O
these	O
agents	O
.	O

We	O
hypothesized	O
that	O
combined	O
HFO	O
and	O
TGI	O
(	O
HFO	O
-	O
TGI	O
)	O
might	O
result	O
in	O
improved	O
gas	B-ENZY
exchange	O
relative	O
to	O
both	O
standard	O
HFO	O
and	O
CMV	O
according	O
to	O
the	O
ARDS	O
Network	O
protocol	O
.	O

In	O
2005	O
,	O
horseshoe	O
bats	O
were	O
identified	O
as	O
the	O
natural	O
reservoir	O
of	O
a	O
group	O
of	O
coronaviruses	O
that	O
are	O
distantly	O
related	O
to	O
SARS	O
-	O
CoV	O
.	O
The	O
genome	O
sequences	O
of	O
bat	B-ENZY
SARS	O
-	O
like	O
coronavirus	O
had	O
about	O
88	O
-	O
92	O
%	O
nt	O
identity	O
with	O
that	O
of	O
the	O
SARS	O
-	O
CoV	O
.	O
The	O
prevalence	O
of	O
antibodies	O
and	O
viral	O
RNA	O
in	O
different	O
bat	B-ENZY
species	O
and	O
the	O
characteristics	O
of	O
the	O
bat	B-ENZY
SARS	O
-	O
like	O
coronavirus	O
were	O
elucidated	O
.	O

Newer	O
diagnostic	O
tests	O
such	O
as	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
have	O
greatly	O
expanded	O
our	O
understanding	O
of	O
the	O
importance	O
of	O
these	O
respiratory	O
viruses	O
.	O

In	O
particular	O
,	O
the	O
human	O
homologue	O
of	O
ACE	B-ENZY
(	O
ACE2	O
)	O
has	O
added	O
a	O
higher	O
level	O
of	O
complexity	O
to	O
the	O
RAAS	O
.	O

Our	O
results	O
show	O
that	O
type	O
I	O
feline	O
coronavirus	O
surface	O
glycoprotein	O
fails	O
to	O
recognize	O
feline	O
aminopeptidase	B-ENZY
N	I-ENZY
as	O
a	O
functional	O
receptor	O
on	O
three	O
continuous	O
feline	O
cell	O
lines	O
.	O

This	O
suggests	O
that	O
feline	O
aminopeptidase	B-ENZY
N	I-ENZY
is	O
not	O
a	O
receptor	O
for	O
type	O
I	O
feline	O
coronaviruses	O
.	O

The	O
final	O
rescue	O
therapy	O
for	O
patients	O
with	O
severe	O
hypoxia	O
refractory	O
to	O
conventional	O
therapy	O
modalities	O
is	O
the	O
extracorporeal	O
gas	B-ENZY
exchange	O
.	O

Proteasome	B-ENZY
inhibitors	O
,	O
such	O
as	O
lactacystin	O
and	O
NLVS	O
,	O
could	O
bypass	O
the	O
IBV	O
-	O
induced	O
S	O
-	O
phase	O
arrest	O
by	O
restoring	O
the	O
expression	O
of	O
corresponding	O
cyclin	O
/	O
Cdk	O
complexes	O
.	O

TITLE	O
:	O
The	O
two	O
fACEs	O
of	O
the	O
tissue	O
renin	B-ENZY
-	O
angiotensin	O
systems	O
:	O
implication	O
in	O
cardiovascular	O
diseases	O
.	O

Accordingly	O
,	O
many	O
pharmaceutical	O
inhibitors	O
have	O
been	O
developed	O
to	O
treat	O
several	O
pathologies	O
,	O
like	O
hypertension	O
and	O
heart	O
failure	O
,	O
and	O
angiotensin	O
converting	O
enzyme	O
(	O
ACE	B-ENZY
)	O
became	O
one	O
of	O
the	O
major	O
target	O
in	O
the	O
treatment	O
of	O
these	O
cardiovascular	O
diseases	O
.	O

Like	O
ACE	B-ENZY
,	O
ACE2	O
appears	O
to	O
hydrolyze	O
peptides	O
not	O
related	O
with	O
the	O
RAS	O
and	O
the	O
enzyme	O
has	O
also	O
been	O
identified	O
as	O
a	O
receptor	O
for	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
.	O

Ventilator	O
settings	O
were	O
able	O
to	O
be	O
adjusted	O
to	O
the	O
decreased	O
pulmonary	O
gas	B-ENZY
exchange	O
needs	O
,	O
making	O
protective	O
lung	O
strategies	O
possible	O
.	O

The	O
PAF	O
-	O
mediated	O
pressor	O
response	O
to	O
PLY	O
depends	O
on	O
thromboxane	O
and	O
on	O
the	O
downstream	O
effectors	O
phosphatidylcholine	O
-	O
specific	O
phospholipase	B-ENZY
C	I-ENZY
,	O
protein	B-ENZY
kinase	I-ENZY
C	I-ENZY
,	O
and	O
Rho	O
-	O
kinase	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
required	O
dose	O
and	O
anticoagulatory	O
effect	O
of	O
argatroban	O
(	O
Mitsubishi	O
,	O
Pharma	O
Deutschland	O
GmbH	O
,	O
Dsseldorf	O
,	O
Germany	O
),	O
a	O
direct	O
thrombin	B-ENZY
inhibitor	O
approved	O
for	O
anticoagulation	O
in	O
patients	O
with	O
heparin	O
-	O
induced	O
thrombocytopenia	O
(	O
HIT	O
)	O
undergoing	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
).	O

TITLE	O
:	O
The	O
use	O
of	O
hepatitis	O
C	O
virus	O
NS3	O
/	O
4A	O
and	O
secreted	O
alkaline	B-ENZY
phosphatase	I-ENZY
to	O
quantitate	O
cell	O
-	O
cell	O
membrane	O
fusion	O
mediated	O
by	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
S	O
protein	O
and	O
the	O
receptor	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
.	O

Phospholipase	B-ENZY
C	I-ENZY
treatment	O
of	O
the	O
lung	O
and	O
tracheal	O
tissue	O
homogenates	O
from	O
IBV	O
-	O
positive	O
chickens	O
increased	O
the	O
detection	O
limit	O
for	O
M	O
-	O
41	O
strain	O
from	O
1	O
.	O
3	O
%	O
positive	O
samples	O
in	O
simple	O
hemagglutination	O
assay	O
to	O
30	O
.	O
6	O
%	O
positivity	O
when	O
the	O
same	O
samples	O
were	O
treated	O
with	O
phospholipase	B-ENZY
C	I-ENZY
.	O
Similarly	O
,	O
reverse	O
transcription	O
-	O
PCR	O
was	O
a	O
much	O
better	O
M	O
-	O
41	O
detection	O
tool	O
as	O
compared	O
with	O
the	O
classical	O
agar	O
gel	O
precipitation	O
assay	O
utilized	O
to	O
screen	O
tissue	O
homogenates	O
from	O
IBV	O
-	O
positive	O
chickens	O
.	O

While	O
it	O
is	O
generalized	O
that	O
3CL	O
(	O
pro	O
)	O
and	O
the	O
structurally	O
related	O
3C	O
(	O
pro	O
)	O
viral	O
peptidases	O
cleave	O
their	O
substrates	O
via	O
a	O
mechanism	O
similar	O
to	O
that	O
underlying	O
the	O
peptide	O
hydrolysis	O
by	O
chymotrypsin	B-ENZY
-	O
like	O
serine	O
proteinases	O
(	O
CLSPs	O
),	O
some	O
of	O
the	O
hypothesized	O
key	O
intermediates	O
have	O
not	O
been	O
structurally	O
characterized	O
.	O

The	O
SARS	O
-	O
CoV	O
/	O
GAPDH	B-ENZY
RNA	O
ratio	O
remained	O
relatively	O
stable	O
in	O
most	O
organ	O
tissue	O
types	O
for	O
all	O
these	O
time	O
durations	O
.	O

Complete	O
genome	O
sequencing	O
of	O
four	O
strains	O
of	O
bat	B-ENZY
-	O
CoV	O
HKU2	O
revealed	O
the	O
smallest	O
coronavirus	O
genome	O
(	O
27164	O
nucleotides	O
)	O
and	O
a	O
unique	O
spike	O
protein	O
evolutionarily	O
distinct	O
from	O
the	O
rest	O
of	O
the	O
genome	O
.	O

Three	O
consecutive	O
bronchoalveolar	O
lavages	O
(	O
BAL	B-ENZY
)	O
were	O
performed	O
shortly	O
after	O
intubation	O
(	O
T0	O
),	O
and	O
four	O
days	O
(	O
T1	O
)	O
and	O
eight	O
days	O
(	O
T2	O
)	O
after	O
intubation	O
.	O

ABSTRACT	O
:	O
Prone	O
position	O
is	O
used	O
to	O
treat	O
patients	O
with	O
acute	O
lung	O
injury	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
because	O
it	O
improves	O
gas	B-ENZY
exchange	O
and	O
respiratory	O
mechanics	O
.	O

Expression	O
of	O
M	O
suppressed	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
induced	O
NF	O
-	O
kappaB	O
activation	O
using	O
a	O
luciferase	B-ENZY
reporter	O
assay	O
.	O

Of	O
240	O
patients	O
registered	O
with	O
SCD	O
,	O
52	O
(	O
22	O
%)	O
developed	O
55	O
episodes	O
of	O
ACS	B-ENZY
.	O

Prevention	O
of	O
VOCs	O
,	O
prompt	O
and	O
effective	O
treatment	O
of	O
respiratory	O
infections	O
and	O
caution	O
in	O
the	O
use	O
of	O
morphine	O
during	O
a	O
VOC	O
should	O
reduce	O
the	O
incidence	O
of	O
ACS	B-ENZY
.	O

Between	O
September	O
19	O
and	O
December	O
31	O
,	O
2003	O
,	O
64	O
suspected	O
cases	O
of	O
ARD	B-ENZY
were	O
reported	O
;	O
of	O
these	O
reported	O
cases	O
,	O
21	O
(	O
33	O
%)	O
died	O
.	O

Although	O
airway	O
cells	O
secrete	O
TNF	O
-	O
alpha	O
in	O
response	O
to	O
ricin	O
,	O
blocking	O
TNF	O
-	O
alpha	O
did	O
not	O
prevent	O
ricin	O
-	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O
Decreased	O
levels	O
of	O
IkappaB	O
-	O
alpha	O
in	O
airway	O
cells	O
exposed	O
to	O
ricin	O
suggest	O
that	O
translational	O
suppression	O
may	O
be	O
responsible	O
for	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O
Inhibition	O
of	O
p38	O
MAPK	B-ENZY
by	O
a	O
chemical	O
inhibitor	O
or	O
NF	O
-	O
kappaB	O
by	O
short	O
interfering	O
RNA	O
resulted	O
in	O
a	O
marked	O
reduction	O
in	O
the	O
expression	O
of	O
proinflammatory	O
genes	O
,	O
demonstrating	O
the	O
importance	O
of	O
these	O
two	O
pathways	O
in	O
ricin	O
intoxication	O
.	O

Therefore	O
,	O
the	O
p38	O
MAPK	B-ENZY
and	O
NF	O
-	O
kappaB	O
pathways	O
are	O
potential	O
therapeutic	O
targets	O
for	O
reducing	O
the	O
inflammatory	O
consequences	O
of	O
ricin	O
poisoning	O
.	O

The	O
univariate	O
analysis	O
and	O
multivariate	O
analysis	O
demonstrated	O
that	O
the	O
clinical	O
conditions	O
such	O
as	O
elder	O
age	O
,	O
shock	O
,	O
dyspnea	O
,	O
abnormal	O
arterial	O
blood	O
gas	B-ENZY
,	O
hemopneumothorax	O
,	O
pulmonary	O
contusion	O
,	O
flail	O
chest	O
,	O
coexisting	O
pulmonary	O
diseases	O
,	O
multiple	O
abdominal	O
injury	O
and	O
high	O
ISS	O
score	O
were	O
the	O
independent	O
high	O
risk	O
factors	O
related	O
to	O
ARDS	O
.	O

Most	O
importantly	O
,	O
our	O
results	O
provide	O
the	O
structural	O
basis	O
for	O
rational	O
design	O
of	O
wide	O
-	O
spectrum	O
antiviral	O
drugs	O
targeting	O
the	O
chymotrypsin	B-ENZY
-	O
like	O
cysteine	O
proteinases	O
from	O
coronaviruses	O
and	O
picornaviruses	O
.	O

Reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
on	O
the	O
partial	O
ORF3	O
gene	O
including	O
51	O
nucleotide	O
deletions	O
revealed	O
that	O
all	O
PEDVs	O
fell	O
into	O
two	O
types	O
,	O
wild	O
-	O
and	O
attenuated	O
-	O
type	O
PEDVs	O
.	O

The	O
discovery	O
of	O
this	O
virus	O
was	O
soon	O
followed	O
by	O
the	O
discovery	O
of	O
the	O
civet	O
and	O
bat	B-ENZY
SARS	O
-	O
CoV	O
and	O
the	O
human	O
coronaviruses	O
NL63	O
and	O
HKU1	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
bismuth	O
complexes	O
were	O
synthesized	O
and	O
characterized	O
,	O
and	O
most	O
of	O
them	O
exhibited	O
inhibition	O
against	O
the	O
SARS	O
coronavirus	O
helicase	O
ATPase	B-ENZY
and	O
duplex	O
-	O
unwinding	O
activities	O
at	O
micromolar	O
concentrations	O
.	O

ABSTRACT	O
:	O
The	O
contribution	O
of	O
DRAK2	O
[	O
death	O
-	O
associated	O
protein	B-ENZY
kinase	I-ENZY
(	O
DAPK	O
)-	O
related	O
apoptosis	O
-	O
inducing	O
kinase	O
2	O
]	O
to	O
anti	O
-	O
viral	O
memory	O
T	O
cell	O
responses	O
following	O
infection	O
with	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
was	O
examined	O
.	O

In	O
alveolar	O
epithelial	O
cells	O
exposed	O
to	O
severe	O
hypoxia	O
,	O
we	O
have	O
reported	O
that	O
increased	O
production	O
of	O
mitochondrial	O
reactive	O
oxygen	O
species	O
leads	O
to	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
endocytosis	O
and	O
degradation	O
.	O

ABSTRACT	O
:	O
A	O
phase	O
I	O
trial	O
was	O
initiated	O
to	O
establish	O
the	O
dose	O
-	O
limiting	O
toxicities	O
(	O
DLTs	O
)	O
and	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	B-ENZY
)	O
of	O
chronomodulated	O
5	O
-	O
fluorouracil	O
and	O
cisplatin	O
given	O
concurrently	O
with	O
preoperative	O
radiotherapy	O
in	O
patients	O
with	O
esophageal	O
cancer	O
.	O

TITLE	O
:	O
Association	O
between	O
urokinase	B-ENZY
haplotypes	O
and	O
outcome	O
from	O
infection	O
-	O
associated	O
acute	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
Alterations	O
in	O
coagulation	O
,	O
including	O
elevated	O
pulmonary	O
and	O
systemic	O
concentrations	O
of	O
urokinase	B-ENZY
,	O
are	O
frequent	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
(	O
ALI	O
).	O

Genetic	O
polymorphisms	O
and	O
haplotypes	O
in	O
the	O
urokinase	B-ENZY
gene	O
were	O
determined	O
.	O

These	O
results	O
identify	O
a	O
specific	O
urokinase	B-ENZY
haplotype	O
as	O
a	O
genetic	O
risk	O
factor	O
for	O
higher	O
mortality	O
and	O
more	O
severe	O
clinical	O
outcome	O
in	O
patients	O
with	O
infection	O
-	O
associated	O
ALI	O
.	O

Compression	O
-	O
only	O
CPR	B-ENZY
was	O
preferred	O
to	O
SCPR	O
to	O
resuscitate	O
strangers	O
experiencing	O
cardiac	O
arrest	O
after	O
the	O
emergence	O
of	O
SARS	O
.	O

Based	O
on	O
this	O
relatively	O
short	O
window	O
period	O
,	O
we	O
speculate	O
that	O
this	O
uncharacterized	O
SLCoV	O
lineage	O
may	O
contain	O
the	O
direct	O
ancestor	O
of	O
SCoV	O
.	O
This	O
study	O
sheds	O
light	O
on	O
the	O
possible	O
host	O
bat	B-ENZY
species	O
of	O
the	O
direct	O
ancestor	O
of	O
SCoV	O
,	O
providing	O
valuable	O
information	O
on	O
the	O
scope	O
and	O
focus	O
of	O
surveillance	O
for	O
the	O
origin	O
of	O
SCoV	O
.	O

The	O
ACE	B-ENZY
I	O
/	O
D	O
polymorphism	O
was	O
associated	O
neither	O
with	O
sepsis	O
-	O
induced	O
ARDS	O
susceptibility	O
(	O
p	O
=	O
0	O
.	O
895	O
)	O
or	O
mortality	O
(	O
p	O
=	O
0	O
.	O
950	O
).	O

Gas	B-ENZY
exchange	O
was	O
severely	O
impaired	O
and	O
a	O
chest	O
x	O
-	O
ray	O
indicated	O
chemical	O
pneumonitis	O
.	O

TITLE	O
:	O
Difference	O
in	O
receptor	O
usage	O
between	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
and	O
SARS	O
-	O
like	O
coronavirus	O
of	O
bat	B-ENZY
origin	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
receptor	O
usage	O
of	O
the	O
SL	O
-	O
CoV	O
S	O
by	O
combining	O
a	O
human	O
immunodeficiency	O
virus	O
-	O
based	O
pseudovirus	O
system	O
with	O
cell	O
lines	O
expressing	O
the	O
ACE2	O
molecules	O
of	O
human	O
,	O
civet	O
,	O
or	O
horseshoe	O
bat	B-ENZY
.	O

In	O
this	O
study	O
,	O
RNA	O
aptamers	O
against	O
SCV	O
NTPase	B-ENZY
/	O
Helicase	O
(	O
nsP10	O
)	O
were	O
isolated	O
from	O
RNA	O
library	O
containing	O
random	O
sequences	O
of	O
40	O
nts	O
using	O
in	O
vitro	O
selection	O
technique	O
.	O

TITLE	O
:	O
Detection	O
of	O
12	O
respiratory	O
viruses	O
with	O
two	O
-	O
set	O
multiplex	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
PCR	O
assay	O
using	O
a	O
dual	O
priming	O
oligonucleotide	O
system	O
.	O

However	O
,	O
hACE2	O
-	O
dependent	O
entry	O
of	O
trypsin	B-ENZY
-	O
treated	O
retrovirus	O
pseudotyped	O
viruses	O
expressing	O
JMD	O
mutant	O
S	O
Delta19	O
proteins	O
was	O
greatly	O
reduced	O
.	O

A	O
patient	O
with	O
SAP	O
developed	O
manifest	O
ACS	B-ENZY
and	O
was	O
treated	O
with	O
bilateral	O
subcostal	O
laparostomy	O
.	O

The	O
predominant	O
organisms	O
include	O
Enterobacteriaceae	O
(	O
i	O
.	O
e	O
.,	O
Escherichia	O
coli	O
,	O
Klebsiella	O
pneumoniae	O
)	O
,	O
Clostridium	O
spp	B-ENZY
.,	O
enteric	O
pathogens	O
(	O
salmonellae	O
,	O
Coxsackie	O
B2	O
virus	O
,	O
coronavirus	O
,	O
rotavirus	O
),	O
and	O
potential	O
pathogens	O
(	O
Bacteroides	O
fragilis	O
).	O

We	O
show	O
that	O
3CLpro	O
has	O
mechanistic	O
features	O
common	O
and	O
disparate	O
to	O
the	O
archetypical	O
proteases	O
papain	B-ENZY
and	O
chymotrypsin	B-ENZY
.	O

TITLE	O
:	O
Glucose	B-ENZY
-	I-ENZY
6	I-ENZY
-	I-ENZY
phosphate	I-ENZY
dehydrogenase	I-ENZY
deficiency	O
enhances	O
human	O
coronavirus	O
229E	O
infection	O
.	O

Accordingly	O
,	O
ectopic	O
expression	O
of	O
G6PD	B-ENZY
in	O
G6PD	B-ENZY
-	O
deficient	O
cells	O
or	O
addition	O
of	O
antioxidant	O
(	O
such	O
as	O
alpha	O
-	O
lipoic	O
acid	O
)	O
to	O
G6PD	B-ENZY
-	O
knockdown	O
cells	O
attenuated	O
the	O
increased	O
susceptibility	O
to	O
HCoV	O
229E	O
infection	O
.	O

Although	O
decreased	O
in	O
BAL	B-ENZY
,	O
Th2	O
cytokine	O
levels	O
were	O
higher	O
in	O
serum	O
after	O
DEX	O
treatment	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
focus	O
on	O
the	O
recent	O
findings	O
related	O
to	O
the	O
ACE2	O
-	O
Ang	O
(	O
1	O
-	O
7	O
)-	O
Mas	O
axis	O
and	O
,	O
in	O
particular	O
,	O
on	O
its	O
putative	O
role	O
as	O
an	O
ACE	B-ENZY
-	O
Ang	O
II	O
-	O
AT	O
(	O
1	O
)	O
receptor	O
counter	O
-	O
regulatory	O
axis	O
within	O
the	O
RAS	O
.	O

Notably	O
,	O
injection	O
of	O
SARS	O
-	O
CoV	O
Spike	O
into	O
mice	O
worsens	O
acute	O
lung	O
failure	O
in	O
vivo	O
that	O
can	O
be	O
attenuated	O
by	O
blocking	O
the	O
renin	B-ENZY
-	O
angiotensin	O
pathway	O
,	O
suggesting	O
the	O
activation	O
of	O
pulmonary	O
RAS	O
influences	O
the	O
pathogenesis	O
of	O
ARDS	O
and	O
SARS	O
.	O

Chronic	O
alcohol	O
ingestion	O
increases	O
expression	O
of	O
apical	O
sodium	O
channels	O
in	O
the	O
alveolar	O
epithelium	O
;	O
however	O
,	O
its	O
effects	O
on	O
the	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
complex	O
that	O
drives	O
sodium	O
and	O
fluid	O
transport	O
out	O
of	O
the	O
alveolar	O
space	O
have	O
not	O
been	O
examined	O
.	O

TITLE	O
:	O
Structural	O
,	O
biochemical	O
,	O
and	O
in	O
vivo	O
characterization	O
of	O
the	O
first	O
virally	O
encoded	O
cyclophilin	B-ENZY
from	O
the	O
Mimivirus	O
.	O

TITLE	O
:	O
Analysis	O
of	O
the	O
mechanism	O
of	O
antibody	O
-	O
dependent	O
enhancement	O
of	O
feline	O
infectious	O
peritonitis	O
virus	O
infection	O
:	O
aminopeptidase	B-ENZY
N	I-ENZY
is	O
not	O
important	O
and	O
a	O
process	O
of	O
acidification	O
of	O
the	O
endosome	O
is	O
necessary	O
.	O

TITLE	O
:	O
Genomic	O
characterizations	O
of	O
bat	B-ENZY
coronaviruses	O
(	O
1A	O
,	O
1B	O
and	O
HKU8	O
)	O
and	O
evidence	O
for	O
co	O
-	O
infections	O
in	O
Miniopterus	O
bats	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
reported	O
the	O
detection	O
of	O
bat	B-ENZY
coronaviruses	O
(	O
bat	B-ENZY
CoVs	O
1A	O
,	O
1B	O
,	O
HKU7	O
,	O
HKU8	O
and	O
bat	B-ENZY
-	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
)	O
in	O
Miniopterus	O
spp	B-ENZY
.	O

Interestingly	O
,	O
co	O
-	O
infections	O
of	O
bat	B-ENZY
CoVs	O
1B	O
and	O
HKU8	O
in	O
M	O
.	O
pusillus	O
are	O
detected	O
in	O
seven	O
of	O
38	O
virus	O
-	O
positive	O
specimens	O
collected	O
from	O
2004	O
to	O
2006	O
.	O

TITLE	O
:	O
Importance	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
Trp	B-ENZY
-	O
rich	O
region	O
in	O
viral	O
infectivity	O
.	O

To	O
investigate	O
the	O
importance	O
of	O
Trp	B-ENZY
-	O
rich	O
region	O
in	O
SARS	O
-	O
CoV	O
entry	O
,	O
we	O
produced	O
different	O
mutated	O
S	O
proteins	O
using	O
Alanine	O
scan	O
strategy	O
.	O

After	O
a	O
median	O
duration	O
of	O
18	O
(	O
range	O
,	O
14	O
-	O
27	O
)	O
hours	O
in	O
PP	O
,	O
PaO	B-ENZY
(	O
2	O
)/	O
F	O
(	O
I	O
)	O
O	O
(	O
2	O
)	O
improved	O
in	O
14	O
(	O
87	O
.	O
5	O
%)	O
patients	O
.	O

Microscopic	O
examination	O
and	O
blood	O
gas	B-ENZY
analysis	O
indicated	O
severe	O
injury	O
of	O
the	O
lung	O
tissues	O
in	O
ALI	O
group	O
.	O

(	O
2	O
)	O
Caspase	B-ENZY
-	I-ENZY
3	I-ENZY
,	O
p73	O
mRNA	O
expressions	O
in	O
lung	O
tissue	O
in	O
HFOV	O
group	O
and	O
HFOV	O
+	O
PS	O
group	O
were	O
significantly	O
lower	O
than	O
those	O
of	O
CMV	O
group	O
and	O
CMV	O
+	O
PS	O
group	O
(	O
all	O
P	O
<	O
0	O
.	O
01	O
).	O

Caspase	B-ENZY
-	I-ENZY
3	I-ENZY
and	O
p73	O
mRNA	O
expression	O
in	O
lung	O
tissue	O
in	O
groups	O
with	O
exogenous	O
PS	O
group	O
were	O
significantly	O
lower	O
than	O
those	O
of	O
the	O
corresponding	O
group	O
without	O
exogenous	O
PS	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
A	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
for	O
the	O
detection	O
of	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
RNA	O
in	O
clinical	O
samples	O
is	O
described	O
.	O

In	O
addition	O
,	O
both	O
cathepsin	B-ENZY
B	I-ENZY
and	O
cathepsin	B-ENZY
L	I-ENZY
are	O
able	O
to	O
induce	O
a	O
specific	O
cleavage	O
event	O
in	O
the	O
FECV	O
-	O
1683	O
spike	O
protein	O
.	O

Patients	O
having	O
cardiac	O
arrest	O
requiring	O
CPR	B-ENZY
or	O
acute	O
renal	O
failure	O
requiring	O
dialysis	O
before	O
ECLS	O
may	O
have	O
inferior	O
ECLS	O
outcomes	O
.	O

In	O
direct	O
Annexin	O
V	O
staining	O
assays	O
,	O
the	O
3a	O
protein	O
-	O
expressing	O
cells	O
showed	O
increased	O
apoptosis	O
that	O
was	O
attenuated	O
with	O
the	O
p38	O
MAPK	B-ENZY
inhibitor	O
SB203580	O
.	O

During	O
pulmonary	O
tissue	O
injury	O
an	O
endogenous	O
secretory	O
isoform	O
of	O
RAGE	O
called	O
EsRAGE	O
is	O
noticed	O
at	O
high	O
levels	O
in	O
broncho	O
-	O
alveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
and	O
plasma	O
.	O

Challenge	O
of	O
saline	O
(	O
SAL	O
)-	O
pretreated	O
animals	O
with	O
LPS	O
resulted	O
in	O
lung	O
injury	O
as	O
evidenced	O
by	O
increases	O
in	O
wet	O
lung	O
weight	O
(	O
edema	O
),	O
increases	O
in	O
lipid	O
peroxidation	O
(	O
marker	O
of	O
oxidative	O
stress	O
),	O
decreases	O
of	O
lung	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	B-ENZY
)	O
(	O
injury	O
marker	O
for	O
pulmonary	O
endothelial	O
cells	O
)	O
and	O
increases	O
in	O
the	O
pro	O
-	O
inflammatory	O
eicosanoids	O
,	O
thromboxane	O
B	O
(	O
2	O
)	O
and	O
leukotriene	O
B	O
(	O
4	O
).	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
known	O
to	O
take	O
an	O
endosomal	O
pathway	O
for	O
cell	O
entry	O
;	O
however	O
,	O
it	O
is	O
thought	O
to	O
enter	O
directly	O
from	O
the	O
cell	O
surface	O
when	O
a	O
receptor	O
-	O
bound	O
virion	O
spike	O
(	O
S	O
)	O
protein	O
is	O
affected	O
by	O
trypsin	B-ENZY
,	O
which	O
induces	O
cleavage	O
of	O
the	O
S	O
protein	O
and	O
activates	O
its	O
fusion	O
potential	O
.	O

ABSTRACT	O
:	O
We	O
present	O
three	O
cases	O
of	O
patients	O
(	O
at	O
the	O
age	O
of	O
56	O
years	O
,	O
49	O
years	O
and	O
74	O
years	O
respectively	O
)	O
with	O
severe	O
acute	O
pancreatitis	O
(	O
SAP	O
),	O
complicated	O
by	O
intra	O
-	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-ENZY
)	O
and	O
respiratory	O
insufficiency	O
with	O
limitations	O
of	O
mechanical	O
ventilation	O
.	O

HCV	O
was	O
associated	O
with	O
greater	O
risk	O
of	O
progression	O
to	O
severe	O
liver	O
failure	O
(	O
aOR	B-ENZY
3	O
.	O
55	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
88	O
-	O
6	O
.	O
70	O
).	O

Further	O
studies	O
would	O
be	O
important	O
to	O
delineate	O
whether	O
the	O
Asian	O
leopard	O
cat	O
CoV	O
was	O
a	O
result	O
of	O
interspecies	O
jumping	O
from	O
birds	O
,	O
a	O
situation	O
analogous	O
to	O
that	O
of	O
bat	B-ENZY
and	O
civet	O
severe	O
acute	O
respiratory	O
syndrome	O
CoVs	O
.	O

These	O
results	O
demonstrate	O
that	O
nAb	O
-	O
mediated	O
immune	O
pressure	O
is	O
likely	O
a	O
driving	O
force	O
for	O
positive	O
selection	O
during	O
intra	O
-	O
species	O
transmission	O
of	O
SARS	O
-	O
CoV	O
.	O
Somatic	O
hypermutation	O
(	O
SHM	O
)	O
of	O
a	O
single	O
VL	O
CDR	B-ENZY
can	O
markedly	O
broaden	O
the	O
activity	O
of	O
a	O
strain	O
-	O
specific	O
nAb	O
.	O

The	O
chest	O
X	O
-	O
ray	O
showed	O
some	O
signs	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
in	O
spite	O
of	O
normal	O
blood	O
gas	B-ENZY
values	O
.	O

ABSTRACT	O
:	O
The	O
helicase	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
possesses	O
NTPase	B-ENZY
,	O
duplex	O
RNA	O
/	O
DNA	O
-	O
unwinding	O
and	O
RNA	O
-	O
capping	O
activities	O
that	O
are	O
essential	O
for	O
viral	O
replication	O
and	O
proliferation	O
.	O

TITLE	O
:	O
Efficiency	O
in	O
extracorporeal	O
membrane	O
oxygenation	O
-	O
cellular	O
deposits	O
on	O
polymethylpentene	O
membranes	O
increase	O
resistance	O
to	O
blood	O
flow	O
and	O
reduce	O
gas	B-ENZY
exchange	O
capacity	O
.	O

However	O
,	O
in	O
some	O
patients	O
,	O
long	O
-	O
term	O
durability	O
is	O
limited	O
due	O
to	O
fibrous	O
and	O
cellular	O
accumulations	O
on	O
the	O
gas	B-ENZY
exchange	O
surface	O
which	O
can	O
increase	O
resistance	O
to	O
blood	O
flow	O
and	O
diffusion	O
path	O
.	O

This	O
system	O
enabled	O
high	O
-	O
throughput	O
analysis	O
of	O
SARS	O
-	O
CoV	O
S	O
protein	O
-	O
mediated	O
cell	O
entry	O
by	O
measuring	O
alkaline	B-ENZY
phosphatase	I-ENZY
activity	O
.	O

In	O
addition	O
to	O
the	O
cellular	O
receptor	O
,	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
,	O
the	O
TGEV	O
spike	O
protein	O
binds	O
to	O
sialic	O
acid	O
residues	O
.	O

ABSTRACT	O
:	O
The	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
of	O
acylthiocarbamates	O
(	O
ATCs	O
),	O
a	O
new	O
class	O
of	O
non	O
-	O
nucleoside	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
inhibitors	O
,	O
have	O
been	O
expanded	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
infection	O
of	O
293	O
/	O
ACE2	O
cells	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
activated	O
several	O
apoptosis	O
-	O
associated	O
events	O
,	O
namely	O
,	O
cleavage	O
of	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
,	O
caspase	B-ENZY
-	I-ENZY
8	I-ENZY
,	O
and	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
1	O
(	O
PARP	O
),	O
and	O
chromatin	O
condensation	O
and	O
the	O
phosphorylation	O
and	O
hence	O
inactivation	O
of	O
the	O
eukaryotic	O
translation	O
initiation	O
factor	O
2alpha	O
(	O
eIF2alpha	O
).	O

We	O
identified	O
a	O
reference	O
data	O
set	O
of	O
624	O
mechanically	O
-	O
ventilated	O
patients	O
in	O
the	O
MIMIC	O
-	O
II	O
intensive	O
care	O
database	O
with	O
and	O
without	O
low	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratios	O
(	O
termed	O
respiratory	O
instability	O
),	O
and	O
developed	O
prediction	O
algorithms	O
for	O
distinguishing	O
these	O
patients	O
prior	O
to	O
the	O
critical	O
event	O
.	O

Follow	O
-	O
up	O
was	O
conducted	O
for	O
14	O
days	O
to	O
observe	O
the	O
clinical	O
manifestation	O
,	O
and	O
time	O
of	O
ventilatory	O
support	O
,	O
arterial	O
blood	O
gas	B-ENZY
analysis	O
and	O
radiological	O
examination	O
of	O
chest	O
were	O
performed	O
.	O

Phosphate	O
release	O
assay	O
and	O
FRET	O
-	O
based	O
assay	O
of	O
the	O
ADK	O
analogues	O
showed	O
that	O
the	O
ADKs	O
selectively	O
inhibit	O
the	O
duplex	O
DNA	O
-	O
unwinding	O
activity	O
without	O
significant	O
impact	O
on	O
the	O
helicase	O
ATPase	B-ENZY
activity	O
.	O

TITLE	O
:	O
Suppression	O
of	O
host	O
gene	O
expression	O
by	O
nsp1	O
proteins	O
of	O
group	O
2	O
bat	B-ENZY
coronaviruses	O
.	O

TITLE	O
:	O
A	O
coronavirus	O
detected	O
in	O
the	O
vampire	O
bat	B-ENZY
Desmodus	O
rotundus	O
.	O

Phylogenetic	O
analysis	O
of	O
ORF1b	O
revealed	O
that	O
BatCoV	O
DR	O
/	O
2007	O
originates	O
from	O
a	O
unique	O
lineage	O
in	O
the	O
archetypical	O
group	O
2	O
coronaviruses	O
,	O
as	O
described	O
for	O
bat	B-ENZY
species	O
elsewhere	O
with	O
putative	O
importance	O
in	O
Public	O
Health	O
.	O

In	O
the	O
case	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
it	O
has	O
been	O
shown	O
that	O
virus	O
entry	O
requires	O
the	O
endosomal	O
protease	O
cathepsin	B-ENZY
L	I-ENZY
;	O
however	O
,	O
it	O
was	O
also	O
found	O
that	O
infection	O
of	O
SARS	O
-	O
CoV	O
could	O
be	O
strongly	O
induced	O
by	O
trypsin	B-ENZY
treatment	O
.	O

Most	O
neonates	O
receiving	O
ECMO	O
suffer	O
from	O
meconium	O
aspiration	O
syndrome	O
(	O
MAS	O
),	O
congenital	O
diaphragmatic	O
hernia	O
(	O
CDH	B-ENZY
),	O
sepsis	O
or	O
persistent	O
pulmonary	O
hypertension	O
(	O
PPH	B-ENZY
).	O

It	O
was	O
noted	O
that	O
in	O
severe	O
lung	O
injury	O
,	O
myeloperoxidase	B-ENZY
activity	O
in	O
the	O
blood	O
increased	O
significantly	O
,	O
but	O
still	O
reflected	O
the	O
processes	O
taking	O
place	O
in	O
the	O
lung	O
parenchyma	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
papain	B-ENZY
-	O
like	O
protease	O
ubiquitin	O
-	O
like	O
domain	O
and	O
catalytic	O
domain	O
regulate	O
antagonism	O
of	O
IRF3	O
and	O
NF	O
-	O
kappaB	O
signaling	O
.	O

ABSTRACT	O
:	O
In	O
the	O
search	O
for	O
effective	O
therapeutics	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
6	O
-	O
mercaptopurine	O
(	O
6MP	O
)	O
and	O
6	O
-	O
thioguanine	O
(	O
6TG	O
)	O
were	O
found	O
to	O
be	O
specific	O
inhibitors	O
for	O
the	O
SARS	O
-	O
coronavirus	O
(	O
CoV	O
)	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
),	O
a	O
cysteine	O
protease	O
with	O
deubiquitinating	O
and	O
deISGylating	O
activity	O
.	O

TITLE	O
:	O
Molecular	O
screening	O
and	O
risk	O
factors	O
of	O
enterotoxigenic	O
Escherichia	O
coli	O
and	O
Salmonella	O
spp	B-ENZY
.	O

Infection	O
with	O
Salmonella	O
spp	B-ENZY
.	O
was	O
found	O
to	O
be	O
significantly	O
affected	O
by	O
the	O
animal	O
age	O
(	O
P	O
<	O
0	O
.	O
05	O
;	O
OR	O
:	O
0	O
.	O
376	O
;	O
CI	O
95	O
%:	O
0	O
.	O
511	O
-	O
1	O
.	O
369	O
),	O
Hygiene	O
(	O
P	O
<	O
0	O
.	O
05	O
;	O
OR	O
:	O
0	O
.	O
628	O
;	O
CI	O
95	O
%:	O
1	O
.	O
729	O
-	O
5	O
.	O
612	O
),	O
and	O
region	O
(	O
P	O
<	O
0	O
.	O
01	O
;	O
OR	O
:	O
0	O
.	O
970	O
;	O
CI	O
95	O
%:	O
0	O
.	O
841	O
-	O
1	O
.	O
624	O
).	O

179	O
.	O
0	O
mg	O
/	O
L	O
)	O
cats	O
were	O
detectable	O
,	O
suggesting	O
that	O
the	O
simple	O
infection	O
by	O
FCoVs	O
does	O
not	O
influence	O
TSA	B-ENZY
levels	O
.	O

The	O
discriminating	O
power	O
of	O
TSA	B-ENZY
for	O
FIP	O
is	O
moderate	O
(	O
area	O
under	O
the	O
ROC	O
curve	O
=	O
0	O
.	O
65	O
)	O
and	O
the	O
likelihood	O
ratio	O
is	O
higher	O
than	O
3	O
.	O
0	O
only	O
at	O
high	O
TSA	B-ENZY
levels	O
.	O

No	O
correlations	O
were	O
found	O
between	O
the	O
TSA	B-ENZY
and	O
AGP	O
concentrations	O
in	O
cats	O
with	O
FIP	O
,	O
suggesting	O
that	O
sialylated	O
proteins	O
other	O
than	O
AGP	O
are	O
present	O
.	O

Both	O
the	O
antibody	O
titre	O
and	O
the	O
degree	O
of	O
AGP	O
sialylation	O
were	O
negatively	O
correlated	O
with	O
TSA	B-ENZY
levels	O
,	O
suggesting	O
that	O
increased	O
TSA	B-ENZY
may	O
contribute	O
to	O
reduce	O
the	O
burden	O
of	O
FCoVs	O
.	O

TITLE	O
:	O
Construction	O
of	O
plasmids	O
expressing	O
Sars	O
-	O
CoV	O
encoding	O
proteins	O
and	O
their	O
effects	O
on	O
transcription	O
of	O
hfgl2	O
prothrombinase	B-ENZY
.	O

Lung	O
injury	O
and	O
inflammation	O
were	O
assessed	O
by	O
arterial	O
blood	O
gases	O
and	O
levels	O
of	O
albumin	O
,	O
cells	O
,	O
and	O
cytokines	O
/	O
chemokines	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
at	O
5	O
and	O
24	O
h	O
.	O
Rats	O
with	O
LC	O
+	O
CASP	O
had	O
lower	O
mean	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratios	O
compared	O
with	O
LC	O
alone	O
at	O
24	O
h	O
,	O
and	O
higher	O
BAL	B-ENZY
albumin	O
concentrations	O
compared	O
with	O
either	O
LC	O
or	O
CASP	O
alone	O
.	O

These	O
include	O
two	O
human	O
coronaviruses	O
(	O
human	O
coronavirus	O
NL63	O
and	O
human	O
coronavirus	O
HKU1	O
),	O
10	O
other	O
mammalian	O
coronaviruses	O
[	O
bat	B-ENZY
SARS	O
coronavirus	O
,	O
bat	B-ENZY
coronavirus	O
(	O
bat	B-ENZY
-	O
CoV	O
)	O
HKU2	O
,	O
bat	B-ENZY
-	O
CoV	O
HKU4	O
,	O
bat	B-ENZY
-	O
CoV	O
HKU5	O
,	O
bat	B-ENZY
-	O
CoV	O
HKU8	O
,	O
bat	B-ENZY
-	O
CoV	O
HKU9	O
,	O
bat	B-ENZY
-	O
CoV	O
512	O
/	O
2005	O
,	O
bat	B-ENZY
-	O
CoV	O
1A	O
,	O
equine	O
coronavirus	O
,	O
and	O
beluga	O
whale	O
coronavirus	O
]	O
and	O
four	O
avian	O
coronaviruses	O
(	O
turkey	O
coronavirus	O
,	O
bulbul	O
coronavirus	O
HKU11	O
,	O
thrush	O
coronavirus	O
HKU12	O
,	O
and	O
munia	O
coronavirus	O
HKU13	O
).	O

Furthermore	O
,	O
sequence	O
analysis	O
of	O
CoV	O
S	O
proteins	O
by	O
multiple	O
alignments	O
showed	O
conservation	O
of	O
an	O
XXXR	O
/	O
S	O
motif	O
,	O
cleavable	O
by	O
either	O
furin	B-ENZY
or	O
other	O
trypsin	B-ENZY
-	O
like	O
proteases	O
,	O
at	O
a	O
position	O
equivalent	O
to	O
the	O
second	O
IBV	O
furin	B-ENZY
site	O
.	O

After	O
adjusting	O
for	O
physiology	O
,	O
injury	O
severity	O
,	O
and	O
transfusion	O
,	O
etomidate	O
use	O
remained	O
associated	O
with	O
ARDS	O
(	O
aOR	B-ENZY
=	O
3	O
.	O
9	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
24	O
-	O
12	O
.	O
0	O
).	O

TITLE	O
:	O
Investigation	O
of	O
the	O
pharmacophore	O
space	O
of	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
NTPase	B-ENZY
/	O
helicase	O
by	O
dihydroxychromone	O
derivatives	O
.	O

It	O
was	O
also	O
confirmed	O
previously	O
that	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
pAPN	O
)	O
could	O
bind	O
to	O
PEDV	O
,	O
and	O
anti	O
-	O
pAPN	O
antibodies	O
could	O
inhibit	O
the	O
combination	O
.	O

RESULTS	O
:	O
Sixty	O
-	O
two	O
percent	O
of	O
the	O
patients	O
had	O
at	O
least	O
one	O
previous	O
episode	O
of	O
ACS	B-ENZY
.	O

With	O
each	O
declamping	O
,	O
the	O
gas	B-ENZY
flow	O
through	O
the	O
membrane	O
lung	O
was	O
set	O
to	O
10	O
l	O
of	O
oxygen	O
/	O
min	O
.	O

Prospective	O
observational	O
study	O
in	O
two	O
academic	O
intensive	O
care	O
units	O
enrolling	O
11	O
adults	O
with	O
severe	O
ARDS	O
(	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
<	O
150	O
mmHg	O
at	O
PEEP	O
>	O
5	O
cmH	O
(	O
2	O
)	O
O	O
).	O

Interestingly	O
,	O
consecutive	O
treatment	O
with	O
CPL	B-ENZY
and	O
then	O
chlorpromazine	O
enabled	O
a	O
portion	O
of	O
the	O
virus	O
to	O
enter	O
from	O
cell	O
surface	O
.	O

However	O
,	O
RNase	B-ENZY
L	O
deficiency	O
did	O
not	O
affect	O
overall	O
control	O
of	O
infectious	O
virus	O
,	O
or	O
diminish	O
IFN	O
-	O
alpha	O
/	O
beta	O
expression	O
in	O
the	O
CNS	O
.	O

These	O
data	O
demonstrate	O
a	O
novel	O
protective	O
role	O
for	O
RNase	B-ENZY
L	O
in	O
viral	O
induced	O
CNS	O
encephalomyelitis	O
,	O
which	O
is	O
not	O
reflected	O
in	O
overall	O
viral	O
control	O
or	O
propagation	O
of	O
IFN	O
-	O
alpha	O
/	O
beta	O
mediated	O
signals	O
.	O

High	O
awareness	O
of	O
HPS	B-ENZY
allowed	O
successful	O
management	O
of	O
the	O
patient	O
,	O
even	O
before	O
establishing	O
the	O
diagnosis	O
,	O
by	O
serological	O
tests	O
at	O
the	O
reference	O
laboratory	O
of	O
the	O
Ministry	O
of	O
Health	O
.	O

ABSTRACT	O
:	O
We	O
have	O
shown	O
that	O
mice	O
infected	O
with	O
mouse	O
hepatitis	O
virus	O
A59	O
(	O
MHV	O
-	O
A59	O
)	O
develop	O
autoantibodies	O
(	O
autoAb	O
)	O
to	O
liver	O
and	O
kidney	O
fumarylacetoacetate	B-ENZY
hydrolase	I-ENZY
(	O
FAH	O
).	O

Extracorporeal	O
life	O
support	O
(	O
ECLS	O
)	O
provides	O
a	O
method	O
of	O
gas	B-ENZY
exchange	O
while	O
allowing	O
time	O
for	O
lung	O
recovery	O
in	O
the	O
setting	O
of	O
early	O
,	O
severe	O
ARDS	O
.	O

Systemic	O
and	O
pulmonary	O
hemodynamics	O
,	O
blood	O
gas	B-ENZY
exchange	O
parameters	O
,	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
,	O
and	O
angiotensin	O
II	O
levels	O
were	O
examined	O
before	O
acute	O
respiratory	O
distress	O
syndrome	O
induction	O
and	O
at	O
various	O
time	O
points	O
after	O
administering	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
or	O
saline	O
.	O

H1N1	O
influenza	O
was	O
confirmed	O
with	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
assay	O
in	O
eight	O
patients	O
.	O

ABSTRACT	O
:	O
This	O
study	O
uses	O
statistical	O
predictive	O
modeling	O
and	O
hierarchical	O
cluster	O
analyses	O
to	O
examine	O
inflammatory	O
mediators	O
and	O
cells	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
as	O
putative	O
biomarkers	O
in	O
rats	O
with	O
blunt	O
trauma	O
lung	O
contusion	O
(	O
LC	O
),	O
gastric	O
aspiration	O
(	O
combined	O
acid	O
and	O
small	O
gastric	O
food	O
particles	O
,	O
CASP	O
),	O
or	O
a	O
combination	O
of	O
the	O
two	O
.	O

TITLE	O
:	O
Establishment	O
,	O
immortalisation	O
and	O
characterisation	O
of	O
pteropid	O
bat	B-ENZY
cell	O
lines	O
.	O

Four	O
verspertilionid	O
bat	B-ENZY
species	O
were	O
found	O
to	O
excrete	O
group	O
1	O
CoVs	O
,	O
viz	O
.	O

TITLE	O
:	O
Contribution	O
of	O
the	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
CD13	O
)	O
receptor	O
density	O
to	O
porcine	O
epidemic	O
diarrhea	O
virus	O
infection	O
.	O

As	O
with	O
the	O
other	O
members	O
in	O
the	O
group	O
1	O
,	O
theses	O
viruses	O
are	O
also	O
known	O
to	O
use	O
the	O
host	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
APN	O
)	O
as	O
the	O
major	O
receptor	O
for	O
cell	O
entry	O
.	O

Mean	O
number	O
of	O
BAL	B-ENZY
samples	O
was	O
6	O
.	O
2	O
+/-	O
3	O
.	O
1	O
per	O
patient	O
.	O

Genetic	O
variation	O
in	O
the	O
myosin	B-ENZY
light	I-ENZY
chain	I-ENZY
kinase	I-ENZY
gene	O
was	O
examined	O
.	O

As	O
a	O
result	O
,	O
we	O
have	O
studied	O
the	O
effects	O
of	O
hexokinase	B-ENZY
II	O
gene	O
transfer	O
in	O
vivo	O
using	O
a	O
herpes	O
simplex	O
virus	O
type	O
1	O
(	O
HSV	O
-	O
1	O
)	O
amplicon	O
vector	O
.	O

Thus	O
this	O
novel	O
proteolytic	O
processing	O
of	O
MLK3	O
may	O
negatively	O
control	O
MLK3	O
signalling	O
to	O
JNK	B-ENZY
.	O

ABSTRACT	O
:	O
We	O
present	O
a	O
case	O
of	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
pursuant	O
to	O
inhalation	O
of	O
a	O
compressed	O
gas	B-ENZY
computer	O
keyboard	O
cleaner	O
.	O

The	O
model	O
achieved	O
a	O
satisfactory	O
fit	O
,	O
CFI	B-ENZY
=	O
0	O
.	O
98	O
,	O
NNFI	O
=	O
0	O
.	O
98	O
,	O
RMSEA	O
=	O
0	O
.	O
06	O
,	O
and	O
explained	O
75	O
.	O
2	O
%	O
of	O
the	O
variance	O
in	O
mental	O
health	O
status	O
.	O

Presence	O
of	O
pre	O
-	O
existing	O
comorbid	O
conditions	O
was	O
also	O
associated	O
with	O
greater	O
mortality	O
(	O
AOR	B-ENZY
:	O
1	O
.	O
74	O
;	O
95	O
%	O
confidence	O
interval	O
:	O
1	O
.	O
36	O
,	O
2	O
.	O
21	O
).	O

There	O
were	O
significant	O
differences	O
between	O
the	O
2	O
groups	O
confirmed	O
by	O
t	O
-	O
Test	O
and	O
chi	O
(	O
2	O
)	O
test	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
while	O
no	O
significant	O
differences	O
were	O
observed	O
in	O
prothrombin	O
time	O
,	O
thrombin	B-ENZY
time	O
,	O
prothrombin	O
activity	O
,	O
and	O
international	O
normalized	O
ratio	O
results	O
between	O
the	O
2	O
groups	O
.	O

There	O
were	O
significant	O
differences	O
between	O
the	O
2	O
groups	O
confirmed	O
by	O
t	O
-	O
Test	O
and	O
chi	O
(	O
2	O
)	O
test	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
while	O
no	O
significant	O
differences	O
were	O
observed	O
in	O
prothrombin	O
time	O
,	O
thrombin	B-ENZY
time	O
,	O
prothrombin	O
activity	O
,	O
and	O
international	O
normalized	O
ratio	O
results	O
between	O
the	O
2	O
groups	O
.	O

Both	O
strains	O
showed	O
HA	O
activity	O
with	O
rabbit	O
erythrocytes	O
only	O
after	O
treatment	O
with	O
trypsin	B-ENZY
or	O
neuraminidase	B-ENZY
.	O

ABSTRACT	O
:	O
Our	O
studies	O
and	O
those	O
of	O
many	O
others	O
have	O
implicated	O
hepatocyte	O
necrosis	O
and	O
apoptosis	O
mediated	O
by	O
fibrinogen	O
-	O
like	O
protein	O
-	O
2	O
(	O
fgl2	O
)	O
prothrombinase	B-ENZY
and	O
tumor	O
necrosis	O
factor	O
receptor	O
(	O
TNFR	O
)	O
in	O
the	O
development	O
of	O
fulminant	O
viral	O
hepatitis	O
,	O
a	O
disease	O
with	O
a	O
mortality	O
rate	O
greater	O
than	O
80	O
%	O
in	O
cases	O
lacking	O
immediate	O
organ	O
transplantation	O
.	O

RESULTS	O
:	O
Cytochrome	B-ENZY
p450	I-ENZY
levels	O
in	O
phenobarbital	O
pre	O
-	O
treated	O
animals	O
were	O
significantly	O
higher	O
than	O
non	O
pre	O
-	O
treated	O
animals	O
(	O
300	O
vs	O
100	O
pmol	O
/	O
mg	O
protein	O
).	O

Reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
for	O
14	O
respiratory	O
viruses	O
was	O
performed	O
on	O
nasopharyngeal	O
swabs	O
collected	O
at	O
admission	O
and	O
after	O
recovery	O
in	O
stable	O
condition	O
.	O

TITLE	O
:	O
A	O
small	O
-	O
molecule	O
oxocarbazate	O
inhibitor	O
of	O
human	O
cathepsin	B-ENZY
L	I-ENZY
blocks	O
severe	O
acute	O
respiratory	O
syndrome	O
and	O
ebola	O
pseudotype	O
virus	O
infection	O
into	O
human	O
embryonic	O
kidney	O
293T	O
cells	O
.	O

The	O
reduction	O
in	O
active	O
cathepsin	B-ENZY
L	I-ENZY
in	O
inhibitor	O
-	O
treated	O
cells	O
correlated	O
well	O
with	O
the	O
observed	O
potency	O
of	O
inhibitors	O
observed	O
in	O
the	O
virus	O
pseudotype	O
infection	O
assay	O
.	O

The	O
co	O
-	O
localization	O
signal	O
of	O
SARS	O
-	O
CoV	O
NP	O
and	O
proteasome	B-ENZY
subunit	O
p42	O
in	O
2BS	O
cells	O
was	O
detected	O
using	O
indirect	O
immunofluorescence	O
and	O
confocal	O
microscopy	O
.	O

ABSTRACT	O
:	O
The	O
ubiquitin	O
-	O
proteasome	B-ENZY
system	O
(	O
UPS	O
)	O
is	O
a	O
key	O
player	O
in	O
regulating	O
the	O
intracellular	O
sorting	O
and	O
degradation	O
of	O
proteins	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
papain	B-ENZY
-	O
like	O
novel	O
protease	O
inhibitors	O
:	O
design	O
,	O
synthesis	O
,	O
protein	O
-	O
ligand	O
X	O
-	O
ray	O
structure	O
and	O
biological	O
evaluation	O
.	O

In	O
all	O
domestic	O
cats	O
of	O
different	O
breeds	O
:	O
female	O
Abyssinian	O
,	O
female	O
American	O
shorthair	O
,	O
male	O
Cornish	O
Rex	B-ENZY
,	O
female	O
European	O
Burmese	O
,	O
female	O
Persian	O
,	O
female	O
Siamese	O
,	O
a	O
male	O
Ragdoll	O
and	O
a	O
female	O
African	O
wildcat	O
were	O
sequenced	O
lightly	O
.	O

TITLE	O
:	O
Essential	O
covalent	O
linkage	O
between	O
the	O
chymotrypsin	B-ENZY
-	O
like	O
domain	O
and	O
the	O
extra	O
domain	O
of	O
the	O
SARS	O
-	O
CoV	O
main	O
protease	O
.	O

Domains	O
I	O
and	O
II	O
,	O
hosting	O
the	O
complete	O
catalytic	O
machinery	O
,	O
constitute	O
the	O
N	O
-	O
terminal	O
chymotrypsin	B-ENZY
-	O
like	O
folding	O
scaffold	O
and	O
connect	O
to	O
the	O
extra	O
C	O
-	O
terminal	O
domain	O
III	O
by	O
a	O
long	O
loop	O
.	O

ABSTRACT	O
:	O
Angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	B-ENZY
)	O
2	O
is	O
a	O
homolog	O
to	O
the	O
carboxypeptidase	O
ACE	B-ENZY
,	O
which	O
generates	O
angiotensin	O
II	O
,	O
the	O
main	O
active	O
peptide	O
of	O
renin	B-ENZY
-	O
angiotensin	O
system	O
(	O
RAS	O
).	O

TITLE	O
:	O
Putative	O
probiotic	O
Lactobacillus	O
spp	B-ENZY
.	O

The	O
presence	O
of	O
respiratory	O
virus	O
was	O
associated	O
with	O
increased	O
levels	O
of	O
interferon	O
gamma	O
-	O
inducible	O
protein	O
10	O
(	O
IP	O
-	O
10	O
)	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
eotaxin	O
-	O
1	O
(	O
p	O
=	O
0	O
.	O
017	O
)	O
in	O
BAL	B-ENZY
.	O

The	O
median	O
LIS	B-ENZY
and	O
PaO	B-ENZY
(	O
2	O
)/	O
F	O
(	O
i	O
)	O
O	O
(	O
2	O
)	O
were	O
2	O
.	O
5	O
(	O
2	O
.	O
25	O
-	O
3	O
.	O
25	O
)	O
and	O
178	O
(	O
158	O
-	O
212	O
),	O
respectively	O
.	O

ABSTRACT	O
:	O
SARS	O
coronavirus	O
encodes	O
non	O
-	O
structural	O
protein	O
13	O
(	O
nsP13	O
),	O
a	O
nucleic	O
acid	O
helicase	O
/	O
NTPase	B-ENZY
belonging	O
to	O
superfamily	O
1	O
helicase	O
,	O
which	O
efficiently	O
unwinds	O
both	O
partial	O
-	O
duplex	O
RNA	O
and	O
DNA	O
.	O

TITLE	O
:	O
Bat	B-ENZY
coronaviruses	O
and	O
experimental	O
infection	O
of	O
bats	O
,	O
the	O
Philippines	O
.	O

To	O
propagate	O
group	O
2	O
CoVs	O
obtained	O
from	O
a	O
lesser	O
dog	O
-	O
faced	O
fruit	O
bat	B-ENZY
(	O
Cynopterus	O
brachyotis	O
),	O
we	O
administered	O
intestine	O
samples	O
orally	O
to	O
Leschenault	O
rousette	O
bats	O
(	O
Rousettus	O
leschenaulti	O
)	O
maintained	O
in	O
our	O
laboratory	O
.	O

Complete	O
genome	O
sequencing	O
of	O
the	O
distinct	O
genotypes	O
from	O
two	O
bats	O
,	O
using	O
degenerate	O
/	O
genome	O
-	O
specific	O
primers	O
with	O
overlapping	O
sequences	O
confirmed	O
by	O
specific	O
PCR	O
,	O
supported	O
the	O
coexistence	O
of	O
at	O
least	O
two	O
distinct	O
genomes	O
in	O
each	O
bat	B-ENZY
.	O

The	O
results	O
of	O
molecular	O
modeling	O
and	O
docking	O
within	O
the	O
RT	O
non	O
-	O
nucleoside	O
binding	O
site	O
using	O
AutoDock	O
confirmed	O
that	O
the	O
3	O
series	O
,	O
similar	O
to	O
other	O
non	O
-	O
nucleoside	O
reverse	B-ENZY
transcriptase	I-ENZY
inhibitors	O
such	O
as	O
N	O
-(	O
5	O
-	O
chloro	O
-	O
2	O
-	O
pyridinyl	O
)-	O
N	O
'-[	O
2	O
-(	O
4	O
-	O
ethoxy	O
-	O
3	O
-	O
fluoro	O
-	O
2	O
-	O
pyridinyl	O
)	O
ethyl	O
]-	O
thiourea	O
(	O
PETT	O
),	O
was	O
assumed	O
in	O
a	O
butterfly	O
-	O
like	O
conformation	O
and	O
helped	O
to	O
rationalize	O
some	O
SARs	O
and	O
the	O
biological	O
activity	O
data	O
.	O

Patients	O
with	O
severe	O
Clostridium	O
difficile	O
infection	O
(	O
CDI	O
)	O
are	O
at	O
increased	O
risk	O
for	O
IAH	O
and	O
ACS	B-ENZY
.	O

The	O
antioxidant	O
property	O
was	O
assayed	O
for	O
specific	O
activities	O
including	O
2	O
,	O
2	O
-	O
diphenyl	O
-	O
1	O
-	O
picrylhydrazyl	O
(	O
DPPH	O
)	O
hydroxy	O
radical	O
scavenging	O
activity	O
,	O
reducing	O
power	O
capacity	O
,	O
and	O
superoxide	B-ENZY
dismutase	I-ENZY
(	O
SOD	O
)	O
like	O
activity	O
.	O

Patients	O
infected	O
with	O
extended	O
spectrum	O
beta	B-ENZY
-	I-ENZY
lactamase	I-ENZY
(	O
ESBL	O
)-	O
producing	O
Escherichia	O
coli	O
and	O
Klebsiella	O
species	O
were	O
chosen	O
as	O
controls	O
because	O
they	O
were	O
managed	O
in	O
open	O
cubicles	O
with	O
standard	O
precautions	O
.	O

The	O
blood	O
gas	B-ENZY
analysis	O
was	O
performed	O
24	O
hours	O
after	O
operation	O
.	O

Compared	O
with	O
SO	O
group	O
,	O
the	O
levels	O
of	O
arterial	O
partial	O
pressure	O
of	O
oxygen	O
(	O
PaO	B-ENZY
(	O
2	O
))	O
and	O
pH	O
value	O
in	O
model	O
group	O
were	O
significantly	O
decreased	O
[	O
PaO	B-ENZY
(	O
2	O
)	O
(	O
mm	O
Hg	O
,	O
1	O
mm	O
Hg	O
=	O
0	O
.	O
133	O
kPa	O
):	O
79	O
.	O
24	O
	O
5	O
.	O
84	O
vs	O
.	O
96	O
.	O
78	O
	O
3	O
.	O
81	O
,	O
pH	O
value	O
:	O
7	O
.	O
269	O
	O
0	O
.	O
054	O
vs	O
.	O
7	O
.	O
391	O
	O
0	O
.	O
054	O
],	O
arterial	O
partial	O
pressure	O
of	O
carbon	O
dioxide	O
(	O
PaCO	O
(	O
2	O
)),	O
the	O
serum	O
levels	O
of	O
AMY	O
,	O
W	O
/	O
D	O
ratio	O
and	O
the	O
serum	O
levels	O
of	O
sPLA	O
(	O
2	O
)	O
were	O
significantly	O
increased	O
[	O
PaCO	O
(	O
2	O
)	O
(	O
mm	O
Hg	O
):	O
47	O
.	O
57	O
	O
2	O
.	O
55	O
vs	O
.	O
27	O
.	O
69	O
	O
1	O
.	O
02	O
,	O
AMY	O
(	O
U	O
/	O
L	O
):	O
7	O
144	O
.	O
19	O
	O
727	O
.	O
91	O
vs	O
.	O
1	O
193	O
.	O
41	O
	O
192	O
.	O
54	O
,	O
W	O
/	O
D	O
ratio	O
:	O
8	O
.	O
57	O
	O
2	O
.	O
45	O
vs	O
.	O
3	O
.	O
70	O
	O
0	O
.	O
90	O
,	O
sPLA	O
(	O
2	O
)	O
(	O
nmol	O
	O
min	O
(-	O
1	O
)	O
	O
ml	O
(-	O
1	O
)):	O
45	O
.	O
13	O
	O
6	O
.	O
05	O
vs	O
.	O
29	O
.	O
94	O
	O
6	O
.	O
39	O
],	O
the	O
expression	O
of	O
sPLA	O
(	O
2	O
)-	O
II	O
mRNA	O
(	O
1	O
.	O
28	O
	O
0	O
.	O
21	O
vs	O
.	O
0	O
.	O
80	O
	O
0	O
.	O
08	O
)	O
and	O
protein	O
were	O
significantly	O
increased	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

RESULTS	O
:	O
Compared	O
with	O
SO	O
group	O
,	O
the	O
levels	O
of	O
arterial	O
partial	O
pressure	O
of	O
oxygen	O
(	O
PaO	B-ENZY
(	O
2	O
))	O
and	O
pH	O
value	O
in	O
model	O
group	O
were	O
significantly	O
decreased	O
[	O
PaO	B-ENZY
(	O
2	O
)	O
(	O
mm	O
Hg	O
,	O
1	O
mm	O
Hg	O
=	O
0	O
.	O
133	O
kPa	O
):	O
79	O
.	O
24	O
	O
5	O
.	O
84	O
vs	O
.	O
96	O
.	O
78	O
	O
3	O
.	O
81	O
,	O
pH	O
value	O
:	O
7	O
.	O
269	O
	O
0	O
.	O
054	O
vs	O
.	O
7	O
.	O
391	O
	O
0	O
.	O
054	O
],	O
arterial	O
partial	O
pressure	O
of	O
carbon	O
dioxide	O
(	O
PaCO	O
(	O
2	O
)),	O
the	O
serum	O
levels	O
of	O
AMY	O
,	O
W	O
/	O
D	O
ratio	O
and	O
the	O
serum	O
levels	O
of	O
sPLA	O
(	O
2	O
)	O
were	O
significantly	O
increased	O
[	O
PaCO	O
(	O
2	O
)	O
(	O
mm	O
Hg	O
):	O
47	O
.	O
57	O
	O
2	O
.	O
55	O
vs	O
.	O
27	O
.	O
69	O
	O
1	O
.	O
02	O
,	O
AMY	O
(	O
U	O
/	O
L	O
):	O
7	O
144	O
.	O
19	O
	O
727	O
.	O
91	O
vs	O
.	O
1	O
193	O
.	O
41	O
	O
192	O
.	O
54	O
,	O
W	O
/	O
D	O
ratio	O
:	O
8	O
.	O
57	O
	O
2	O
.	O
45	O
vs	O
.	O
3	O
.	O
70	O
	O
0	O
.	O
90	O
,	O
sPLA	O
(	O
2	O
)	O
(	O
nmol	O
	O
min	O
(-	O
1	O
)	O
	O
ml	O
(-	O
1	O
)):	O
45	O
.	O
13	O
	O
6	O
.	O
05	O
vs	O
.	O
29	O
.	O
94	O
	O
6	O
.	O
39	O
],	O
the	O
expression	O
of	O
sPLA	O
(	O
2	O
)-	O
II	O
mRNA	O
(	O
1	O
.	O
28	O
	O
0	O
.	O
21	O
vs	O
.	O
0	O
.	O
80	O
	O
0	O
.	O
08	O
)	O
and	O
protein	O
were	O
significantly	O
increased	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

Within	O
the	O
purpose	O
of	O
developing	O
new	O
antiseptics	O
molecules	O
,	O
the	O
antiseptic	O
virucidal	O
activity	O
of	O
two	O
calix	O
[	O
4	O
]	O
arene	O
derivatives	O
,	O
the	O
tetra	O
-	O
para	O
-	O
sulfonato	O
-	O
calix	O
[	O
4	O
]	O
arene	O
(	O
C	O
[	O
4	O
]	O
S	O
)	O
and	O
the	O
1	O
,	O
3	O
-	O
bis	B-ENZY
(	O
bithiazolyl	O
)-	O
tetra	O
-	O
para	O
-	O
sulfonato	O
-	O
calix	O
[	O
4	O
]	O
arene	O
(	O
C	O
[	O
4	O
]	O
S	O
-	O
BTZ	O
)	O
were	O
evaluated	O
toward	O
the	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
229E	O
).	O

The	O
importance	O
of	O
bats	O
as	O
natural	O
hosts	O
for	O
several	O
important	O
viral	O
zoonoses	O
,	O
including	O
Ebola	O
,	O
Marburg	O
,	O
Nipah	O
,	O
Hendra	O
,	O
and	O
rabies	O
viruses	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
has	O
been	O
established	O
;	O
however	O
,	O
the	O
large	O
viral	O
population	O
diversity	O
(	O
virome	O
)	O
of	O
bats	O
has	O
been	O
partially	O
determined	O
for	O
only	O
a	O
few	O
of	O
the	O
	O
1	O
,	O
200	O
bat	B-ENZY
species	O
.	O

The	O
pre	O
-	O
ECMO	O
ventilator	O
time	O
was	O
shorter	O
in	O
group	O
A	O
than	O
in	O
group	O
B	O
.	O
Significant	O
differences	O
were	O
found	O
between	O
the	O
two	O
groups	O
in	O
the	O
P	O
/	O
F	O
ratio	O
and	O
LIS	B-ENZY
from	O
pre	O
-	O
ECMO	O
introduction	O
to	O
72	O
hours	O
after	O
.	O

Detailed	O
clinical	O
examination	O
,	O
urinalysis	O
,	O
renal	O
function	O
tests	O
,	O
arterial	O
blood	O
gas	B-ENZY
analysis	O
,	O
thyroid	O
hormones	O
,	O
and	O
electrocardiogram	O
were	O
carried	O
out	O
.	O

Thus	O
,	O
TLV	O
provided	O
gas	B-ENZY
exchange	O
superior	O
to	O
CMV	O
in	O
this	O
laboratory	O
model	O
of	O
severe	O
ARDS	O
.	O

ABSTRACT	O
:	O
Neutral	B-ENZY
endopeptidase	I-ENZY
(	O
NEP	O
),	O
an	O
enzyme	O
that	O
cleaves	O
inflammatory	O
bioactive	O
peptides	O
,	O
may	O
play	O
a	O
protective	O
role	O
in	O
the	O
pathogenesis	O
of	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Poly	O
-	O
ubiquitination	O
of	O
ERK1	O
showed	O
a	O
relationship	O
between	O
ERK1	O
and	O
ubiquitin	O
proteasome	B-ENZY
signalling	O
pathways	O
associated	O
with	O
IFN	O
antagonism	O
by	O
PLpro	O
.	O

Sequence	O
alignment	O
and	O
structural	O
bioinformatics	O
analyses	O
revealed	O
that	O
the	O
catalytic	O
residues	O
(	O
Cys51	O
and	O
His148	O
)	O
are	O
highly	O
conserved	O
in	O
FMDV	O
Lb	O
(	O
pro	O
)	O
of	O
all	O
seven	O
serotypes	O
and	O
that	O
the	O
topology	O
of	O
FMDV	O
Lb	O
(	O
pro	O
)	O
is	O
remarkably	O
similar	O
to	O
that	O
of	O
ubiquitin	O
-	O
specific	O
protease	O
14	O
(	O
USP14	O
),	O
a	O
cellular	O
deubiquitylation	O
enzyme	O
(	O
DUB	O
),	O
and	O
to	O
that	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
),	O
a	O
coronaviral	O
DUB	O
.	O

The	O
HEXMO	O
prototype	O
provided	O
sufficient	O
gas	B-ENZY
exchange	O
to	O
prevent	O
hypoxemia	O
.	O

Age	O
was	O
51	O
	O
16	O
years	O
,	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
74	O
	O
19	O
,	O
and	O
PaCO	O
(	O
2	O
)	O
54	O
	O
10	O
mmHg	O
.	O

CONCLUSIONS	O
:	O
We	O
demonstrate	O
the	O
clinical	O
feasibility	O
of	O
routine	O
PP	O
in	O
patients	O
with	O
a	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
below	O
100	O
mmHg	O
after	O
24	O
-	O
48	O
h	O
and	O
suggest	O
that	O
,	O
when	O
combined	O
with	O
a	O
low	O
stretch	O
ventilation	O
strategy	O
,	O
it	O
is	O
protective	O
with	O
a	O
high	O
survival	O
rate	O
.	O

Finally	O
,	O
SARS	O
-	O
S	O
-	O
driven	O
cell	O
-	O
cell	O
fusion	O
was	O
independent	O
of	O
cathepsin	B-ENZY
L	I-ENZY
,	O
a	O
protease	O
essential	O
for	O
virus	O
-	O
cell	O
fusion	O
.	O

Faecal	O
samples	O
from	O
84	O
Australian	O
dairy	O
and	O
dairy	O
beef	O
properties	O
(	O
597	O
samples	O
)	O
were	O
screened	O
for	O
rotavirus	O
and	O
coronavirus	O
using	O
real	O
-	O
time	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
,	O
for	O
Salmonella	O
spp	B-ENZY
.	O

Salmonella	O
spp	B-ENZY
.	O
and	O
rotavirus	O
were	O
more	O
frequently	O
identified	O
in	O
dairy	O
beef	O
operations	O
.	O

The	O
stiff	O
ARDS	O
lung	O
and	O
huge	O
air	O
leaks	O
from	O
BPF	O
resulted	O
in	O
the	O
failure	O
of	O
different	O
protective	O
mechanical	O
ventilation	O
strategies	O
to	O
provide	O
viable	O
gas	B-ENZY
exchange	O
.	O

Full	O
Text	O
in	O
free	O
PDF	B-ENZY
www	O
.	O
bmj	O
.	O
sk	O
.	O

When	O
infected	O
Vero	O
cells	O
were	O
cultured	O
for	O
3	O
days	O
in	O
the	O
absence	O
of	O
trypsin	B-ENZY
but	O
were	O
then	O
treated	O
transiently	O
with	O
trypsin	B-ENZY
,	O
infectious	O
viruses	O
were	O
immediately	O
released	O
from	O
infected	O
cells	O
.	O

ABSTRACT	O
:	O
Delayed	O
acute	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-ENZY
)	O
due	O
to	O
retroperitoneal	O
bleeding	O
is	O
rare	O
.	O

Life	O
-	O
threatening	O
delayed	O
retroperitoneal	O
bleeding	O
may	O
occur	O
suddenly	O
two	O
weeks	O
after	O
trauma	O
causing	O
ACS	B-ENZY
.	O

Within	O
viable	O
bat	B-ENZY
populations	O
,	O
sufficiently	O
long	O
incubation	O
periods	O
allow	O
enough	O
infected	O
individuals	O
to	O
enter	O
hibernation	O
and	O
survive	O
until	O
the	O
following	O
year	O
,	O
and	O
hence	O
avoid	O
an	O
epizootic	O
fadeout	O
of	O
rabies	O
virus	O
.	O

TITLE	O
:	O
Receptor	O
-	O
bound	O
porcine	O
epidemic	O
diarrhea	O
virus	O
spike	O
protein	O
cleaved	O
by	O
trypsin	B-ENZY
induces	O
membrane	O
fusion	O
.	O

During	O
the	O
viral	O
entry	O
stage	O
,	O
trypsin	B-ENZY
increased	O
the	O
penetration	O
of	O
Vero	O
-	O
cell	O
-	O
attached	O
PEDV	O
by	O
approximately	O
twofold	O
.	O

These	O
findings	O
strongly	O
suggest	O
that	O
the	O
PEDV	O
S	O
protein	O
may	O
undergo	O
a	O
conformational	O
change	O
after	O
receptor	O
binding	O
and	O
cleavage	O
by	O
exogenous	O
trypsin	B-ENZY
,	O
which	O
induces	O
membrane	O
fusion	O
.	O

Continuous	O
and	O
categorical	O
data	O
from	O
index	O
cases	O
were	O
compared	O
with	O
that	O
from	O
71	O
control	O
cases	O
of	O
ACS	B-ENZY
in	O
patients	O
with	O
hemoglobin	O
SS	O
disease	O
.	O

Diuresis	O
,	O
respiratory	O
support	O
,	O
vasodilator	O
therapy	O
,	O
and	O
gradual	O
attenuation	O
of	O
the	O
activation	O
of	O
renin	B-ENZY
-	O
angiotensin	O
-	O
aldosterone	O
system	O
(	O
RAAS	O
)	O
and	O
sympathetic	O
nervous	O
system	O
(	O
SNS	O
)	O
are	O
the	O
keystones	O
of	O
AHFS	O
management	O
.	O

An	O
increase	O
of	O
eukaryotic	O
translation	O
initiation	O
factor	O
2	O
(	O
eIF2	O
)	O
phosphorylation	O
and	O
an	O
enhanced	O
nuclease	O
,	O
most	O
likely	O
RNase	B-ENZY
L	O
,	O
activity	O
were	O
observed	O
in	O
rTGEV	O
-	O
7	O
virus	O
infected	O
cells	O
.	O

Furthermore	O
,	O
during	O
states	O
of	O
severe	O
gas	B-ENZY
exchange	O
disturbance	O
or	O
impaired	O
neurological	O
conditions	O
with	O
the	O
threat	O
of	O
aspiration	O
or	O
cardiovascular	O
instability	O
,	O
it	O
is	O
a	O
life	O
-	O
saving	O
intervention	O
on	O
every	O
ICU	O
.	O

Our	O
study	O
indicates	O
that	O
short	O
-	O
term	O
HFOV	O
,	O
using	O
lower	O
mean	O
airway	O
pressures	O
than	O
recommended	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
appears	O
safe	O
in	O
patients	O
with	O
COPD	O
while	O
securing	O
adequate	O
pulmonary	O
gas	B-ENZY
exchange	O
.	O

We	O
wished	O
to	O
determine	O
the	O
potential	O
for	O
pulmonary	O
overexpression	O
of	O
the	O
extracellular	O
isoform	O
of	O
superoxide	B-ENZY
dismutase	I-ENZY
(	O
EC	O
-	O
SOD	O
)	O
to	O
reduce	O
the	O
severity	O
of	O
endotoxin	O
-	O
induced	O
lung	O
injury	O
.	O

TITLE	O
:	O
Local	O
renin	B-ENZY
-	O
angiotensin	O
II	O
systems	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
and	O
its	O
homologue	O
ACE2	O
:	O
their	O
potential	O
role	O
in	O
the	O
pathogenesis	O
of	O
chronic	O
obstructive	O
pulmonary	O
diseases	O
,	O
pulmonary	O
hypertension	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
enzyme	O
responsible	O
for	O
its	O
synthesis	O
,	O
Angiotensin	O
-	O
converting	O
-	O
enzyme	O
(	O
ACE	B-ENZY
),	O
is	O
present	O
in	O
high	O
concentrations	O
in	O
lung	O
tissue	O
.	O

The	O
balance	O
between	O
ACE	B-ENZY
and	O
ACE2	O
is	O
crucial	O
for	O
controlling	O
AngII	O
levels	O
.	O

In	O
the	O
BAL	B-ENZY
samples	O
,	O
only	O
one	O
of	O
the	O
analysed	O
cytokines	O
,	O
IL	O
-	O
1	O
was	O
present	O
at	O
detectable	O
levels	O
in	O
two	O
patients	O
(	O
21	O
pg	O
/	O
ml	O
and	O
11	O
pg	O
/	O
ml	O
respectively	O
).	O

Rescue	O
therapies	O
,	O
like	O
recruitment	O
maneuvers	O
(	O
8	O
to	O
35	O
%),	O
prone	O
positioning	O
(	O
12	O
to	O
24	O
%)	O
and	O
tracheal	O
gas	B-ENZY
insufflation	O
(	O
3	O
%)	O
were	O
frequently	O
applied	O
.	O

Decreased	O
wet	O
-	O
dry	O
weight	O
ratios	O
of	O
the	O
lungs	O
,	O
lower	O
histological	O
lung	O
injury	O
scores	O
and	O
higher	O
PaO	B-ENZY
(	O
2	O
)	O
were	O
found	O
in	O
all	O
low	O
tidal	O
volume	O
/	O
hypercapnia	O
groups	O
(	O
group	O
2	O
,	O
3	O
,	O
4	O
)	O
as	O
compared	O
to	O
the	O
group	O
with	O
conventional	O
tidal	O
volume	O
/	O
normocapnia	O
(	O
group	O
1	O
).	O

RESULTS	O
:	O
The	O
primary	O
endpoint	O
occurred	O
in	O
271	O
PAC	O
patients	O
versus	O
196	O
without	O
PAC	O
(	O
21	O
.	O
3	O
%	O
vs	O
.	O
15	O
.	O
4	O
%;	O
adjusted	O
odds	O
ratio	O
[	O
AOR	B-ENZY
],	O
1	O
.	O
68	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
1	O
.	O
24	O
to	O
2	O
.	O
26	O
;	O
P	O
<	O
0	O
.	O
001	O
).	O

Although	O
activation	O
of	O
NF	O
-	O
B	O
and	O
Erk	B-ENZY
MAPK	B-ENZY
has	O
been	O
implicated	O
for	O
HSV	O
replication	O
and	O
growth	O
,	O
HCWE	O
showed	O
no	O
effect	O
on	O
HSV	O
-	O
2	O
-	O
induced	O
Erk	B-ENZY
activation	O
.	O

ABSTRACT	O
:	O
The	O
entire	O
pig	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
pAPN	O
)	O
gene	O
was	O
amplified	O
by	O
RT	O
-	O
PCR	O
using	O
total	O
RNA	O
extracted	O
from	O
intestinal	O
brush	O
border	O
membrane	O
of	O
a	O
newborn	O
piglet	O
.	O

Arterial	O
blood	O
gas	B-ENZY
analysis	O
,	O
ventilator	O
parameters	O
,	O
hemodynamic	O
parameter	O
,	O
and	O
adverse	O
events	O
were	O
recorded	O
serially	O
.	O

Results	O
suggest	O
that	O
the	O
reduction	O
in	O
90	O
-	O
day	O
mortality	O
in	O
the	O
cisatracurium	O
group	O
was	O
confined	O
to	O
those	O
patients	O
with	O
a	O
PaO	B-ENZY
(	O
2	O
)/	O
F	O
(	O
i	O
)	O
O	O
(	O
2	O
)	O
ratio	O
<	O
120	O
.	O

The	O
current	O
study	O
investigated	O
the	O
ability	O
of	O
aerosolized	O
extracellular	O
superoxide	B-ENZY
dismutase	I-ENZY
(	O
EC	O
-	O
SOD	O
)	O
to	O
protect	O
the	O
lungs	O
from	O
hyperoxic	O
injury	O
.	O

The	O
compounds	O
were	O
tested	O
for	O
antiparasitic	O
activities	O
against	O
Leishmania	O
major	O
and	O
Trypanosoma	O
brucei	O
,	O
and	O
for	O
protease	O
inhibition	O
against	O
several	O
cysteine	O
proteases	O
such	O
as	O
falcipain	O
,	O
rhodesain	O
,	O
cathepsin	B-ENZY
L	I-ENZY
,	O
cathepsin	B-ENZY
B	I-ENZY
,	O
and	O
viral	O
proteases	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	O
),	O
and	O
PL	O
(	O
pro	O
).	O

TITLE	O
:	O
Virus	O
-	O
binding	O
activity	O
of	O
the	O
truncated	O
C	O
subunit	O
of	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
expressed	O
in	O
Escherichia	O
coli	O
.	O

ABSTRACT	O
:	O
Seven	O
overlapping	O
truncated	O
forms	O
of	O
the	O
C	O
subunit	O
of	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
pAPN	O
-	O
C	O
)	O
were	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

Treatment	O
for	O
ARDS	O
comprised	O
continuous	O
hemodiafiltration	O
(	O
CHDF	O
),	O
high	O
-	O
dose	O
glucocorticoid	O
therapy	O
or	O
administration	O
of	O
a	O
neutrophil	B-ENZY
elastase	I-ENZY
inhibitor	O
(	O
sivelestat	O
).	O

Patient	O
information	O
collected	O
by	O
case	O
report	O
forms	O
was	O
compared	O
between	O
HPS	B-ENZY
-	O
confirmed	O
and	O
test	O
-	O
negative	O
patients	O
.	O

The	O
physical	O
interaction	O
between	O
the	O
SARS	O
-	O
CoV	O
nucleocapsid	O
and	O
cellular	O
pyruvate	B-ENZY
kinase	I-ENZY
(	O
liver	O
)	O
proteins	O
was	O
further	O
confirmed	O
by	O
GST	O
pull	O
-	O
down	O
assay	O
,	O
co	O
-	O
immunoprecipitation	O
assay	O
and	O
confocal	O
microscopy	O
.	O

Exposure	O
to	O
alcohol	O
reduced	O
alveolar	O
fluid	O
clearance	O
,	O
downregulated	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
in	O
the	O
lung	O
tissue	O
and	O
worsened	O
hyperoxia	O
-	O
induced	O
lung	O
injury	O
.	O

They	O
all	O
have	O
a	O
single	O
papain	B-ENZY
-	O
like	O
protease	O
domain	O
in	O
the	O
nsp3	O
gene	O
;	O
an	O
accessory	O
gene	O
,	O
NS6	O
open	O
reading	O
frame	O
(	O
ORF	O
),	O
located	O
between	O
the	O
M	O
and	O
N	O
genes	O
;	O
and	O
a	O
variable	O
number	O
of	O
accessory	O
genes	O
(	O
up	O
to	O
four	O
)	O
downstream	O
of	O
the	O
N	O
gene	O
.	O

Arterial	O
blood	O
gas	B-ENZY
(	O
pH	O
,	O
PaO2	O
and	O
PaCO2	O
)	O
post	O
-	O
ECMO	O
of	O
2	O
hours	O
and	O
24	O
-	O
hour	O
significantly	O
improved	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Both	O
extrinsic	O
and	O
intrinsic	O
pathways	O
activated	O
downstream	O
effector	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
,	O
followed	O
by	O
the	O
cleavage	O
of	O
PARP	O
,	O
resulting	O
in	O
cell	O
apoptosis	O
.	O

RESULTS	O
:	O
Ten	O
adult	O
patients	O
with	O
severe	O
ARDS	O
secondary	O
to	O
H1N1	O
infection	O
(	O
Pao	B-ENZY
(	O
2	O
)/	O
fraction	O
of	O
inspired	O
oxygen	O
,	O
69	O
mm	O
Hg	O
[	O
56	O
-	O
84	O
];	O
Murray	O
score	O
,	O
3	O
.	O
5	O
[	O
3	O
.	O
5	O
-	O
3	O
.	O
8	O
])	O
were	O
included	O
,	O
and	O
60	O
%	O
survived	O
to	O
hospital	O
discharge	O
.	O

The	O
virus	O
was	O
detected	O
in	O
11	O
(	O
8	O
.	O
1	O
%)	O
of	O
136	O
rabbit	O
fecal	O
samples	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
(	O
RT	O
-	O
PCR	O
),	O
with	O
a	O
viral	O
load	O
of	O
up	O
to	O
10	O
(	O
8	O
)	O
copies	O
/	O
ml	O
.	O

Domestic	O
crossbred	O
,	O
Persian	O
and	O
Himalayan	O
cats	O
were	O
significantly	O
under	O
-	O
represented	O
in	O
the	O
FIP	O
cohort	O
,	O
while	O
several	O
breeds	O
were	O
over	O
-	O
represented	O
,	O
including	O
British	O
Shorthair	O
,	O
Devon	O
Rex	B-ENZY
and	O
Abyssinian	O
.	O

The	O
range	O
of	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
was	O
42	O
-	O
69	O
.	O
9	O
,	O
alveolar	O
-	O
arterial	O
oxygen	O
gradient	O
(	O
AaDO	O
(	O
2	O
))	O
602	O
-	O
645	O
,	O
and	O
oxygenation	O
index	O
(	O
OI	O
)	O
27	O
.	O
4	O
-	O
68	O
.	O

BtKY27	O
and	O
BtKY33	O
are	O
members	O
of	O
the	O
established	O
bat	B-ENZY
CoV	O
species	O
in	O
Alphacoronavirus	O
genus	O
and	O
BtKY06	O
is	O
a	O
member	O
of	O
the	O
established	O
bat	B-ENZY
CoV	O
species	O
in	O
Betacoronavirus	O
genus	O
.	O

The	O
majority	O
of	O
published	O
reports	O
of	O
ACS	B-ENZY
are	O
in	O
neonates	O
with	O
abdominal	O
wall	O
defects	O
and	O
in	O
adults	O
following	O
trauma	O
or	O
burns	O
,	O
but	O
it	O
is	O
poorly	O
described	O
in	O
children	O
.	O

Most	O
compounds	O
presented	O
selective	O
inhibitory	O
properties	O
in	O
the	O
10	O
-	O
20	O
M	O
range	O
against	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
associated	O
ribonuclease	B-ENZY
H	I-ENZY
activity	O
,	O
without	O
affecting	O
the	O
integrase	O
and	O
reverse	B-ENZY
transcriptase	I-ENZY
DNA	O
polymerase	O
activities	O
.	O

Using	O
peripheral	O
blood	O
samples	O
from	O
drug	O
-	O
allergic	O
patients	O
,	O
the	O
drug	O
-	O
induced	O
lymphocyte	O
stimulation	O
test	O
(	O
DLST	O
)	O
and	O
the	O
leukocyte	O
migration	O
test	O
(	O
LMT	B-ENZY
)	O
can	O
detect	O
the	O
presence	O
of	O
drug	O
-	O
sensitized	O
T	O
cells	O
.	O

Rapid	O
diagnosis	O
by	O
blood	O
gas	B-ENZY
analysis	O
and	O
instant	O
therapy	O
by	O
toloudine	O
blue	O
(	O
TB	O
)	O
can	O
effectively	O
prevent	O
a	O
potentially	O
lethal	O
course	O
.	O

Adoptive	O
transfer	O
of	O
TCR	O
(+)	O
DN	O
T	O
cells	O
led	O
to	O
dramatically	O
decreased	O
survival	O
in	O
MHV	O
-	O
3	O
-	O
infected	O
mice	O
,	O
accompanied	O
by	O
deteriorated	O
histopathology	O
and	O
elevated	O
ALT	O
and	O
AST	B-ENZY
levels	O
.	O

After	O
6	O
hours	O
of	O
HFNC	O
O	O
(	O
2	O
)	O
therapy	O
,	O
nonresponders	O
presented	O
a	O
lower	O
Pao	B-ENZY
(	O
2	O
)/	O
fraction	O
of	O
inspired	O
oxygen	O
(	O
median	O
,	O
135	O
[	O
interquartile	O
range	O
,	O
84	O
-	O
210	O
]	O
vs	O
73	O
[	O
56	O
-	O
81	O
]	O
mm	O
Hg	O
P	O
<	O
.	O
05	O
)	O
and	O
needed	O
higher	O
oxygen	O
flow	O
rate	O
.	O

We	O
describe	O
57	O
critically	O
ill	O
patients	O
treated	O
with	O
the	O
investigational	O
intravenous	O
neuraminidase	B-ENZY
inhibitor	O
drug	O
peramivir	O
for	O
influenza	O
A	O
(	O
H1N1	O
)	O
pdm09	O
[	O
pH1N1	O
].	O

Other	O
enteropathogens	O
identified	O
in	O
dogs	O
with	O
and	O
without	O
diarrhea	O
included	O
hookworms	O
(	O
58	O
%	O
and	O
48	O
%,	O
respectively	O
),	O
Giardia	O
spp	B-ENZY
(	O
22	O
%	O
and	O
16	O
%,	O
respectively	O
),	O
canine	O
enteric	O
coronavirus	O
(	O
2	O
%	O
and	O
18	O
%,	O
respectively	O
),	O
whipworms	O
(	O
12	O
%	O
and	O
8	O
%,	O
respectively	O
),	O
Cryptosporidium	O
spp	B-ENZY
(	O
12	O
%	O
and	O
2	O
%,	O
respectively	O
),	O
ascarids	O
(	O
8	O
%	O
and	O
8	O
%,	O
respectively	O
),	O
Salmonella	O
spp	B-ENZY
(	O
2	O
%	O
and	O
6	O
%,	O
respectively	O
),	O
Cystoisospora	O
spp	B-ENZY
(	O
2	O
%	O
and	O
4	O
%,	O
respectively	O
),	O
canine	O
distemper	O
virus	O
(	O
8	O
%	O
and	O
0	O
%,	O
respectively	O
),	O
Dipylidium	O
caninum	O
(	O
2	O
%	O
and	O
2	O
%,	O
respectively	O
),	O
canine	O
parvovirus	O
(	O
2	O
%	O
and	O
2	O
%,	O
respectively	O
),	O
and	O
rotavirus	O
(	O
2	O
%	O
and	O
0	O
%,	O
respectively	O
).	O

TITLE	O
:	O
Influenza	O
A	O
H1N1	O
induces	O
declines	O
in	O
alveolar	O
gas	B-ENZY
exchange	O
in	O
mice	O
consistent	O
with	O
rapid	O
post	O
-	O
infection	O
progression	O
from	O
acute	O
lung	O
injury	O
to	O
ARDS	O
.	O

Impaired	O
gas	B-ENZY
exchange	O
in	O
influenza	O
-	O
infected	O
mice	O
was	O
accompanied	O
by	O
progressive	O
hemoglobin	O
desaturation	O
,	O
hypercapnia	O
,	O
uncompensated	O
respiratory	O
acidosis	O
,	O
hyperkalemia	O
,	O
and	O
polycythemia	O
.	O

Influenza	O
virus	O
infection	O
is	O
treated	O
worldwide	O
mainly	O
by	O
neuraminidase	B-ENZY
inhibitors	O
(	O
NAIs	O
).	O

The	O
results	O
demonstrate	O
that	O
the	O
newly	O
developed	O
assay	O
can	O
purify	O
and	O
subsequently	O
detect	O
BCV	O
,	O
BRV	O
,	O
and	O
Cryptosporidium	O
spp	B-ENZY
.	O

In	O
the	O
univariate	O
analysis	O
,	O
in	O
-	O
ICU	O
mortality	O
was	O
associated	O
with	O
SAPS	O
-	O
II	O
(	O
p	O
=	O
0	O
.	O
0131	O
),	O
ARDS	O
(	O
p	O
<	O
0	O
.	O
0001	O
),	O
shock	O
(	O
p	O
<	O
0	O
.	O
0001	O
),	O
and	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
or	O
cytomegalovirus	O
(	O
CMV	O
)	O
on	O
BAL	B-ENZY
(	O
p	O
=	O
0	O
.	O
0031	O
).	O

The	O
levels	O
of	O
creatine	B-ENZY
kinase	I-ENZY
(	O
CK	B-ENZY
),	O
creatine	B-ENZY
kinase	I-ENZY
-	O
MB	O
(	O
CK	B-ENZY
-	O
MB	O
)	O
and	O
cardiac	O
troponin	O
I	O
(	O
cTnI	O
)	O
in	O
milder	O
,	O
moderate	O
and	O
severe	O
poisoning	O
groups	O
were	O
significantly	O
elevated	O
compared	O
by	O
the	O
healthy	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

PLpro	O
upregulated	O
HSP27	O
,	O
linking	O
with	O
activation	O
of	O
p38	O
MAPK	B-ENZY
and	O
ERK1	O
/	O
2	O
signaling	O
.	O

TITLE	O
:	O
A	O
framework	O
for	O
the	O
study	O
of	O
zoonotic	O
disease	O
emergence	O
and	O
its	O
drivers	O
:	O
spillover	O
of	O
bat	B-ENZY
pathogens	O
as	O
a	O
case	O
study	O
.	O

Moreover	O
,	O
there	O
are	O
very	O
few	O
bat	B-ENZY
cell	O
lines	O
or	O
reagents	O
available	O
for	O
investigating	O
CoV	O
replication	O
in	O
bat	B-ENZY
cells	O
or	O
for	O
isolating	O
bat	B-ENZY
CoVs	O
adapted	O
to	O
specific	O
bat	B-ENZY
species	O
.	O

BCoV	O
was	O
detected	O
in	O
nasal	O
swabs	O
and	O
pulmonary	O
lesions	O
using	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
)	O
assay	O
and	O
virus	O
isolation	O
.	O

CONCLUSIONS	O
:	O
Treatment	O
with	O
inhaled	O
epoprostenol	O
improved	O
gas	B-ENZY
exchange	O
in	O
severely	O
hypoxemic	O
surgical	O
patients	O
.	O

TITLE	O
:	O
Structural	O
basis	O
for	O
multifunctional	O
roles	O
of	O
mammalian	O
aminopeptidase	B-ENZY
N	I-ENZY
.	O
ABSTRACT	O
:	O
Mammalian	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
APN	O
)	O
plays	O
multifunctional	O
roles	O
in	O
many	O
physiological	O
processes	O
,	O
including	O
peptide	O
metabolism	O
,	O
cell	O
motility	O
and	O
adhesion	O
,	O
and	O
coronavirus	O
entry	O
.	O

Moreover	O
it	O
should	O
be	O
reported	O
that	O
many	O
of	O
the	O
known	O
RT	O
inhibitors	O
,	O
targeting	O
the	O
polymerase	O
function	O
,	O
enhance	O
the	O
RNase	B-ENZY
H	I-ENZY
activity	O
,	O
indicating	O
that	O
,	O
although	O
spatially	O
distinct	O
,	O
a	O
close	O
relation	O
occurs	O
between	O
the	O
two	O
functions	O
.	O

The	O
purpose	O
of	O
this	O
prospective	O
case	O
-	O
control	O
study	O
was	O
to	O
survey	O
the	O
detection	O
rate	O
of	O
respiratory	O
viruses	O
in	O
children	O
with	O
Kawasaki	O
disease	O
(	O
KD	O
)	O
by	O
using	O
multiplex	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
and	O
to	O
investigate	O
the	O
clinical	O
implications	O
of	O
the	O
prevalence	O
of	O
respiratory	O
viruses	O
during	O
the	O
acute	O
phase	O
of	O
KD	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
is	O
a	O
key	O
enzyme	O
that	O
plays	O
an	O
important	O
role	O
in	O
SARS	O
virus	O
replication	O
.	O

The	O
chickens	O
were	O
administrated	O
combined	O
ND	O
,	O
IB	O
and	O
AI	O
inactivated	O
vaccines	O
containing	O
SPP	B-ENZY
at	O
10	O
,	O
30	O
and	O
50	O
mg	O
/	O
mL	O
,	O
using	O
an	O
oil	O
adjuvant	O
vaccine	O
as	O
a	O
control	O
.	O

In	O
conclusion	O
,	O
an	O
appropriate	O
dose	O
of	O
SPP	B-ENZY
may	O
be	O
a	O
safe	O
and	O
efficacious	O
immune	O
stimulator	O
candidate	O
that	O
is	O
suitable	O
for	O
vaccines	O
to	O
produce	O
early	O
and	O
persistent	O
prophylaxis	O
.	O

Analyses	O
of	O
these	O
viruses	O
in	O
the	O
context	O
of	O
their	O
hosts	O
and	O
ecological	O
habitat	O
indicated	O
that	O
host	O
species	O
is	O
a	O
strong	O
selective	O
driver	O
in	O
CoV	O
evolution	O
,	O
even	O
in	O
allopatric	O
populations	O
separated	O
by	O
significant	O
geographical	O
distance	O
;	O
and	O
that	O
a	O
single	O
species	O
/	O
genus	O
of	O
bat	B-ENZY
can	O
contain	O
multiple	O
CoVs	O
.	O

In	O
addition	O
,	O
kallistatin	O
levels	O
were	O
positively	O
correlated	O
with	O
anti	O
-	O
thrombin	B-ENZY
III	O
and	O
protein	O
C	O
and	O
inversely	O
correlated	O
with	O
IL	O
-	O
1	O
,	O
IL	O
-	O
6	O
,	O
and	O
CRP	O
levels	O
.	O

CONCLUSIONS	O
:	O
SF	O
-	O
aero	O
produced	O
improvements	O
in	O
gas	B-ENZY
exchange	O
and	O
lung	O
mechanics	O
similar	O
to	O
those	O
produced	O
by	O
bolus	O
administration	O
but	O
with	O
less	O
lung	O
injury	O
and	O
fewer	O
cerebral	O
hemodynamic	O
changes	O
.	O

ABSTRACT	O
:	O
Intra	O
-	O
abdominal	O
hypertension	O
(	O
IAH	O
)	O
contributes	O
to	O
organ	O
dysfunction	O
and	O
leads	O
to	O
the	O
development	O
of	O
the	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-ENZY
).	O

CONCLUSIONS	O
:	O
Acute	O
rejection	O
,	O
lymphocytic	O
bronchiolitis	O
,	O
colonization	O
with	O
pseudomonas	O
,	O
infection	O
,	O
and	O
BAL	B-ENZY
eosinophilia	O
and	O
neutrophilia	O
are	O
risk	O
factors	O
for	O
the	O
later	O
development	O
not	O
only	O
of	O
RAS	O
but	O
also	O
of	O
BOS	O
.	O

The	O
catalytic	O
domain	O
of	O
TMPRSS2	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
and	O
used	O
for	O
an	O
inhibitor	O
screen	O
with	O
previously	O
synthesized	O
inhibitors	O
of	O
various	O
trypsin	B-ENZY
-	O
like	O
serine	O
proteases	O
.	O

Inhibition	O
of	O
endogenous	O
cathepsin	B-ENZY
L	I-ENZY
or	O
TMPRSS2	O
demonstrated	O
that	O
both	O
proteases	O
can	O
activate	O
229E	O
-	O
S	O
for	O
entry	O
into	O
cells	O
that	O
are	O
naturally	O
susceptible	O
to	O
infection	O
.	O

ABSTRACT	O
:	O
The	O
role	O
of	O
mast	O
cells	O
(	O
MCs	B-ENZY
)	O
in	O
allergic	O
reactions	O
and	O
parasitic	O
infections	O
is	O
well	O
established	O
.	O

In	O
this	O
study	O
,	O
investigation	O
is	O
made	O
to	O
determine	O
if	O
MCs	B-ENZY
are	O
associated	O
with	O
Canine	O
parvovirus	O
-	O
2	O
(	O
CPV	O
-	O
2	O
)-	O
induced	O
enteritis	O
with	O
crypt	O
abscess	O
(	O
ECA	O
).	O

However	O
,	O
alanine	B-ENZY
aminotransferase	I-ENZY
levels	O
increased	O
in	O
the	O
chloroquine	O
-	O
treated	O
groups	O
.	O

Upon	O
transfer	O
to	O
the	O
ICU	O
,	O
arterial	O
blood	O
gas	B-ENZY
revealed	O
severe	O
acute	O
-	O
on	O
-	O
chronic	O
respiratory	O
acidosis	O
(	O
pH	O
7	O
.	O
00	O
,	O
PCO2	O
120	O
mm	O
Hg	O
,	O
PO2	O
211	O
mm	O
Hg	O
).	O

HFRS	O
is	O
considered	O
to	O
be	O
distinct	O
from	O
hantavirus	O
(	O
cardio	O
-)	O
pulmonary	O
syndrome	O
(	O
HPS	B-ENZY
or	O
HCPS	O
),	O
described	O
in	O
the	O
New	O
World	O
.	O

Viral	O
antigen	O
was	O
detected	O
by	O
specific	O
anti	O
-	O
PUUV	O
immunostaining	O
,	O
showing	O
,	O
for	O
the	O
first	O
time	O
,	O
greenish	O
intracytoplasmic	O
inclusions	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
macrophages	O
.	O

TITLE	O
:	O
Cell	O
-	O
type	O
-	O
specific	O
activation	O
of	O
the	O
oligoadenylate	O
synthetase	O
-	O
RNase	B-ENZY
L	O
pathway	O
by	O
a	O
murine	O
coronavirus	O
.	O

It	O
has	O
been	O
reported	O
that	O
a	O
cyclophilin	B-ENZY
inhibitor	O
,	O
cyclosporin	O
A	O
(	O
CsA	O
),	O
could	O
inhibit	O
the	O
replication	O
of	O
coronaviruses	O
.	O

The	O
available	O
published	O
data	O
dealing	O
with	O
the	O
use	O
of	O
NIV	O
in	O
ACS	B-ENZY
were	O
obtained	O
in	O
patients	O
with	O
hypercapnic	O
encephalopathy	O
complicating	O
severe	O
exacerbations	O
of	O
COPD	O
.	O

ABSTRACT	O
:	O
To	O
clarify	O
the	O
evolutionary	O
relationships	O
among	O
betavoronaviruses	O
that	O
infect	O
bats	O
,	O
we	O
analyzed	O
samples	O
collected	O
during	O
2010	O
-	O
2011	O
from	O
14	O
insectivorous	O
bat	B-ENZY
species	O
in	O
China	O
.	O

These	O
bat	B-ENZY
CoVs	O
were	O
unrelated	O
to	O
known	O
human	O
or	O
animal	O
pathogens	O
,	O
indicating	O
an	O
absence	O
of	O
recent	O
zoonotic	O
spill	O
-	O
over	O
events	O
.	O

We	O
examined	O
a	O
furin	B-ENZY
cleavage	O
site	O
in	O
the	O
region	O
between	O
receptor	O
-	O
binding	O
(	O
S1	O
)	O
and	O
fusion	O
(	O
S2	O
)	O
domains	O
of	O
the	O
spike	O
of	O
serotype	O
1	O
FCoV	O
.	O
FECV	O
sequences	O
were	O
compared	O
with	O
FIPV	O
sequences	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
tested	O
the	O
ethanolic	O
extracts	O
obtained	O
by	O
the	O
Hypericum	O
hircinum	O
L	O
.	O
(	O
Hypericaceae	O
)	O
growing	O
in	O
Sardinia	O
(	O
Italy	O
)	O
on	O
the	O
HIV	O
-	O
1	O
RT	O
-	O
associated	O
RNase	B-ENZY
H	I-ENZY
function	O
and	O
found	O
that	O
they	O
have	O
inhibitory	O
effects	O
.	O

Laboratory	O
analyses	O
showed	O
raised	O
concentrations	O
of	O
lactate	O
dehydrogenase	O
(	O
23	O
[	O
49	O
%])	O
and	O
aspartate	B-ENZY
aminotransferase	I-ENZY
(	O
seven	O
[	O
15	O
%])	O
and	O
thrombocytopenia	O
(	O
17	O
[	O
36	O
%])	O
and	O
lymphopenia	O
(	O
16	O
[	O
34	O
%]).	O

All	O
3	O
patients	O
had	O
fever	O
,	O
cough	O
,	O
shortness	O
of	O
breath	O
,	O
bilateral	O
infiltrates	O
on	O
chest	O
x	O
-	O
ray	O
,	O
thrombocytopenia	O
,	O
lymphopenia	O
and	O
rises	O
in	O
serum	O
creatinine	O
kinase	O
and	O
alanine	B-ENZY
transaminase	I-ENZY
.	O

Serious	O
infectious	O
diseases	O
caused	O
by	O
previously	O
identified	O
bat	B-ENZY
viruses	O
continue	O
to	O
emerge	O
throughout	O
in	O
Asia	O
,	O
Australia	O
,	O
Africa	O
and	O
America	O
.	O

We	O
validated	O
the	O
importance	O
of	O
the	O
urokinase	B-ENZY
pathway	O
for	O
SARS	O
-	O
CoV	O
disease	O
severity	O
using	O
genetically	O
defined	O
knockout	O
mice	O
,	O
proteomic	O
correlates	O
of	O
pathway	O
activation	O
,	O
and	O
pathological	O
disease	O
severity	O
.	O

Mathematical	O
prioritization	O
of	O
our	O
gene	O
sets	O
identified	O
the	O
urokinase	B-ENZY
and	O
extracellular	O
matrix	O
remodeling	O
pathways	O
as	O
the	O
most	O
enriched	O
pathways	O
.	O

In	O
contrast	O
,	O
the	O
expression	O
of	O
cytotoxicity	O
-	O
associated	O
genes	O
,	O
i	O
.	O
e	O
.,	O
granzyme	B-ENZY
A	I-ENZY
(	O
GZMA	O
)	O
and	O
perforin	O
mRNA	O
,	O
remained	O
associated	O
with	O
the	O
HALT	O
after	O
boosting	O
.	O

Median	O
duration	O
of	O
MCS	B-ENZY
was	O
4	O
days	O
(	O
0	O
-	O
18	O
days	O
),	O
12	O
patients	O
(	O
75	O
%)	O
were	O
weaned	O
successfully	O
from	O
MCS	B-ENZY
,	O
4	O
of	O
these	O
children	O
(	O
25	O
%)	O
died	O
after	O
weaning	O
,	O
with	O
a	O
median	O
survival	O
time	O
of	O
15	O
days	O
(	O
6	O
-	O
28	O
days	O
).	O

Baseline	O
D	O
-	O
dimer	O
values	O
were	O
3	O
.	O
4	O
(	O
3	O
.	O
0	O
)	O
mg	O
/	O
l	O
and	O
rose	O
significantly	O
to	O
19	O
.	O
5	O
(	O
11	O
.	O
5	O
)	O
mg	O
/	O
l	O
during	O
MCS	B-ENZY
(	O
P	O
<	O
0	O
.	O
001	O
).	O

These	O
results	O
indicate	O
that	O
bat	B-ENZY
cells	O
are	O
more	O
resistant	O
to	O
infection	O
by	O
coronaviruses	O
than	O
to	O
infection	O
by	O
paramyxoviruses	O
,	O
filoviruses	O
and	O
influenza	O
viruses	O
.	O

Furthermore	O
,	O
these	O
results	O
show	O
a	O
receptor	O
-	O
dependent	O
restriction	O
of	O
the	O
infection	O
of	O
bat	B-ENZY
cells	O
by	O
CoV	O
.	O
The	O
implications	O
for	O
the	O
isolation	O
of	O
coronaviruses	O
from	O
bats	O
are	O
discussed	O
.	O

Importantly	O
,	O
the	O
coronavirus	O
is	O
thought	O
to	O
enter	O
cells	O
via	O
two	O
distinct	O
pathways	O
,	O
one	O
mediated	O
by	O
TMPRSS2	O
at	O
the	O
cell	O
surface	O
and	O
the	O
other	O
mediated	O
by	O
cathepsin	B-ENZY
L	I-ENZY
in	O
the	O
endosome	O
.	O

Our	O
data	O
show	O
that	O
knockdown	O
of	O
LIMK1	O
destabilizes	O
whereas	O
knockdown	O
of	O
SSH	O
-	O
1L	O
stabilizes	O
the	O
actin	O
filaments	O
through	O
modulation	O
of	O
cofilin	O
phosphorylation	O
;	O
however	O
,	O
in	O
either	O
case	O
thrombin	B-ENZY
-	O
induced	O
NF	O
-	O
B	O
activity	O
and	O
expression	O
of	O
its	O
target	O
genes	O
(	O
ICAM	O
-	O
1	O
and	O
VCAM	O
-	O
1	O
)	O
is	O
inhibited	O
.	O

Nine	O
(	O
15	O
%)	O
patients	O
had	O
ACS	B-ENZY
;	O
a	O
respiratory	O
virus	O
was	O
detected	O
in	O
all	O
of	O
them	O
.	O

We	O
searched	O
electronic	O
bibliographic	O
databases	O
(	O
MEDLINE	O
,	O
EMBASE	O
,	O
PubMed	O
,	O
and	O
the	O
Cochrane	O
Database	O
from	O
1950	O
until	O
January	O
21	O
,	O
2013	O
)	O
and	O
reference	O
lists	O
of	O
included	O
articles	O
for	O
observational	O
studies	O
reporting	O
risk	O
factors	O
for	O
IAH	O
or	O
ACS	B-ENZY
among	O
adult	O
ICU	O
patients	O
.	O

Large	O
volume	O
crystalloid	O
resuscitation	O
,	O
the	O
respiratory	O
status	O
of	O
the	O
patient	O
,	O
and	O
shock	O
/	O
hypotension	O
were	O
common	O
risk	O
factors	O
for	O
IAH	O
and	O
ACS	B-ENZY
that	O
transcended	O
across	O
presenting	O
patient	O
populations	O
.	O

As	O
data	O
regarding	O
the	O
prevalence	O
and	O
outcome	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
acute	O
liver	O
failure	O
are	O
scant	O
and	O
hypoxemia	O
being	O
a	O
commonly	O
encountered	O
systemic	O
complication	O
,	O
we	O
analyzed	O
radiological	O
,	O
gas	B-ENZY
exchange	O
,	O
and	O
ventilator	O
data	O
in	O
consecutive	O
patients	O
admitted	O
with	O
acute	O
liver	O
failure	O
.	O

Here	O
we	O
report	O
whole	O
-	O
genome	O
sequences	O
of	O
two	O
novel	O
bat	B-ENZY
coronaviruses	O
from	O
Chinese	O
horseshoe	O
bats	O
(	O
family	O
:	O
Rhinolophidae	O
)	O
in	O
Yunnan	O
,	O
China	O
:	O
RsSHC014	O
and	O
Rs3367	O
.	O

Hemodynamics	O
,	O
arterial	O
blood	O
gas	B-ENZY
,	O
and	O
the	O
plasma	O
levels	O
of	O
lactate	O
,	O
creatinine	O
and	O
potassium	O
were	O
measured	O
at	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
4	O
h	O
after	O
treatment	O
.	O

An	O
ideally	O
homogeneous	O
lung	O
would	O
have	O
the	O
same	O
expansion	O
in	O
all	O
regions	O
;	O
lung	O
expansion	O
was	O
measured	O
by	O
CT	O
scan	O
as	O
gas	B-ENZY
/	O
tissue	O
ratio	O
and	O
lung	O
inhomogeneities	O
were	O
measured	O
as	O
lung	O
regions	O
with	O
lower	O
gas	B-ENZY
/	O
tissue	O
ratio	O
than	O
their	O
neighboring	O
lung	O
regions	O
.	O

The	O
only	O
pathogen	O
identified	O
by	O
PCR	O
on	O
BAL	B-ENZY
and	O
serology	O
was	O
Mycoplasma	O
pneumoniae	O
.	O

No	O
Salmonella	O
spp	B-ENZY
.	O

Retrospective	O
analysis	O
of	O
complications	O
,	O
gas	B-ENZY
exchange	O
,	O
and	O
invasiveness	O
of	O
mechanical	O
ventilation	O
during	O
first	O
and	O
second	O
PrP	O
on	O
ECMO	O
at	O
specified	O
time	O
points	O
(	O
before	O
,	O
during	O
,	O
and	O
after	O
PrP	O
).	O

TITLE	O
:	O
The	O
effects	O
of	O
Nigella	O
sativa	O
(	O
Ns	O
),	O
Anthemis	O
hyalina	O
(	O
Ah	O
)	O
and	O
Citrus	O
sinensis	O
(	O
Cs	O
)	O
extracts	O
on	O
the	O
replication	O
of	O
coronavirus	O
and	O
the	O
expression	O
of	O
TRP	B-ENZY
genes	O
family	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
extracts	O
of	O
Ah	O
,	O
Ns	O
and	O
Cs	O
on	O
the	O
replication	O
of	O
coronavirus	O
(	O
CoV	O
)	O
and	O
on	O
the	O
expression	O
of	O
TRP	B-ENZY
genes	O
during	O
coronavirus	O
infection	O
,	O
HeLa	O
-	O
CEACAM1a	O
(	O
HeLa	O
-	O
epithelial	O
carcinoembryonic	O
antigen	O
-	O
related	O
cell	O
adhesion	O
molecule	O
1a	O
)	O
cells	O
were	O
inoculated	O
with	O
MHV	O
-	O
A59	O
(	O
mouse	O
hepatitis	O
virus	O
-	O
A59	O
)	O
at	O
moi	O
of	O
30	O
.	O

The	O
most	O
prevalent	O
pathogens	O
in	O
the	O
diarrheic	O
dogs	O
were	O
CPA	O
(	O
40	O
/	O
104	O
dogs	O
,	O
38	O
.	O
5	O
%),	O
CPV	O
-	O
2	O
(	O
36	O
/	O
104	O
dogs	O
,	O
34	O
.	O
6	O
%),	O
and	O
Giardia	O
spp	B-ENZY
.	O

In	O
addition	O
to	O
the	O
typical	O
symptoms	O
of	O
fever	O
,	O
neck	O
lymphadenopathy	O
,	O
lip	B-ENZY
fissure	O
and	O
/	O
or	O
strawberry	O
tongue	O
,	O
skin	O
rash	O
,	O
nonpurulent	O
bulbar	O
conjunctivitis	O
,	O
palm	O
/	O
sole	O
erythema	O
,	O
and	O
induration	O
followed	O
by	O
periungual	O
desquamation	O
,	O
these	O
KD	O
cases	O
also	O
exhibited	O
cough	O
(	O
69	O
%),	O
rhinorrhea	O
(	O
58	O
%),	O
and	O
diarrhea	O
(	O
45	O
%).	O

TITLE	O
:	O
MERS	O
-	O
CoV	O
papain	B-ENZY
-	O
like	O
protease	O
has	O
deISGylating	O
and	O
deubiquitinating	O
activities	O
.	O

Both	O
viruses	O
appeared	O
to	O
have	O
managed	O
to	O
jump	O
over	O
the	O
species	O
barrier	O
from	O
a	O
bat	B-ENZY
reservoir	O
to	O
the	O
human	O
population	O
.	O

TITLE	O
:	O
Nidovirus	O
papain	B-ENZY
-	O
like	O
proteases	O
:	O
multifunctional	O
enzymes	O
with	O
protease	O
,	O
deubiquitinating	O
and	O
deISGylating	O
activities	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
specific	O
detection	O
of	O
anti	O
-	O
FCoV	O
antibodies	O
was	O
possible	O
in	O
all	O
plasma	O
,	O
serum	O
,	O
whole	O
blood	O
,	O
and	O
ascitic	O
fluid	O
samples	O
using	O
the	O
ICA	O
kit	O
with	O
protein	O
A	O
blotted	O
as	O
the	O
test	O
line	O
(	O
CJNP	O
/	O
TPA	B-ENZY
).	O

This	O
work	O
not	O
only	O
provides	O
a	O
new	O
understanding	O
of	O
the	O
abilities	O
of	O
MERS	O
-	O
CoV	O
and	O
closely	O
related	O
bat	B-ENZY
viruses	O
to	O
subvert	O
virus	O
sensing	O
but	O
also	O
might	O
prove	O
useful	O
in	O
revealing	O
new	O
strategies	O
for	O
the	O
development	O
of	O
vaccines	O
and	O
antivirals	O
.	O

Morever	O
,	O
recent	O
studies	O
performed	O
in	O
Saudi	O
Arabia	O
showed	O
that	O
one	O
individual	O
of	O
the	O
bat	B-ENZY
Taphozous	O
perforatus	O
harbored	O
a	O
short	O
nucleotide	O
segment	O
identical	O
to	O
the	O
homologous	O
segment	O
present	O
in	O
the	O
viral	O
strain	O
isolated	O
from	O
the	O
index	O
-	O
case	O
of	O
the	O
epidemic	O
.	O

Broncho	O
-	O
alveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
of	O
the	O
first	O
week	O
and	O
sera	O
of	O
the	O
first	O
month	O
from	O
the	O
two	O
patients	O
were	O
used	O
in	O
this	O
study	O
.	O

Knockdown	O
of	O
the	O
cellular	O
Cyclophilin	B-ENZY
A	O
(	O
CypA	O
/	O
PPIA	O
)	O
gene	O
in	O
Caco	O
-	O
2	O
cells	O
prevents	O
replication	O
of	O
HCoV	O
-	O
NL63	O
,	O
suggesting	O
that	O
CypA	O
is	O
required	O
for	O
virus	O
replication	O
.	O

was	O
diagnosed	O
in	O
46	O
calves	O
(	O
2	O
.	O
9	O
%)	O
whereas	O
15	O
calves	O
(	O
1	O
.	O
0	O
%)	O
had	O
a	O
mixed	O
-	O
infection	O
with	O
Cryptosporidium	O
spp	B-ENZY
.	O

and	O
51	O
calves	O
(	O
3	O
.	O
3	O
%)	O
with	O
Eimeria	O
spp	B-ENZY
.	O

LoFS	O
increased	O
muscle	O
phosphorylated	O
-	O
AMP	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
and	O
p38	O
in	O
BL	O
-	O
6	O
and	O
Min	O
mice	O
.	O

The	O
changes	O
in	O
the	O
expression	O
of	O
genes	O
related	O
to	O
eggshell	O
formation	O
(	O
collagen	O
types	O
I	O
and	O
V	O
,	O
and	O
CaBP	O
-	O
D28K	O
),	O
densities	O
of	O
cytotoxic	O
cells	O
(	O
CD8	O
(+)	O
and	O
TCR	O
-	O
	O
(+)	O
T	O
cells	O
),	O
and	O
gene	O
expression	O
of	O
molecules	O
related	O
to	O
cytotoxic	O
immunoreaction	O
(	O
B	O
-	O
NK	O
,	O
perforin	O
,	O
granzyme	O
,	O
and	O
IL	O
-	O
2	O
)	O
and	O
proinflammatory	O
cytokines	O
(	O
IL	O
-	O
1	O
,	O
IL	O
-	O
6	O
and	O
IFN	O
-	O
	O
)	O
were	O
examined	O
by	O
quantitative	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
or	O
immunohistochemistry	O
in	O
the	O
isthmus	O
and	O
uterus	O
.	O

METHODS	O
:	O
Nasopharyngeal	O
samples	O
were	O
collected	O
from	O
5235	O
adult	O
pilgrims	O
from	O
22	O
countries	O
and	O
screened	O
for	O
MERS	O
-	O
CoV	O
using	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
.	O

Previous	O
studies	O
suggested	O
that	O
SARS	O
-	O
CoV	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
inhibits	O
activation	O
of	O
the	O
IRF3	O
pathway	O
,	O
which	O
would	O
normally	O
elicit	O
a	O
robust	O
IFN	O
response	O
,	O
but	O
the	O
mechanism	O
(	O
s	O
)	O
used	O
by	O
SARS	O
PLpro	O
to	O
inhibit	O
activation	O
of	O
the	O
IRF3	O
pathway	O
is	O
not	O
fully	O
known	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
express	O
a	O
deubiquitinating	O
protein	O
,	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
-	O
2	O
(	O
PLP2	O
),	O
that	O
removes	O
both	O
ubiquitin	O
and	O
the	O
ubiquitin	O
-	O
like	O
interferon	O
(	O
IFN	O
)-	O
stimulated	O
gene	O
15	O
(	O
ISG15	O
)	O
protein	O
from	O
target	O
proteins	O
.	O

Here	O
,	O
a	O
viral	O
metagenomic	O
analysis	O
of	O
268	O
bat	B-ENZY
rectal	O
swabs	O
collected	O
from	O
four	O
counties	O
in	O
Yunnan	O
Province	O
has	O
identified	O
hundreds	O
of	O
sequences	O
relating	O
to	O
alpha	O
-	O
and	O
betacoronaviruses	O
.	O

Our	O
data	O
suggest	O
that	O
neutrophil	B-ENZY
elastase	I-ENZY
inhibitor	O
attenuates	O
high	O
-	O
tidal	O
-	O
volume	O
mechanical	O
ventilation	O
-	O
induced	O
neutrophil	O
influx	O
,	O
oxidative	O
stress	O
,	O
and	O
production	O
of	O
MIP	O
-	O
2	O
,	O
at	O
least	O
partly	O
,	O
through	O
inhibition	O
of	O
NF	O
-	O
B	O
/	O
NRF	O
pathway	O
.	O

The	O
goal	O
of	O
mechanical	O
ventilation	O
in	O
acute	O
hypoxemic	O
respiratory	O
failure	O
is	O
to	O
support	O
adequate	O
gas	B-ENZY
exchange	O
without	O
harming	O
the	O
lungs	O
.	O

This	O
study	O
presents	O
a	O
unique	O
chronological	O
characterization	O
of	O
SNV	O
infection	O
and	O
provides	O
mechanistic	O
data	O
into	O
the	O
pathophysiology	O
of	O
HPS	B-ENZY
in	O
a	O
closely	O
related	O
surrogate	O
animal	O
model	O
.	O

Based	O
on	O
these	O
results	O
and	O
previous	O
data	O
,	O
in	O
silico	O
docking	O
analysis	O
showed	O
a	O
putative	O
RDS1643	O
binding	O
region	O
that	O
reaches	O
into	O
the	O
PFV	O
RNase	B-ENZY
H	I-ENZY
active	O
site	O
.	O

ABSTRACT	O
:	O
Isolation	O
of	O
porcine	O
epidemic	O
diarrhea	O
coronavirus	O
(	O
PEDV	O
)	O
from	O
clinical	O
material	O
in	O
cell	O
culture	O
requires	O
supplementation	O
of	O
trypsin	B-ENZY
.	O

Multiplex	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
MRT	O
-	O
PCR	O
)	O
assays	O
for	O
detection	O
of	O
multiple	O
viruses	O
are	O
being	O
used	O
increasingly	O
in	O
clinical	O
settings	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
encodes	O
a	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
with	O
both	O
deubiquitinating	O
(	O
DUB	O
)	O
and	O
deISGylating	O
activities	O
that	O
are	O
proposed	O
to	O
counteract	O
the	O
post	O
-	O
translational	O
modification	O
of	O
signaling	O
molecules	O
that	O
activate	O
the	O
innate	O
immune	O
response	O
.	O

A	O
detailed	O
analysis	O
revealed	O
that	O
the	O
PEDV	O
N	O
protein	O
targets	O
TBK1	B-ENZY
by	O
direct	O
interaction	O
and	O
that	O
this	O
binding	O
sequesters	O
the	O
association	O
between	O
TBK1	B-ENZY
and	O
IRF3	O
,	O
which	O
in	O
turn	O
inhibits	O
both	O
IRF3	O
activation	O
and	O
type	O
I	O
IFN	O
production	O
.	O

Compared	O
to	O
9	O
patients	O
without	O
daytime	O
,	O
nocturnal	O
,	O
or	O
postexercise	O
hypoxia	O
,	O
25	O
patients	O
with	O
hypoxia	O
under	O
at	O
least	O
one	O
of	O
these	O
three	O
conditions	O
had	O
greater	O
anemia	O
severity	O
(	O
P	O
=	O
0	O
.	O
01	O
),	O
lower	O
HbF	O
levels	O
(	O
P	O
=	O
0	O
.	O
04	O
),	O
and	O
higher	O
aspartate	B-ENZY
aminotransferase	I-ENZY
levels	O
(	O
P	O
=	O
0	O
.	O
03	O
).	O

The	O
methanol	O
extract	O
of	O
T	O
.	O
terrestris	O
fruits	O
showed	O
potent	O
inhibition	O
against	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
),	O
an	O
essential	O
proteolylic	O
enzyme	O
for	O
protection	O
to	O
pathogenic	O
virus	O
and	O
bacteria	O
.	O

TITLE	O
:	O
Structural	O
and	O
functional	O
characterization	O
of	O
MERS	O
coronavirus	O
papain	B-ENZY
-	O
like	O
protease	O
.	O

In	O
the	O
present	O
study	O
,	O
MERS	O
-	O
CoV	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
is	O
expressed	O
,	O
and	O
its	O
structural	O
and	O
functional	O
consequences	O
are	O
elucidated	O
.	O

In	O
lung	O
tissue	O
,	O
LPS	O
-	O
induced	O
acute	O
injury	O
and	O
neutrophil	O
accumulation	O
were	O
strongly	O
inhibited	O
by	O
GAPDH	B-ENZY
pre	O
-	O
injection	O
.	O

Pulmonary	O
,	O
proinflammatory	O
cytokine	O
gene	O
expression	O
and	O
serum	O
chemokine	O
expression	O
in	O
GAPDH	B-ENZY
pre	O
-	O
injected	O
mice	O
were	O
also	O
reduced	O
.	O

ABSTRACT	O
:	O
Viral	O
2	O
',	O
5	O
'-	O
phosphodiesterases	O
(	O
2	O
',	O
5	O
'-	O
PDEs	O
)	O
help	O
disparate	O
RNA	O
viruses	O
evade	O
the	O
antiviral	O
activity	O
of	O
interferon	O
(	O
IFN	O
)	O
by	O
degrading	O
2	O
',	O
5	O
'-	O
oligoadenylate	O
(	O
2	O
-	O
5A	O
)	O
activators	O
of	O
RNase	B-ENZY
L	O
.	O
A	O
kinase	O
anchoring	O
proteins	O
(	O
AKAPs	O
)	O
bind	O
the	O
regulatory	O
subunits	O
of	O
protein	B-ENZY
kinase	I-ENZY
A	I-ENZY
(	O
PKA	B-ENZY
)	O
to	O
localize	O
and	O
organize	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
signaling	O
during	O
diverse	O
physiological	O
processes	O
.	O

TITLE	O
:	O
Crystal	O
structure	O
of	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
of	O
MERS	O
coronavirus	O
reveals	O
unusual	O
,	O
potentially	O
druggable	O
active	O
-	O
site	O
features	O
.	O

We	O
characterized	O
the	O
full	O
genome	O
of	O
an	O
African	O
bat	B-ENZY
virus	O
closely	O
related	O
to	O
MERS	O
-	O
CoV	O
and	O
show	O
that	O
human	O
,	O
camel	O
,	O
and	O
bat	B-ENZY
viruses	O
belong	O
to	O
the	O
same	O
viral	O
species	O
.	O

These	O
exchanges	O
may	O
have	O
taken	O
place	O
either	O
in	O
bat	B-ENZY
ancestors	O
or	O
in	O
camels	O
acting	O
as	O
mixing	O
vessels	O
for	O
viruses	O
from	O
different	O
hosts	O
.	O

ABSTRACT	O
:	O
This	O
review	O
focuses	O
on	O
the	O
important	O
contributions	O
that	O
macromolecular	O
crystallography	O
has	O
made	O
over	O
the	O
past	O
12	O
years	O
to	O
elucidating	O
structures	O
and	O
mechanisms	O
of	O
the	O
essential	O
proteases	O
of	O
coronaviruses	O
,	O
the	O
main	O
protease	O
(	O
M	O
(	O
pro	O
)	O
)	O
and	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PL	O
(	O
pro	O
)	O
).	O

To	O
investigate	O
the	O
DKA	O
binding	O
site	O
of	O
RNase	B-ENZY
H	I-ENZY
and	O
the	O
mechanism	O
of	O
action	O
,	O
six	O
couples	O
of	O
ester	O
and	O
acid	O
DKAs	O
,	O
derived	O
from	O
6	O
-[	O
1	O
-(	O
4	O
-	O
fluorophenyl	O
)	O
methyl	O
-	O
1H	O
-	O
pyrrol	O
-	O
2	O
-	O
yl	O
)]-	O
2	O
,	O
4	O
-	O
dioxo	O
-	O
5	O
-	O
hexenoic	O
acid	O
ethyl	O
ester	O
(	O
RDS1643	O
),	O
were	O
synthesized	O
and	O
tested	O
on	O
both	O
RNase	B-ENZY
H	I-ENZY
and	O
IN	O
functions	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
novel	O
pyrimidinylthioacetanilides	O
were	O
designed	O
,	O
synthesized	O
,	O
and	O
evaluated	O
for	O
their	O
biological	O
activity	O
as	O
potent	O
HIV	O
-	O
1	O
non	O
-	O
nucleoside	O
reverse	B-ENZY
transcriptase	I-ENZY
inhibitors	O
(	O
NNRTIs	O
).	O

ABSTRACT	O
:	O
A	O
series	O
of	O
non	O
-	O
nucleoside	O
reverse	B-ENZY
transcriptase	I-ENZY
inhibitors	O
derived	O
from	O
indole	O
-	O
based	O
	O
-	O
amino	O
acids	O
were	O
designed	O
and	O
synthesized	O
.	O

ABSTRACT	O
:	O
The	O
recently	O
reported	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
phylogenetically	O
closely	O
related	O
to	O
the	O
bat	B-ENZY
coronaviruses	O
(	O
BatCoVs	O
)	O
HKU4	O
and	O
HKU5	O
.	O

Significant	O
improvement	O
was	O
observed	O
in	O
HR	O
,	O
MAP	O
,	O
PaO2	O
/	O
FiO2	O
,	O
total	O
bilirubin	O
(	O
TBIL	O
)	O
and	O
alanine	B-ENZY
aminotransferase	I-ENZY
(	O
ALT	O
)	O
levels	O
after	O
treatment	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
anti	O
-	O
apoptosis	O
action	O
of	O
BMSCs	O
was	O
reversed	O
by	O
SB216763	O
,	O
a	O
specific	O
inhibitor	O
of	O
GSK	B-ENZY
-	O
3	O
that	O
also	O
activates	O
Wnt	O
/	O
	O
-	O
catenin	O
signaling	O
.	O

Modern	O
extracorporeal	O
lung	O
support	O
devices	O
allow	O
an	O
effective	O
extracorporeal	O
gas	B-ENZY
exchange	O
and	O
have	O
become	O
an	O
inherent	O
component	O
of	O
intensive	O
care	O
treatment	O
of	O
critically	O
ill	O
patients	O
.	O

This	O
discovery	O
aroused	O
great	O
interest	O
in	O
understanding	O
the	O
evolutionary	O
history	O
and	O
pandemic	O
potential	O
of	O
bat	B-ENZY
-	O
influenza	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
membrane	O
-	O
associated	O
papain	B-ENZY
-	O
like	O
protease	O
PLP2	O
(	O
PLP2	O
-	O
TM	O
)	O
of	O
coronaviruses	O
acts	O
as	O
a	O
novel	O
autophagy	O
-	O
inducing	O
protein	O
.	O

ABSTRACT	O
:	O
Acute	O
chest	O
syndrome	O
(	O
ACS	B-ENZY
)	O
is	O
the	O
leading	O
cause	O
of	O
ICU	O
admission	O
in	O
patients	O
with	O
sickle	O
cell	O
disease	O
and	O
is	O
characterized	O
by	O
golden	O
sputum	O
,	O
which	O
is	O
commonly	O
attributed	O
to	O
the	O
presence	O
of	O
bilirubin	O
.	O

IAH	O
contributes	O
to	O
multiple	O
physiologic	O
alterations	O
and	O
leads	O
to	O
the	O
development	O
of	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-ENZY
)	O
that	O
induces	O
multiorgan	O
failure	O
.	O

Changes	O
in	O
the	O
expression	O
levels	O
of	O
transforming	O
growth	O
factor	O
beta	O
1	O
(	O
TGF	O
-	O
1	O
),	O
caspase	B-ENZY
-	I-ENZY
8	I-ENZY
,	O
and	O
heat	O
shock	O
protein	O
90	O
alpha	O
(	O
HSP90	O
)	O
were	O
also	O
verified	O
by	O
western	O
blot	O
analysis	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
endoplasmic	O
reticulum	O
-	O
resident	O
glucosidases	O
impairs	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
and	O
human	O
coronavirus	O
NL63	O
spike	O
protein	O
-	O
mediated	O
entry	O
by	O
altering	O
the	O
glycan	O
processing	O
of	O
angiotensin	B-ENZY
I	I-ENZY
-	I-ENZY
converting	I-ENZY
enzyme	I-ENZY
2	O
.	O

Indeed	O
,	O
we	O
demonstrate	O
here	O
that	O
iminosugar	O
treatment	O
altered	O
the	O
N	O
-	O
linked	O
glycan	O
structure	O
of	O
angiotensin	B-ENZY
I	I-ENZY
-	I-ENZY
converting	I-ENZY
enzyme	I-ENZY
2	O
(	O
ACE2	O
),	O
which	O
did	O
not	O
affect	O
its	O
expression	O
on	O
the	O
cell	O
surface	O
or	O
its	O
binding	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
glycoprotein	O
.	O

We	O
report	O
results	O
for	O
treating	O
acute	O
allergic	O
and	O
non	O
-	O
allergic	O
bronchoconstriction	O
in	O
sheep	O
using	O
S	O
-	O
1226	O
(	O
a	O
gas	B-ENZY
mixture	O
containing	O
carbon	O
dioxide	O
and	O
small	O
volumes	O
of	O
nebulized	O
perflubron	O
).	O

Fusion	O
of	O
MHV	O
was	O
severely	O
inhibited	O
by	O
a	O
pan	O
-	O
lysosomal	O
protease	O
inhibitor	O
,	O
while	O
trafficking	O
of	O
MHV	O
to	O
lysosomes	O
and	O
processing	O
by	O
lysosomal	O
proteases	O
was	O
no	O
longer	O
required	O
when	O
a	O
furin	B-ENZY
cleavage	O
site	O
was	O
introduced	O
in	O
the	O
S	O
protein	O
immediately	O
upstream	O
of	O
the	O
fusion	O
peptide	O
.	O

Light	O
microscopy	O
analysis	O
of	O
BAL	B-ENZY
cytocentrifugates	O
showed	O
the	O
presence	O
of	O
characteristic	O
large	O
,	O
mononuclear	O
,	O
plasmoblastic	O
/	O
plasmocytoid	O
-	O
like	O
cells	O
never	O
described	O
before	O
.	O

TITLE	O
:	O
Ecological	O
dynamics	O
of	O
emerging	O
bat	B-ENZY
virus	O
spillover	O
.	O

Sequence	O
analysis	O
of	O
the	O
gltA	O
and	O
rpoB	O
revealed	O
	O
96	O
%	O
identity	O
to	O
B	O
.	O
bovis	O
,	O
a	O
previously	O
suggested	O
cutoff	O
value	O
for	O
sequence	O
-	O
based	O
differentiation	O
of	O
Bartonella	O
spp	B-ENZY
.,	O
suggesting	O
that	O
this	O
approach	O
does	O
not	O
have	O
sufficient	O
discriminatory	O
power	O
for	O
differentiating	O
ruminant	O
-	O
related	O
Bartonella	O
spp	B-ENZY
.	O

Finally	O
,	O
sequential	O
passage	O
of	O
MERS	O
-	O
CoV	O
in	O
permissive	O
bat	B-ENZY
cells	O
established	O
persistent	O
infection	O
with	O
concomitant	O
downregulation	O
of	O
CD26	O
/	O
DPP4	O
surface	O
expression	O
.	O

Future	O
research	O
should	O
include	O
validation	O
of	O
the	O
clinical	O
criteria	O
for	O
anaphylaxis	O
diagnosis	O
in	O
infants	O
,	O
prospective	O
longitudinal	O
monitoring	O
of	O
baseline	O
serum	O
tryptase	B-ENZY
levels	O
in	O
healthy	O
and	O
atopic	O
infants	O
during	O
the	O
first	O
year	O
of	O
life	O
,	O
studies	O
of	O
infant	O
comorbidities	O
and	O
cofactors	O
that	O
increase	O
the	O
risk	O
of	O
severe	O
anaphylaxis	O
,	O
development	O
of	O
autoinjectors	O
containing	O
a	O
0	O
.	O
1	O
-	O
mg	O
epinephrine	O
dose	O
suitable	O
for	O
infants	O
,	O
and	O
inclusion	O
of	O
infants	O
in	O
prospective	O
studies	O
of	O
immune	O
modulation	O
to	O
prevent	O
anaphylaxis	O
recurrences	O
.	O

ABSTRACT	O
:	O
Compared	O
with	O
the	O
conventional	O
forms	O
of	O
partial	O
support	O
,	O
neurally	O
adjusted	O
ventilatory	O
assist	O
was	O
repeatedly	O
shown	O
to	O
improve	O
patient	O
-	O
ventilator	O
synchrony	O
and	O
reduce	O
the	O
risk	O
of	O
overassistance	O
,	O
while	O
guaranteeing	O
adequate	O
inspiratory	O
effort	O
and	O
gas	B-ENZY
exchange	O
.	O

TITLE	O
:	O
Antiviral	O
potential	O
of	O
ERK	B-ENZY
/	O
MAPK	B-ENZY
and	O
PI3K	O
/	O
AKT	O
/	O
mTOR	O
signaling	O
modulation	O
for	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
as	O
identified	O
by	O
temporal	O
kinome	O
analysis	O
.	O

Recently	O
,	O
the	O
coronavirus	O
papain	B-ENZY
-	O
like	O
proteases	O
(	O
PLPs	O
)	O
have	O
been	O
identified	O
as	O
suppressors	O
of	O
the	O
innate	O
immune	O
response	O
.	O

ABSTRACT	O
:	O
Background	O
:	O
Bat	B-ENZY
-	O
borne	O
viruses	O
pose	O
a	O
potential	O
risk	O
to	O
human	O
health	O
and	O
are	O
the	O
focus	O
of	O
increasing	O
scientific	O
interest	O
.	O

A	O
total	O
of	O
447	O
fecal	O
samples	O
,	O
representing	O
24	O
European	O
bat	B-ENZY
species	O
were	O
tested	O
.	O

TITLE	O
:	O
Detection	O
of	O
infectious	O
bronchitis	O
virus	O
with	O
the	O
use	O
of	O
real	O
-	O
time	O
quantitative	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
PCR	O
and	O
correlation	O
with	O
virus	O
detection	O
in	O
embryonated	O
eggs	O
.	O

ALT	O
levels	O
were	O
elevated	O
in	O
25	O
children	O
(	O
41	O
%)	O
and	O
31	O
(	O
51	O
.	O
66	O
%)	O
children	O
had	O
increased	O
levels	O
of	O
AST	B-ENZY
.	O

The	O
coronaviral	O
proteases	O
,	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
and	O
3C	O
-	O
like	O
protease	O
(	O
3CLpro	O
),	O
are	O
attractive	O
antiviral	O
drug	O
targets	O
because	O
they	O
are	O
essential	O
for	O
coronaviral	O
replication	O
.	O

This	O
review	O
provides	O
an	O
up	O
-	O
to	O
-	O
date	O
discussion	O
on	O
the	O
SARS	O
-	O
CoV	O
papain	B-ENZY
-	O
like	O
protease	O
including	O
a	O
brief	O
overview	O
of	O
the	O
SARS	O
-	O
CoV	O
genome	O
and	O
replication	O
followed	O
by	O
a	O
more	O
in	O
-	O
depth	O
discussion	O
on	O
the	O
structure	O
and	O
catalytic	O
mechanism	O
of	O
SARS	O
-	O
CoV	O
PLpro	O
,	O
the	O
multiple	O
cellular	O
functions	O
of	O
SARS	O
-	O
CoV	O
PLpro	O
,	O
the	O
inhibition	O
of	O
SARS	O
-	O
CoV	O
PLpro	O
by	O
small	O
molecule	O
inhibitors	O
,	O
and	O
the	O
prospect	O
of	O
inhibiting	O
papain	B-ENZY
-	O
like	O
protease	O
from	O
other	O
coronaviruses	O
.	O

Mycoplasma	O
bovis	O
was	O
identified	O
by	O
PCR	O
testing	O
or	O
culture	O
in	O
19	O
calves	O
,	O
and	O
78	O
calves	O
were	O
found	O
to	O
be	O
positive	O
for	O
Mycoplasma	O
spp	B-ENZY
.	O

TITLE	O
:	O
Structure	O
-	O
activity	O
relationship	O
of	O
pyrrolyl	O
diketo	O
acid	O
derivatives	O
as	O
dual	O
inhibitors	O
of	O
HIV	O
-	O
1	O
integrase	O
and	O
reverse	B-ENZY
transcriptase	I-ENZY
ribonuclease	B-ENZY
H	I-ENZY
domain	O
.	O

We	O
newly	O
synthesized	O
pyrrolyl	O
derivatives	O
that	O
exhibited	O
good	O
potency	O
against	O
IN	O
and	O
a	O
moderate	O
inhibition	O
of	O
the	O
RNase	B-ENZY
H	I-ENZY
function	O
of	O
RT	O
,	O
confirming	O
the	O
possibility	O
of	O
developing	O
dual	O
HIV	O
-	O
1	O
IN	O
/	O
RNase	B-ENZY
H	I-ENZY
inhibitors	O
and	O
obtaining	O
new	O
information	O
for	O
the	O
further	O
development	O
of	O
more	O
effective	O
dual	O
HIV	O
-	O
1	O
inhibitors	O
.	O

The	O
relative	O
sensitivity	O
and	O
specificity	O
of	O
the	O
assay	O
were	O
found	O
to	O
be	O
93	O
.	O
90	O
%	O
and	O
100	O
%,	O
respectively	O
,	O
compared	O
to	O
that	O
of	O
the	O
UpE	O
and	O
open	O
reading	O
frame	O
1A	O
(	O
Orf1A	O
)	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
(	O
RT	O
-	O
PCR	O
).	O

In	O
the	O
present	O
study	O
,	O
we	O
report	O
the	O
discovery	O
of	O
bat	B-ENZY
CoV	O
genes	O
in	O
Indonesian	O
Moluccan	O
naked	O
-	O
backed	O
fruit	O
bats	O
(	O
Dobsonia	O
moluccensis	O
).	O

For	O
analysing	O
coronavirus	O
diversity	O
in	O
a	O
bat	B-ENZY
species	O
-	O
rich	O
country	O
,	O
a	O
total	O
of	O
421	O
anal	O
swabs	O
/	O
faecal	O
samples	O
from	O
Costa	O
Rican	O
bats	O
were	O
screened	O
for	O
CoV	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	O
)	O
gene	O
sequences	O
by	O
a	O
pancoronavirus	O
PCR	O
.	O

Here	O
,	O
we	O
show	O
that	O
MPER	O
can	O
undergo	O
self	O
-	O
oligomerization	O
and	O
heteromerization	O
with	O
IFP	O
,	O
events	O
that	O
are	O
Trp	B-ENZY
-	O
dependent	O
.	O

Then	O
,	O
we	O
treated	O
different	O
bat	B-ENZY
cells	O
,	O
mouse	O
embryonic	O
fibroblasts	O
(	O
MEF	O
)	O
and	O
splenocytes	O
with	O
polyinosinic	O
-	O
polycytidylic	O
acid	O
(	O
polyI	O
:	O
C	O
)	O
and	O
vesicular	O
stomatitis	O
virus	O
(	O
VSV	O
)	O
to	O
assess	O
and	O
compare	O
antiviral	O
immune	O
responses	O
between	O
bats	O
and	O
mice	O
.	O

In	O
N11	O
protein	O
,	O
we	O
identified	O
hepatitis	O
E	O
E2S	O
-	O
like	O
domains	O
,	O
SARS	O
spike	O
protein	O
-	O
like	O
domains	O
,	O
and	O
toxin	O
components	O
shared	O
by	O
alpha	O
-	O
bungarotoxin	O
,	O
staphylococcal	O
enterotoxin	O
I	O
,	O
anthrax	O
lethal	O
factor	O
,	O
clostridium	O
botulinum	B-ENZY
neurotoxin	I-ENZY
,	O
and	O
clostridium	O
tetanus	O
toxin	O
.	O

Sequence	O
analysis	O
comparing	O
Pteropus	O
alecto	O
furin	B-ENZY
and	O
cathepsin	B-ENZY
L	I-ENZY
to	O
proteases	O
from	O
other	O
mammalian	O
species	O
showed	O
a	O
high	O
degree	O
of	O
conservation	O
;	O
however	O
significant	O
amino	O
acid	O
variation	O
occurs	O
at	O
the	O
C	O
-	O
terminus	O
of	O
Pteropus	O
alecto	O
furin	B-ENZY
.	O

Here	O
,	O
we	O
describe	O
a	O
method	O
for	O
incorporating	O
a	O
proteinaceous	O
viral	O
receptor	O
,	O
feline	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
fAPN	O
),	O
into	O
SLBs	O
using	O
cell	O
blebbing	O
of	O
mammalian	O
cells	O
expressing	O
fAPN	O
in	O
the	O
plasma	O
membrane	O
.	O

Goat	O
anti	O
-	O
turkey	O
IgG	O
(	O
H	O
+	O
L	O
)	O
conjugated	O
with	O
horseradish	O
peroxidase	B-ENZY
was	O
used	O
as	O
detector	O
antibody	O
.	O

Subsequent	O
hunting	O
for	O
novel	O
coronaviruses	O
(	O
CoVs	O
)	O
led	O
to	O
the	O
discovery	O
of	O
two	O
additional	O
human	O
and	O
over	O
40	O
animal	O
CoVs	O
,	O
including	O
the	O
prototype	O
lineage	O
C	O
betacoronaviruses	O
,	O
Tylonycteris	O
bat	B-ENZY
CoV	O
HKU4	O
and	O
Pipistrellus	O
bat	B-ENZY
CoV	O
HKU5	O
;	O
these	O
are	O
phylogenetically	O
closely	O
related	O
to	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
CoV	O
,	O
which	O
has	O
affected	O
more	O
than	O
1	O
,	O
000	O
patients	O
with	O
over	O
35	O
%	O
fatality	O
since	O
its	O
emergence	O
in	O
2012	O
.	O

Hypertension	O
and	O
cardiogenic	O
shock	O
were	O
associated	O
with	O
the	O
emergence	O
of	O
moderate	O
transient	O
dysfunction	O
of	O
gas	B-ENZY
exchange	O
postoperatively	O
(	O
P	O
=	O
0	O
.	O
02	O
and	O
P	O
=	O
0	O
.	O
019	O
,	O
respectively	O
)	O
and	O
were	O
risk	O
factors	O
for	O
this	O
dysfunction	O
(	O
P	O
=	O
0	O
.	O
0023	O
and	O
P	O
=	O
0	O
.	O
0017	O
,	O
respectively	O
).	O

Diabetes	O
mellitus	O
was	O
also	O
a	O
risk	O
factor	O
for	O
transient	O
dysfunction	O
of	O
gas	B-ENZY
exchange	O
(	O
P	O
=	O
0	O
.	O
03	O
).	O

Severe	O
transient	O
dysfunction	O
of	O
gas	B-ENZY
exchange	O
was	O
associated	O
with	O
patients	O
who	O
had	O
renal	O
replacement	O
therapy	O
(	O
P	O
=	O
0	O
.	O
0005	O
),	O
hemotherapy	O
(	O
P	O
=	O
0	O
.	O
0001	O
),	O
enteral	O
nutrition	O
(	O
P	O
=	O
0	O
.	O
0012	O
),	O
or	O
cardiac	O
arrhythmia	O
(	O
P	O
=	O
0	O
.	O
0451	O
).	O

The	O
day	O
-	O
by	O
-	O
day	O
Berlin	O
and	O
LIS	B-ENZY
categories	O
were	O
inversely	O
associated	O
with	O
albumin	O
levels	O
(	O
P	O
=	O
0	O
.	O
01	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
directly	O
with	O
CRP	O
levels	O
(	O
P	O
=	O
0	O
.	O
02	O
,	O
P	O
=	O
0	O
.	O
04	O
,	O
respectively	O
).	O

When	O
the	O
Berlin	O
or	O
LIS	B-ENZY
category	O
increased	O
,	O
albumin	O
levels	O
decreased	O
	O
1	O
g	O
/	O
L	O
(	O
AUROC	O
0	O
.	O
72	O
-	O
0	O
.	O
77	O
,	O
P	O
=	O
0	O
.	O
001	O
)	O
and	O
CRP	O
increased	O
	O
104	O
mg	O
/	O
L	O
(	O
only	O
significant	O
for	O
Berlin	O
,	O
AUROC	O
0	O
.	O
69	O
,	O
P	O
=	O
0	O
.	O
04	O
).	O

These	O
effects	O
may	O
be	O
related	O
to	O
its	O
ability	O
to	O
suppress	O
production	O
of	O
inflammatory	O
cytokines	O
through	O
ERK	B-ENZY
pathway	O
.	O

Nonetheless	O
,	O
the	O
HKU1	O
-	O
HE	O
was	O
similar	O
to	O
OC43	O
-	O
HE	O
,	O
also	O
possessed	O
sialate	O
-	O
O	O
-	O
acetylesterase	B-ENZY
activity	O
,	O
and	O
acted	O
as	O
a	O
receptor	O
-	O
destroying	O
enzyme	O
(	O
RDE	O
)	O
capable	O
of	O
eliminating	O
the	O
binding	O
of	O
HKU1	O
-	O
S1	O
to	O
RD	O
cells	O
,	O
whereas	O
the	O
O	O
-	O
acetylesterase	B-ENZY
-	O
inactive	O
HKU1	O
-	O
HE	O
mutant	O
lost	O
this	O
capacity	O
.	O

These	O
results	O
demonstrate	O
that	O
hCoV	O
-	O
HKU1	O
exploits	O
O	O
-	O
Ac	O
-	O
Sia	O
as	O
a	O
cellular	O
attachment	O
receptor	O
determinant	O
to	O
initiate	O
the	O
infection	O
of	O
host	O
cells	O
and	O
that	O
its	O
HE	O
protein	O
possesses	O
the	O
corresponding	O
sialate	O
-	O
O	O
-	O
acetylesterase	B-ENZY
RDE	O
activity	O
.	O

TITLE	O
:	O
A	O
Luciferase	B-ENZY
Reporter	O
Gene	O
Assay	O
to	O
Measure	O
Ebola	O
Virus	O
Viral	O
Protein	O
35	O
-	O
Associated	O
Inhibition	O
of	O
Double	O
-	O
Stranded	O
RNA	O
-	O
Stimulated	O
,	O
Retinoic	O
Acid	O
-	O
Inducible	O
Gene	O
1	O
-	O
Mediated	O
Induction	O
of	O
Interferon	O
	O
.	O

Summarily	O
,	O
endotracheal	O
suctioning	O
may	O
impair	O
gas	B-ENZY
exchange	O
and	O
decrease	O
lung	O
compliance	O
in	O
ARF	O
patients	O
receiving	O
mechanical	O
ventilation	O
under	O
both	O
PCV	O
and	O
VCV	O
modes	O
,	O
but	O
endotracheal	O
suctioning	O
effects	O
on	O
gas	B-ENZY
exchange	O
were	O
more	O
severe	O
and	O
longer	O
-	O
lasting	O
under	O
PCV	O
mode	O
than	O
VCV	O
.	O

Likewise	O
,	O
an	O
attenuated	O
response	O
was	O
observed	O
in	O
PVK	O
cells	O
infected	O
with	O
recombinant	O
NDVs	O
expressing	O
the	O
NiV	O
IFN	O
antagonist	O
proteins	O
V	O
and	O
W	O
.	O
This	O
study	O
provides	O
the	O
first	O
global	O
profile	O
of	O
a	O
robust	O
virus	O
-	O
induced	O
innate	O
immune	O
response	O
in	O
bats	O
and	O
indicates	O
that	O
henipavirus	O
IFN	O
antagonist	O
mechanisms	O
are	O
likely	O
active	O
in	O
bat	B-ENZY
cells	O
.	O

Viral	O
infections	O
are	O
reportedly	O
asymptomatic	O
or	O
heavily	O
attenuated	O
in	O
bat	B-ENZY
populations	O
.	O

Here	O
,	O
we	O
engineered	O
VeroE6	O
cells	O
to	O
stably	O
express	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
pAPN	O
)	O
and	O
used	O
them	O
as	O
a	O
platform	O
to	O
obtain	O
a	O
high	O
-	O
growth	O
variant	O
of	O
PEDV	O
,	O
termed	O
PEDVAVCT12	O
.	O

The	O
genome	O
of	O
HCoV	O
-	O
EMC	O
is	O
most	O
closely	O
related	O
to	O
Tylonycteris	O
bat	B-ENZY
coronavirus	O
HKU4	O
(	O
Ty	O
-	O
BatCoV	O
HKU4	O
)	O
and	O
Pipistrellus	O
bat	B-ENZY
coronavirus	O
HKU5	O
(	O
Pi	O
-	O
BatCoV	O
HKU5	O
)	O
we	O
discovered	O
in	O
2006	O
.	O

Previous	O
studies	O
showed	O
that	O
the	O
2	O
'-	O
O	O
-	O
MTase	O
activity	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nonstructural	O
protein	O
16	O
(	O
nsp16	O
)	O
needs	O
to	O
be	O
activated	O
by	O
nsp10	O
,	O
whereas	O
nsp16	O
of	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
alone	O
possesses	O
2	O
'-	O
O	O
-	O
MTase	O
activity	O
(	O
E	O
.	O
Decroly	O
et	O
al	O
.,	O
J	O
Virol	O
82	O
:	O
8071	O
-	O
8084	O
,	O
2008	O
,	O
http	O
://	O
dx	O
.	O
doi	O
.	O
org	O
/	O
10	O
.	O
1128	O
/	O
JVI	O
.	O
00407	O
-	O
08	O
;	O
M	O
.	O
Bouvet	O
et	O
al	O
.,	O
PLoS	O
Pathog	O
6	O
:	O
e1000863	O
,	O
2010	O
,	O
http	O
://	O
dx	O
.	O
doi	O
.	O
org	O
/	O
10	O
.	O
1371	O
/	O
journal	O
.	O
ppat	B-ENZY
.	O
1000863	O
;	O
E	O
.	O
Decroly	O
et	O
al	O
.,	O
PLoS	O
Pathog	O
7	O
:	O
e1002059	O
,	O
2011	O
,	O
http	O
://	O
dx	O
.	O
doi	O
.	O
org	O
/	O
10	O
.	O
1371	O
/	O
journal	O
.	O
ppat	B-ENZY
.	O
1002059	O
;	O
Y	O
.	O
Chen	O
et	O
al	O
.,	O
PLoS	O
Pathog	O
7	O
:	O
e1002294	O
,	O
2011	O
,	O
http	O
://	O
dx	O
.	O
doi	O
.	O
org	O
/	O
10	O
.	O
1371	O
/	O
journal	O
.	O
ppat	B-ENZY
.	O
1002294	O
)	O
.	O

TITLE	O
:	O
Two	O
Mutations	O
Were	O
Critical	O
for	O
Bat	B-ENZY
-	O
to	O
-	O
Human	O
Transmission	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
.	O

TITLE	O
:	O
Anthrax	O
lethal	B-ENZY
toxin	I-ENZY
-	O
induced	O
lung	O
injury	O
and	O
treatment	O
by	O
activating	O
MK2	O
.	O

ABSTRACT	O
:	O
Anthrax	O
is	O
associated	O
with	O
severe	O
vascular	O
leak	O
,	O
which	O
is	O
caused	O
by	O
the	O
bacterial	O
lethal	B-ENZY
toxin	I-ENZY
(	O
LeTx	O
).	O

The	O
biological	O
activity	O
of	O
LeTx	O
resides	O
in	O
the	O
lethal	O
factor	O
metalloprotease	O
that	O
specifically	O
degrades	O
MAP	B-ENZY
kinase	I-ENZY
kinases	O
(	O
MKKs	O
).	O

LeTx	O
effects	O
were	O
linked	O
specifically	O
to	O
blocking	O
activation	O
of	O
p38	O
substrate	O
and	O
MAP	B-ENZY
kinase	I-ENZY
-	O
activated	O
protein	B-ENZY
kinase	I-ENZY
2	O
(	O
MAPKAPK2	O
or	O
MK2	O
)	O
and	O
phosphorylation	O
of	O
the	O
latter	O
'	O
s	O
substrate	O
,	O
heat	O
shock	O
protein	O
27	O
(	O
HSP27	O
).	O

p38	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
is	O
central	O
to	O
the	O
regulation	O
of	O
multiple	O
inflammatory	O
mediators	O
implicated	O
in	O
acute	O
organ	O
dysfunction	O
and	O
is	O
the	O
target	O
for	O
a	O
novel	O
class	O
of	O
cytokine	O
-	O
suppressive	O
anti	O
-	O
inflammatory	O
drugs	O
.	O

The	O
novel	O
p38	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
inhibitor	O
dilmapimod	O
appears	O
well	O
tolerated	O
and	O
may	O
merit	O
further	O
evaluation	O
for	O
prevention	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
other	O
organ	O
injury	O
in	O
larger	O
clinical	O
trials	O
.	O

Treatment	O
with	O
ERK	B-ENZY
inhibitors	O
or	O
ERK1	O
/	O
2	O
knockdown	O
significantly	O
suppressed	O
viral	O
progeny	O
production	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
ERK	B-ENZY
signaling	O
pathway	O
plays	O
an	O
important	O
role	O
in	O
the	O
PEDV	O
life	O
cycle	O
and	O
beneficially	O
contributes	O
to	O
viral	O
infection	O
.	O

The	O
ubiquitin	O
-	O
proteasome	B-ENZY
,	O
autophagy	O
,	O
and	O
calpain	O
-	O
caspase	O
pathways	O
have	O
all	O
been	O
implicated	O
in	O
early	O
-	O
phase	O
muscle	O
dysfunction	O
.	O

ABSTRACT	O
:	O
Because	O
some	O
bats	O
host	O
viruses	O
with	O
zoonotic	O
potential	O
,	O
we	O
investigated	O
human	O
-	O
bat	B-ENZY
interactions	O
in	O
rural	O
Ghana	O
during	O
2011	O
-	O
2012	O
.	O

Meanwhile	O
blood	O
gas	B-ENZY
was	O
analyzed	O
and	O
oxygenation	O
index	O
(	O
OI	O
)	O
calculated	O
.	O

TITLE	O
:	O
Targeting	O
zoonotic	O
viruses	O
:	O
Structure	O
-	O
based	O
inhibition	O
of	O
the	O
3C	O
-	O
like	O
protease	O
from	O
bat	B-ENZY
coronavirus	O
HKU4	O
--	O
The	O
likely	O
reservoir	O
host	O
to	O
the	O
human	O
coronavirus	O
that	O
causes	O
Middle	O
East	O
Respiratory	O
Syndrome	O
(	O
MERS	O
).	O

The	O
lopinavir	O
/	O
ritonavir	O
-	O
treated	O
and	O
interferon	O
-	O
1b	O
-	O
treated	O
animals	O
had	O
better	O
outcome	O
than	O
the	O
untreated	O
animals	O
,	O
with	O
improved	O
clinical	O
(	O
mean	O
clinical	O
scores	O
	O
50	O
.	O
9	O
%-	O
95	O
.	O
0	O
%	O
and	O
	O
weight	O
loss	O
than	O
the	O
untreated	O
animals	O
),	O
radiological	O
(	O
minimal	O
pulmonary	O
infiltrates	O
),	O
and	O
pathological	O
(	O
mild	O
bronchointerstitial	O
pneumonia	O
)	O
findings	O
,	O
and	O
lower	O
mean	O
viral	O
loads	O
in	O
necropsied	O
lung	O
(	O
0	O
.	O
59	O
-	O
1	O
.	O
06	O
log10	O
copies	O
/	O
glyceraldehyde	O
3	O
-	O
phosphate	O
dehydrogenase	O
[	O
GAPDH	B-ENZY
];	O
P	O
<	O
.	O
050	O
)	O
and	O
extrapulmonary	O
(	O
0	O
.	O
11	O
-	O
1	O
.	O
29	O
log10	O
copies	O
/	O
GAPDH	B-ENZY
;	O
P	O
<	O
.	O
050	O
in	O
kidney	O
)	O
tissues	O
.	O

In	O
contrast	O
,	O
all	O
MMF	O
-	O
treated	O
animals	O
developed	O
severe	O
and	O
/	O
or	O
fatal	O
disease	O
with	O
higher	O
mean	O
viral	O
loads	O
(	O
0	O
.	O
15	O
-	O
0	O
.	O
54	O
log10	O
copies	O
/	O
GAPDH	B-ENZY
)	O
than	O
the	O
untreated	O
animals	O
.	O

However	O
,	O
two	O
distinct	O
features	O
were	O
observed	O
in	O
the	O
CCoV	O
-	O
I	O
genome	O
:	O
(	O
i	O
)	O
the	O
presence	O
of	O
an	O
additional	O
ORF	O
between	O
the	O
spike	O
(	O
S	O
)	O
protein	O
gene	O
and	O
ORF3a	O
;	O
(	O
ii	O
)	O
the	O
diversity	O
of	O
the	O
S	O
protein	O
,	O
which	O
is	O
more	O
closely	O
related	O
to	O
that	O
of	O
feline	O
coronavirus	O
type	O
I	O
and	O
presents	O
a	O
furin	B-ENZY
cleavage	O
site	O
.	O

Early	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
is	O
critical	O
in	O
distinguishing	O
the	O
diagnosis	O
to	O
initiate	O
proper	O
management	O
.	O

The	O
dual	O
luciferase	B-ENZY
reporter	O
assay	O
showed	O
that	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
NPIPB3	O
attenuated	O
the	O
antagonistic	O
activity	O
of	O
SARS	O
-	O
CoV	O
ORF6	O
on	O
IFN	O
-	O
	O
-	O
induced	O
ISRE	O
(	O
IFN	O
stimulated	O
response	O
element	O
)-	O
responsive	O
firefly	B-ENZY
luciferase	I-ENZY
activity	O
.	O

Pulse	O
oximetry	O
and	O
pulmonary	O
ultrasound	O
may	O
be	O
useful	O
tools	O
to	O
screen	O
for	O
,	O
or	O
rule	O
out	O
,	O
impaired	O
oxygenation	O
or	O
lung	O
abnormalities	O
consistent	O
with	O
ARDS	O
in	O
under	O
-	O
resourced	O
settings	O
where	O
arterial	O
blood	O
gas	B-ENZY
testing	O
and	O
chest	O
radiography	O
are	O
not	O
readily	O
available	O
.	O

We	O
have	O
been	O
suggested	O
that	O
treatment	O
of	O
septic	O
baboons	O
with	O
compstatin	O
,	O
a	O
C3	B-ENZY
convertase	I-ENZY
inhibitor	O
protects	O
against	O
ARDS	O
-	O
induced	O
fibroproliferation	O
.	O

Bat	B-ENZY
viruses	O
formed	O
three	O
large	O
clades	O
in	O
close	O
and	O
more	O
distant	O
sister	O
relationships	O
.	O

HCoV	O
-	O
229E	O
and	O
the	O
alpaca	O
virus	O
showed	O
a	O
major	O
deletion	O
in	O
the	O
spike	O
S1	O
region	O
compared	O
to	O
all	O
bat	B-ENZY
viruses	O
.	O

131	O
genes	O
from	O
apoptosis	O
cluster	O
(	O
80	O
down	O
-	O
regulated	O
and	O
51	O
up	O
-	O
regulated	O
)	O
along	O
with	O
increase	O
of	O
apoptosis	O
,	O
p53	O
,	O
p38	O
MAPK	B-ENZY
,	O
VEGF	O
and	O
chemokines	O
/	O
cytokines	O
signaling	O
pathways	O
were	O
probably	O
involved	O
in	O
apoptosis	O
process	O
.	O

Multivariate	O
analysis	O
associated	O
hospital	O
mortality	O
with	O
age	O
and	O
Pao	B-ENZY
CONCLUSIONS	O
:	O
The	O
overall	O
hospital	O
mortality	O
(	O
38	O
%)	O
was	O
similar	O
to	O
that	O
of	O
other	O
studies	O
and	O
according	O
to	O
the	O
presence	O
of	O
ARDS	O
(	O
Pao	B-ENZY

Eleven	O
out	O
of	O
38	O
PEDV	O
strains	O
were	O
isolated	O
successfully	O
on	O
Vero	O
cells	O
with	O
trypsin	B-ENZY
treatment	O
and	O
subjected	O
to	O
genome	O
sequence	O
analysis	O
.	O

Overall	O
,	O
149	O
subjects	O
with	O
ACS	B-ENZY
(	O
namely	O
,	O
acute	O
myocardial	O
infarct	O
with	O
or	O
without	O
ST	O
-	O
segment	O
elevation	O
or	O
unstable	O
angina	O
),	O
with	O
no	O
previous	O
history	O
of	O
CHD	O
,	O
admitted	O
to	O
three	O
cardiac	O
intensive	O
care	O
units	O
were	O
included	O
and	O
evaluated	O
by	O
the	O
Structured	O
Clinical	O
Interview	O
for	O
Complicated	O
Grief	O
(	O
SCI	O
-	O
CG	O
),	O
Hamilton	O
Depression	O
Rating	O
Scale	O
,	O
Hamilton	O
Anxiety	O
Rating	O
Scale	O
,	O
and	O
the	O
36	O
-	O
item	O
Short	O
-	O
Form	O
Health	O
Survey	O
(	O
MOS	O
-	O
SF	O
-	O
36	O
).	O

The	O
occurrence	O
of	O
ACS	B-ENZY
12	O
-	O
48	O
months	O
(	O
P	O
=	O
0	O
.	O
019	O
)	O
after	O
the	O
loss	O
was	O
positively	O
correlated	O
with	O
SCI	O
-	O
CG	O
scores	O
.	O

RESULTS	O
:	O
Of	O
the	O
total	O
sample	O
of	O
149	O
subjects	O
with	O
ACS	B-ENZY
,	O
118	O
(	O
79	O
.	O
2	O
%)	O
met	O
criteria	O
for	O
DSM	O
-	O
5	O
persistent	O
complex	O
bereavement	O
disorder	O
.	O

Similar	O
behavior	O
was	O
observed	O
in	O
tracer	O
gas	B-ENZY
,	O
particle	O
experiments	O
,	O
and	O
flight	O
infection	O
data	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

ABSTRACT	O
:	O
Recently	O
several	O
infectious	O
agents	O
with	O
a	O
zoonotic	O
potential	O
have	O
been	O
detected	O
in	O
different	O
bat	B-ENZY
species	O
.	O

The	O
phospholipid	O
profile	O
of	O
BAL	B-ENZY
large	O
and	O
small	O
aggregate	O
fractions	O
was	O
also	O
different	O
from	O
uninfected	O
controls	O
,	O
with	O
a	O
significant	O
increase	O
in	O
the	O
amounts	O
of	O
sphingomyelin	O
and	O
lysophosphatidylcholine	O
and	O
the	O
decrease	O
in	O
phosphatidylglycerol	O
.	O

To	O
determine	O
the	O
presence	O
of	O
CoVs	O
in	O
French	O
bats	O
,	O
fecal	O
samples	O
were	O
collected	O
between	O
July	O
and	O
August	O
of	O
2014	O
from	O
four	O
bat	B-ENZY
species	O
in	O
seven	O
different	O
locations	O
around	O
the	O
city	O
of	O
Bourges	O
in	O
France	O
.	O

Based	O
on	O
the	O
analysis	O
of	O
a	O
fragment	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	O
)	O
gene	O
,	O
phylogenetic	O
analyses	O
show	O
that	O
alpha	O
-	O
CoVs	O
sequences	O
detected	O
in	O
French	O
bats	O
are	O
closely	O
related	O
to	O
other	O
European	O
bat	B-ENZY
alpha	O
-	O
CoVs	O
.	O

Gas	B-ENZY
exchange	O
,	O
hemodynamics	O
,	O
hemolysis	O
,	O
and	O
coagulation	O
activation	O
were	O
examined	O
over	O
a	O
period	O
of	O
8	O
h	O
.	O
No	O
device	O
failed	O
during	O
the	O
observation	O
period	O
.	O

On	O
the	O
other	O
hand	O
,	O
diverse	O
coronaviruses	O
phylogenetically	O
related	O
to	O
MERS	O
-	O
CoV	O
have	O
been	O
discovered	O
worldwide	O
in	O
a	O
wide	O
range	O
of	O
bat	B-ENZY
species	O
,	O
some	O
of	O
which	O
can	O
be	O
classified	O
to	O
the	O
same	O
coronavirus	O
species	O
as	O
MERS	O
-	O
CoV	O
.	O
Coronaviruses	O
genetically	O
related	O
to	O
human	O
coronavirus	O
229E	O
and	O
NL63	O
have	O
been	O
detected	O
in	O
bats	O
as	O
well	O
.	O

Understanding	O
the	O
bat	B-ENZY
origin	O
of	O
human	O
coronaviruses	O
is	O
helpful	O
for	O
the	O
prediction	O
and	O
prevention	O
of	O
another	O
pandemic	O
emergence	O
in	O
the	O
future	O
.	O

Treatment	O
of	O
G6PD	B-ENZY
-	O
knockdown	O
cells	O
with	O
siRNA	O
against	O
HSCARG	O
enhanced	O
the	O
DNA	O
binding	O
activity	O
of	O
NF	O
-	O
B	O
and	O
the	O
expression	O
of	O
TNF	O
-	O
	O
and	O
MX1	O
,	O
but	O
suppressed	O
the	O
expression	O
of	O
viral	O
genes	O
;	O
however	O
,	O
the	O
overexpression	O
of	O
HSCARG	O
inhibited	O
the	O
antiviral	O
response	O
.	O

Twenty	O
-	O
nine	O
of	O
forty	O
children	O
(	O
72	O
.	O
5	O
%)	O
had	O
a	O
positive	O
MCT	B-ENZY
.	O

The	O
conjugation	O
of	O
double	O
strand	O
probes	O
onto	O
polymeric	O
microgels	O
allows	O
for	O
a	O
sensitive	O
detection	O
of	O
DNA	O
sequences	O
from	O
HIV	O
,	O
HCV	O
and	O
SARS	O
corona	O
viruses	O
with	O
a	O
LOD	B-ENZY
of	O
1	O
.	O
4	O
fM	O
,	O
3	O
.	O
7	O
fM	O
and	O
1	O
.	O
4	O
fM	O
,	O
respectively	O
,	O
and	O
with	O
a	O
dynamic	O
range	O
of	O
10	O
(-	O
9	O
)-	O
10	O
(-	O
15	O
)	O
M	O
.	O
Such	O
combination	O
enhances	O
the	O
sensitivity	O
of	O
the	O
detection	O
of	O
almost	O
five	O
orders	O
of	O
magnitude	O
when	O
compared	O
to	O
the	O
only	O
probe	O
.	O

TITLE	O
:	O
Activation	O
of	O
RNase	B-ENZY
L	O
by	O
Murine	O
Coronavirus	O
in	O
Myeloid	O
Cells	O
Is	O
Dependent	O
on	O
Basal	O
Oas	O
Gene	O
Expression	O
and	O
Independent	O
of	O
Virus	O
-	O
Induced	O
Interferon	O
.	O

Infection	O
with	O
ns2	O
(	O
H126R	O
)	O
activated	O
RNase	B-ENZY
L	O
in	O
Ifih1	O
(-/-)	O
BMM	O
to	O
a	O
similar	O
extent	O
as	O
in	O
wild	O
-	O
type	O
(	O
WT	O
)	O
BMM	O
,	O
despite	O
the	O
lack	O
of	O
IFN	O
induction	O
in	O
the	O
absence	O
of	O
MDA5	O
expression	O
.	O

However	O
,	O
ns2	O
(	O
H126R	O
)	O
failed	O
to	O
induce	O
RNase	B-ENZY
L	O
activation	O
in	O
BMM	O
treated	O
with	O
IFNAR1	O
-	O
blocking	O
antibody	O
,	O
as	O
well	O
as	O
in	O
Ifnar1	O
(-/-)	O
BMM	O
,	O
both	O
expressing	O
low	O
basal	O
levels	O
of	O
Oas	O
genes	O
.	O

We	O
included	O
subjects	O
with	O
respiratory	O
failure	O
,	O
admitted	O
to	O
a	O
respiratory	O
intermediate	O
care	O
unit	O
,	O
who	O
required	O
arterial	O
blood	O
gas	B-ENZY
analysis	O
.	O

However	O
,	O
there	O
are	O
no	O
approved	O
drugs	O
inhibiting	O
RNase	B-ENZY
H	I-ENZY
and	O
the	O
efficiency	O
of	O
DNA	O
polymerase	O
inhibitors	O
can	O
be	O
diminished	O
by	O
the	O
presence	O
of	O
drug	O
resistance	O
mutations	O
.	O

Eleven	O
of	O
the	O
new	O
compounds	O
were	O
tested	O
and	O
found	O
active	O
against	O
influenza	O
A	O
neuraminidase	B-ENZY
virus	O
(	O
H3N2	O
).	O

According	O
to	O
the	O
severity	O
,	O
patients	O
were	O
divided	O
into	O
three	O
groups	O
(	O
Mild	O
group	O
,	O
Moderate	O
group	O
and	O
Severe	O
group	O
);	O
the	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
system	O
II	O
score	O
(	O
APACHE	O
II	O
),	O
the	O
lung	O
injury	O
score	O
(	O
LIS	B-ENZY
),	O
the	O
pulse	O
contour	O
curve	O
continuous	O
cardiac	O
output	O
(	O
PiCCO	O
)	O
and	O
other	O
clinical	O
indicators	O
were	O
respectively	O
monitored	O
in	O
the	O
period	O
of	O
24	O
,	O
48	O
,	O
72	O
hrs	O
after	O
admission	O
;	O
then	O
the	O
correlation	O
of	O
EVLWI	O
,	O
PVPI	O
and	O
oxygenation	O
index	O
(	O
OI	O
)	O
among	O
groups	O
were	O
analyzed	O
;	O
According	O
to	O
the	O
prognosis	O
,	O
patients	O
were	O
divided	O
into	O
the	O
survival	O
group	O
and	O
the	O
death	O
group	O
,	O
both	O
given	O
the	O
univariate	O
and	O
multivariate	O
Logistic	O
regression	O
analysis	O
;	O
EVLWI	O
,	O
PVPI	O
,	O
APACHE	O
II	O
score	O
,	O
LIS	B-ENZY
and	O
lactic	O
acid	O
were	O
admitted	O
into	O
the	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curve	O
analysis	O
,	O
and	O
the	O
prognosis	O
was	O
evaluated	O
respectively	O
.	O

RESULTS	O
:	O
With	O
the	O
increase	O
of	O
disease	O
severity	O
,	O
LIS	B-ENZY
and	O
lactic	O
acid	O
gradually	O
increased	O
,	O
the	O
difference	O
was	O
significant	O
among	O
the	O
three	O
groups	O
of	O
Mild	O
,	O
Moderate	O
and	O
Severe	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
We	O
analyzed	O
a	O
multi	O
-	O
drug	O
resistant	O
(	O
MR	O
)	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
),	O
subcloned	O
from	O
a	O
patient	O
-	O
derived	O
subtype	O
CRF02_AG	O
,	O
harboring	O
45	O
amino	O
acid	O
exchanges	O
,	O
amongst	O
them	O
four	O
thymidine	O
analog	O
mutations	O
(	O
TAMs	O
)	O
relevant	O
for	O
high	O
-	O
level	O
AZT	O
(	O
azidothymidine	O
)	O
resistance	O
by	O
AZTMP	O
excision	O
(	O
M41L	O
,	O
D67N	O
,	O
T215Y	O
,	O
K219E	O
)	O
as	O
well	O
as	O
four	O
substitutions	O
of	O
the	O
AZTTP	O
discrimination	O
pathway	O
(	O
A62V	O
,	O
V75I	O
,	O
F116Y	O
and	O
Q151M	O
).	O

To	O
tackle	O
the	O
multi	O
-	O
drug	O
resistance	O
problem	O
,	O
we	O
tested	O
if	O
the	O
MR	O
-	O
RTs	O
could	O
still	O
be	O
inhibited	O
by	O
RNase	B-ENZY
H	I-ENZY
inhibitors	O
.	O

The	O
samples	O
were	O
analyzed	O
for	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
parainfluenza	O
viruses	O
(	O
PIV	O
)	O
types	O
1	O
,	O
2	O
and	O
3	O
,	O
adenovirus	O
,	O
rhinovirus	O
,	O
influenza	O
viruses	O
types	O
A	O
and	O
B	O
and	O
coronavirus	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

With	O
emerging	O
resistance	O
to	O
the	O
drugs	O
currently	O
licensed	O
for	O
treatment	O
and	O
prophylaxis	O
of	O
influenza	O
viruses	O
,	O
primarily	O
the	O
neuraminidase	B-ENZY
inhibitor	O
oseltamivir	O
phosphate	O
(	O
Tamiflu	O
)	O
and	O
the	O
M2	O
inhibitors	O
amantadine	O
and	O
rimantadine	O
,	O
and	O
the	O
lack	O
of	O
effective	O
interventions	O
against	O
other	O
respiratory	O
viruses	O
,	O
the	O
3	O
-	O
day	O
programme	O
focused	O
on	O
the	O
discovery	O
and	O
development	O
of	O
inhibitors	O
of	O
several	O
virus	O
targets	O
and	O
key	O
host	O
cell	O
factors	O
involved	O
in	O
virus	O
replication	O
or	O
mediating	O
the	O
inflammatory	O
response	O
.	O

Furthermore	O
,	O
coronavirus	O
co	O
-	O
infection	O
was	O
detected	O
in	O
all	O
six	O
bat	B-ENZY
species	O
,	O
a	O
phenomenon	O
that	O
fosters	O
recombination	O
and	O
promotes	O
the	O
emergence	O
of	O
novel	O
virus	O
strains	O
.	O

Mechanistic	O
studies	O
showed	O
that	O
teicoplanin	O
blocks	O
Ebola	O
virus	O
entry	O
by	O
specifically	O
inhibiting	O
the	O
activity	O
of	O
cathepsin	B-ENZY
L	I-ENZY
,	O
opening	O
a	O
novel	O
avenue	O
for	O
the	O
development	O
of	O
additional	O
glycopeptides	O
as	O
potential	O
inhibitors	O
of	O
cathepsin	B-ENZY
L	I-ENZY
-	O
dependent	O
viruses	O
.	O

We	O
found	O
that	O
MERS	O
-	O
CoV	O
shared	O
30	O
%	O
of	O
its	O
S	O
protein	O
antigenic	O
sites	O
with	O
HKU4	O
and	O
70	O
%	O
with	O
HKU5	O
bat	B-ENZY
-	O
CoV	O
.	O
Whereas	O
100	O
%	O
of	O
its	O
E	O
,	O
M	O
and	O
N	O
protein	O
'	O
s	O
antigenic	O
sites	O
are	O
found	O
to	O
be	O
conserved	O
with	O
those	O
in	O
HKU4	O
and	O
HKU5	O
.	O

RESULTS	O
:	O
Multiple	O
sequence	O
alignment	O
of	O
the	O
spike	O
(	O
S	O
),	O
membrane	O
(	O
M	O
),	O
enveloped	O
(	O
E	O
)	O
and	O
nucleocapsid	O
(	O
N	O
)	O
proteins	O
was	O
employed	O
to	O
identify	O
the	O
sequence	O
conservation	O
among	O
MERS	O
and	O
Bat	B-ENZY
(	O
HKU4	O
,	O
HKU5	O
)	O
coronaviruses	O
.	O

In	O
this	O
context	O
,	O
owing	O
to	O
its	O
essential	O
role	O
in	O
HIV	O
genome	O
replication	O
,	O
the	O
reverse	B-ENZY
transcriptase	I-ENZY
associated	O
ribonuclease	O
H	O
(	O
RNase	O
H	O
)	O
has	O
proven	O
to	O
be	O
an	O
appealing	O
target	O
.	O

ABSTRACT	O
:	O
The	O
proteasome	B-ENZY
inhibitor	O
bortezomib	O
is	O
indicated	O
for	O
use	O
in	O
the	O
treatment	O
of	O
multiple	O
myeloma	O
(	O
MM	O
)	O
patients	O
.	O

Serum	O
bilirubin	O
,	O
AST	B-ENZY
and	O
ALT	O
levels	O
were	O
higher	O
while	O
age	O
was	O
lower	O
in	O
both	O
overall	O
(	O
p	O
<	O
0	O
.	O
05	O
each	O
)	O
and	O
falciparum	O
malaria	O
cases	O
with	O
hepatopathy	O
than	O
without	O
hepatopathy	O
(	O
p	O
<	O
0	O
.	O
05	O
each	O
).	O

The	O
IFN	O
-	O
inducible	O
oligoadenylate	O
synthetase	O
(	O
OAS	O
)-	O
RNase	B-ENZY
L	O
pathway	O
activates	O
upon	O
sensing	O
of	O
viral	O
double	O
-	O
stranded	O
RNA	O
(	O
dsRNA	O
).	O

Laboratory	O
testing	O
of	O
the	O
50	O
crias	O
included	O
in	O
this	O
study	O
revealed	O
that	O
80	O
%	O
were	O
infected	O
with	O
Eimeria	O
spp	B-ENZY
.,	O
40	O
%	O
with	O
coronavirus	O
,	O
34	O
%	O
with	O
E	O
.	O
coli	O
,	O
32	O
%	O
with	O
rotavirus	O
,	O
22	O
%	O
with	O
Clostridium	O
spp	B-ENZY
.,	O
and	O
20	O
%	O
with	O
Cryptosporidium	O
spp	B-ENZY
.	O

Regional	O
ventilation	O
monitoring	O
using	O
electrical	O
impedance	O
tomography	O
showed	O
an	O
increase	O
in	O
tidal	O
volume	O
and	O
a	O
ventilation	O
shift	O
to	O
the	O
dorsal	O
regions	O
during	O
NAVA	O
,	O
indicating	O
that	O
NAVA	O
could	O
deliver	O
gas	B-ENZY
flow	O
to	O
the	O
dorsal	O
regions	O
to	O
adjust	O
for	O
the	O
magnitude	O
of	O
diaphragmatic	O
excursion	O
.	O

The	O
Eastern	O
bent	O
-	O
wing	O
bat	B-ENZY
Miniopterus	O
fuliginosus	O
is	O
distributed	O
extensively	O
throughout	O
China	O
.	O

We	O
also	O
found	O
that	O
PDCoV	O
infection	O
significantly	O
suppresses	O
the	O
activation	O
of	O
IFN	O
-	O
	O
promoter	O
stimulated	O
by	O
IRF3	O
or	O
its	O
upstream	O
molecules	O
(	O
RIG	O
-	O
I	O
,	O
MDA5	O
,	O
IPS	O
-	O
1	O
,	O
TBK1	B-ENZY
,	O
IKK	O
)	O
in	O
the	O
RIG	O
-	O
I	O
signaling	O
pathway	O
,	O
but	O
does	O
not	O
counteract	O
its	O
activation	O
by	O
the	O
constitutively	O
active	O
mutant	O
of	O
IRF3	O
(	O
IRF3	O
-	O
5D	O
).	O

The	O
cases	O
were	O
classified	O
as	O
autochthonous	O
if	O
PTPs	B-ENZY
were	O
in	O
the	O
DF	O
area	O
.	O

His	O
arterial	O
blood	O
gas	B-ENZY
revealed	O
type	O
1	O
respiratory	O
failure	O
(	O
PaO2	O
<	O
8	O
kPa	O
or	O
60	O
mm	O
Hg	O
with	O
normal	O
or	O
low	O
PaCO2	O
)	O
with	O
a	O
compensated	O
lactic	O
acidosis	O
.	O

A	O
unique	O
open	O
reading	O
frame	O
(	O
ORFX	O
)	O
was	O
identified	O
in	O
the	O
genomes	O
of	O
two	O
recently	O
isolated	O
bat	B-ENZY
SL	O
-	O
CoV	O
strains	O
(	O
WIV1	O
and	O
-	O
16	O
).	O

The	O
results	O
revealed	O
that	O
SARS	O
-	O
CoV	O
PLpro	O
significantly	O
triggered	O
Egr	O
-	O
1	O
dependent	O
activation	O
of	O
TGF	O
-	O
1	O
promoter	O
via	O
ROS	O
/	O
p38	O
MAPK	B-ENZY
/	O
STAT3	O
pathway	O
,	O
correlating	O
with	O
up	O
-	O
regulation	O
of	O
pro	O
-	O
fibrotic	O
responses	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Coronaviral	O
RNA	O
was	O
also	O
detected	O
in	O
bat	B-ENZY
guano	O
from	O
Scotophilus	O
kuhlii	O
and	O
Myotis	O
formosus	O
flavus	O
on	O
the	O
ground	O
and	O
had	O
potential	O
risk	O
for	O
human	O
exposure	O
.	O

ABSTRACT	O
:	O
Hemagglutinin	O
-	O
esterases	O
(	O
HEs	O
)	O
are	O
bimodular	O
envelope	O
proteins	O
of	O
orthomyxoviruses	O
,	O
toroviruses	O
,	O
and	O
coronaviruses	O
with	O
a	O
carbohydrate	O
-	O
binding	O
""""	O
lectin	O
""""	O
domain	O
appended	O
to	O
a	O
receptor	O
-	O
destroying	O
sialate	O
-	O
O	O
-	O
acetylesterase	B-ENZY
"("""	O
esterase	O
""")."	O

Molecular	O
assays	O
such	O
as	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
PCR	O
(	O
rRT	O
-	O
PCR	O
)	O
became	O
the	O
methods	O
of	O
choice	O
for	O
the	O
diagnosis	O
of	O
PEDV	O
infection	O
,	O
providing	O
sensitive	O
,	O
specific	O
and	O
rapid	O
detection	O
of	O
the	O
virus	O
RNA	O
in	O
clinical	O
samples	O
.	O

ABSTRACT	O
:	O
Bat	B-ENZY
species	O
around	O
the	O
world	O
have	O
recently	O
been	O
recognized	O
as	O
major	O
reservoirs	O
of	O
several	O
zoonotic	O
viruses	O
,	O
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
Nipah	O
virus	O
and	O
Hendra	O
virus	O
.	O

TITLE	O
:	O
JNK	B-ENZY
and	O
p38	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
pathways	O
contribute	O
to	O
porcine	O
epidemic	O
diarrhea	O
virus	O
infection	O
.	O

Our	O
results	O
showed	O
that	O
PEDV	O
activates	O
p38	O
MAPK	B-ENZY
and	O
JNK1	O
/	O
2	O
up	O
to	O
24h	O
post	O
-	O
infection	O
,	O
whereas	O
,	O
thereafter	O
their	O
phosphorylation	O
levels	O
recede	O
to	O
baseline	O
levels	O
or	O
even	O
fall	O
below	O
them	O
.	O

MHV3	O
in	O
vitro	O
infection	O
of	O
macrophagic	O
cells	O
induced	O
rapid	O
and	O
higher	O
viral	O
replication	O
and	O
/	O
or	O
interleukin	O
-	O
6	O
induction	O
in	O
comparison	O
to	O
MHV	O
-	O
A59	O
,	O
and	O
depended	O
on	O
viral	O
activation	O
of	O
TLR2	O
and	O
p38	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
.	O

Limits	O
of	O
detection	O
(	O
LOD	B-ENZY
)	O
with	O
95	O
%	O
probability	O
values	O
were	O
estimated	O
by	O
testing	O
16	O
replicates	O
of	O
upstream	O
of	O
the	O
envelope	O
gene	O
(	O
upE	O
)	O
and	O
open	O
reading	O
frame	O
1a	O
(	O
ORF1a	O
)	O
RNA	O
transcripts	O
.	O

The	O
PK	O
-	O
DNase	B-ENZY
method	O
is	O
suitable	O
for	O
homogenizing	O
sputum	O
samples	O
prior	O
to	O
RNA	O
extraction	O
.	O

The	O
molecular	O
mechanism	O
is	O
the	O
degradation	O
of	O
STAT1	O
by	O
PEDV	O
infection	O
in	O
a	O
proteasome	B-ENZY
-	O
dependent	O
manner	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
the	O
first	O
time	O
determination	O
values	O
of	O
physiological	O
and	O
biochemical	O
indexes	O
after	O
admission	O
including	O
pH	O
value	O
,	O
base	O
excess	O
,	O
PaCO	O
(	O
2	O
),	O
PaO	B-ENZY
(	O
2	O
),	O
hemoglobin	O
,	O
platelet	O
count	O
,	O
and	O
blood	O
sodium	O
of	O
patients	O
among	O
these	O
three	O
years	O
(	O
with	O
t	O
values	O
from	O
0	O
.	O
80	O
to	O
29	O
.	O
10	O
,	O
W	O
values	O
respectively	O
0	O
.	O
110	O
and	O
5	O
.	O
450	O
,	O
P	O
values	O
above	O
0	O
.	O
05	O
),	O
while	O
there	O
were	O
statistically	O
significant	O
differences	O
in	O
standard	O
bicarbonate	O
ion	O
,	O
leucocyte	O
count	O
,	O
neutrophile	O
granulocyte	O
,	O
albumin	O
,	O
urea	O
nitrogen	O
,	O
lactic	O
acid	O
,	O
and	O
blood	O
glucose	O
of	O
patients	O
among	O
these	O
three	O
years	O
(	O
with	O
t	O
values	O
from	O
1	O
542	O
.	O
00	O
to	O
500	O
000	O
.	O
00	O
,	O
W	O
values	O
from	O
637	O
.	O
000	O
to	O
500	O
000	O
.	O
000	O
,	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
).	O

However	O
,	O
overexpression	O
of	O
pAPN	O
in	O
porcine	O
CPK	O
cells	O
(	O
CPK	O
-	O
pAPN	O
cells	O
)	O
slightly	O
increased	O
the	O
production	O
of	O
PEDV	O
,	O
and	O
the	O
increased	O
replication	O
in	O
CPK	O
-	O
pAPN	O
cells	O
was	O
inhibited	O
by	O
bestatin	O
,	O
an	O
inhibitor	O
of	O
the	O
protease	O
activity	O
of	O
aminopeptidase	B-ENZY
N	I-ENZY
.	O
These	O
results	O
suggest	O
that	O
pAPN	O
is	O
not	O
a	O
functional	O
receptor	O
for	O
PEDV	O
,	O
but	O
promotes	O
the	O
infection	O
of	O
PEDV	O
through	O
its	O
protease	O
activity	O
.	O

A	O
total	O
of	O
1425	O
patients	O
with	O
confirmed	O
CAD	B-ENZY
starting	O
rehabilitation	O
were	O
screened	O
for	O
SDB	O
using	O
cardiorespiratory	O
polygraphy	O
(	O
n	O
=	O
921	O
)	O
or	O
polygraphy	O
plus	O
pulse	O
oximetry	O
(	O
n	O
=	O
484	O
).	O

Chemokine	O
receptor	O
expression	O
on	O
neutrophils	O
from	O
blood	O
or	O
BAL	B-ENZY
fluid	O
of	O
patients	O
with	O
ARDS	O
was	O
analysed	O
by	O
flow	O
cytometry	O
.	O

BAL	B-ENZY
fluid	O
from	O
patients	O
with	O
ARDS	O
was	O
highly	O
chemotactic	O
for	O
human	O
neutrophils	O
and	O
neutralising	O
either	O
CCL2	O
or	O
CCL7	O
attenuated	O
the	O
neutrophil	O
chemotactic	O
response	O
.	O

Furthermore	O
,	O
neutrophils	O
isolated	O
from	O
the	O
blood	O
or	O
BAL	B-ENZY
fluid	O
differentially	O
regulated	O
the	O
cell	O
surface	O
expression	O
of	O
chemokine	O
(	O
C	O
-	O
X	O
-	O
C	O
motif	O
)	O
receptor	O
1	O
and	O
C	O
-	O
C	O
chemokine	O
receptor	O
type	O
2	O
during	O
ARDS	O
.	O

TITLE	O
:	O
Xanthine	B-ENZY
Oxidase	I-ENZY
-	O
Derived	O
ROS	O
Display	O
a	O
Biphasic	O
Effect	O
on	O
Endothelial	O
Cells	O
Adhesion	O
and	O
FAK	O
Phosphorylation	O
.	O

(	O
4	O
)	O
The	O
differences	O
of	O
occurrence	O
rates	O
of	O
BE	O
,	O
white	O
blood	O
cell	O
count	O
,	O
procalcitonin	O
,	O
calcium	O
,	O
alanine	B-ENZY
aminotransferase	I-ENZY
,	O
aspartate	B-ENZY
aminotransferase	I-ENZY
,	O
creatinine	O
,	O
urea	O
nitrogen	O
,	O
lactate	O
dehydrogenase	O
,	O
CKMB	O
among	O
the	O
three	O
groups	O
were	O
statistically	O
significant	O
(	O
	O
(	O
2	O
)=	O
59	O
.	O
485	O
,	O
27	O
.	O
634	O
,	O
125	O
.	O
564	O
,	O
102	O
.	O
258	O
,	O
10	O
.	O
175	O
,	O
27	O
.	O
338	O
,	O
80	O
.	O
616	O
,	O
140	O
.	O
521	O
,	O
72	O
.	O
830	O
,	O
72	O
.	O
136	O
,	O
P	O
all	O
<	O
0	O
.	O
05	O
).	O

The	O
occurrence	O
rate	O
of	O
hyperamylasemia	O
or	O
high	O
lipase	B-ENZY
levels	O
in	O
critically	O
ill	O
children	O
were	O
lower	O
than	O
adults	O
,	O
elevated	O
pancreatic	O
enzymes	O
was	O
accompanied	O
by	O
the	O
progression	O
of	O
critical	O
illness	O
,	O
pancreatic	O
enzymes	O
elevated	O
probably	O
due	O
to	O
pancreatic	O
damage	O
,	O
which	O
positively	O
correlated	O
with	O
severity	O
of	O
the	O
disease	O
and	O
the	O
prognosis	O
.	O

CONCLUSIONS	O
:	O
The	O
occurrence	O
rate	O
of	O
hyperamylasemia	O
or	O
high	O
lipase	B-ENZY
levels	O
in	O
critically	O
ill	O
children	O
were	O
lower	O
than	O
adults	O
,	O
elevated	O
pancreatic	O
enzymes	O
was	O
accompanied	O
by	O
the	O
progression	O
of	O
critical	O
illness	O
,	O
pancreatic	O
enzymes	O
elevated	O
probably	O
due	O
to	O
pancreatic	O
damage	O
,	O
which	O
positively	O
correlated	O
with	O
severity	O
of	O
the	O
disease	O
and	O
the	O
prognosis	O
.	O

ABSTRACT	O
:	O
Sevoflurane	O
improves	O
gas	B-ENZY
exchange	O
,	O
and	O
reduces	O
alveolar	O
edema	O
and	O
inflammation	O
in	O
preclinical	O
studies	O
of	O
lung	O
injury	O
,	O
but	O
its	O
therapeutic	O
effects	O
have	O
never	O
been	O
investigated	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Bat	B-ENZY
species	O
from	O
which	O
this	O
group	O
of	O
coronaviruses	O
has	O
been	O
detected	O
are	O
widely	O
distributed	O
across	O
SE	O
Asia	O
,	O
South	O
Asia	O
and	O
Southern	O
China	O
.	O

TITLE	O
:	O
Generation	O
and	O
Characterization	O
of	O
Eptesicus	O
fuscus	O
(	O
Big	O
brown	O
bat	B-ENZY
)	O
kidney	O
cell	O
lines	O
immortalized	O
using	O
the	O
Myotis	O
polyomavirus	O
large	O
T	O
-	O
antigen	O
.	O

We	O
also	O
screened	O
these	O
samples	O
for	O
Bartonella	O
spp	B-ENZY
.	O
and	O
found	O
that	O
38	O
%	O
of	O
individuals	O
tested	O
positive	O
.	O

including	O
several	O
genetic	O
variants	O
of	O
Babesia	O
felis	O
,	O
Babesia	O
lengau	O
,	O
and	O
Babesia	O
canis	O
and	O
a	O
group	O
of	O
novel	O
Babesia	O
sequences	O
which	O
were	O
only	O
96	O
%	O
similar	O
to	O
other	O
Babesia	O
spp	B-ENZY
.	O

And	O
out	O
of	O
all	O
the	O
investigations	O
WBC	O
,	O
neutrophil	O
counts	O
,	O
AST	B-ENZY
and	O
ALT	O
values	O
have	O
some	O
predictive	O
utility	O
.	O

Herein	O
,	O
we	O
identified	O
a	O
novel	O
coronavirus	O
,	O
provisionally	O
designated	O
Rousettus	O
bat	B-ENZY
coronavirus	O
GCCDC1	O
(	O
Ro	O
-	O
BatCoV	O
GCCDC1	O
),	O
in	O
the	O
rectal	O
swab	O
samples	O
of	O
Rousettus	O
leschenaulti	O
bats	O
by	O
using	O
pan	O
-	O
coronavirus	O
RT	O
-	O
PCR	O
and	O
next	O
-	O
generation	O
sequencing	O
.	O

More	O
striking	O
was	O
that	O
Ro	O
-	O
BatCoV	O
GCCDC1	O
contained	O
a	O
unique	O
gene	O
integrated	O
into	O
the	O
3	O
'-	O
end	O
of	O
the	O
genome	O
that	O
has	O
no	O
homologs	O
in	O
any	O
known	O
coronavirus	O
,	O
but	O
which	O
sequence	O
and	O
phylogeny	O
analyses	O
indicated	O
most	O
likely	O
originated	O
from	O
the	O
p10	O
gene	O
of	O
a	O
bat	B-ENZY
orthoreovirus	O
.	O

ABSTRACT	O
:	O
This	O
study	O
aimed	O
to	O
determine	O
knowledge	O
,	O
attitude	O
and	O
practice	O
of	O
airborne	O
and	O
droplet	O
isolation	O
precautions	O
among	O
Dental	O
Health	O
Professionals	O
(	O
DHPs	B-ENZY
)	O
(	O
dental	O
students	O
,	O
interns	O
,	O
practitioners	O
and	O
auxiliaries	O
)	O
during	O
the	O
outbreak	O
of	O
MERS	O
(	O
Middle	O
East	O
Respiratory	O
Syndrome	O
),	O
corona	O
virus	O
infection	O
in	O
Riyadh	O
city	O
,	O
Saudi	O
Arabia	O
.	O

Elevated	O
C	O
-	O
creative	O
protein	O
,	O
aspartate	B-ENZY
aminotransferase	I-ENZY
,	O
creatine	B-ENZY
kinase	I-ENZY
,	O
and	O
lymphocytopenia	O
predicted	O
a	O
higher	O
risk	O
of	O
developing	O
ARDS	O
.	O

We	O
further	O
pinpointed	O
cathepsin	B-ENZY
L	I-ENZY
and	O
cathepsin	B-ENZY
B	I-ENZY
as	O
the	O
lysosomal	O
cysteine	O
proteases	O
that	O
activate	O
the	O
PEDV	O
spike	O
.	O

Here	O
,	O
we	O
found	O
that	O
clinical	O
isolates	O
of	O
HCoV	O
-	O
229E	O
preferentially	O
utilize	O
the	O
cell	O
surface	O
protease	O
TMPRSS2	O
rather	O
than	O
endosomal	O
cathepsin	B-ENZY
L	I-ENZY
.	O
The	O
endosome	O
is	O
a	O
main	O
site	O
of	O
Toll	O
-	O
like	O
receptor	O
recognition	O
,	O
which	O
then	O
triggers	O
an	O
innate	O
immune	O
response	O
;	O
therefore	O
,	O
HCoV	O
-	O
229E	O
presumably	O
evolved	O
to	O
bypass	O
the	O
endosome	O
by	O
entering	O
the	O
cell	O
via	O
TMPRSS2	O
.	O

Moraxella	O
catarrhalis	O
(	O
64	O
%),	O
Streptococcus	O
pneumoniae	O
(	O
42	O
%),	O
Haemophilus	O
influenzae	O
spp	B-ENZY
(	O
29	O
%)	O
and	O
Staphylococcus	O
aureus	O
(	O
22	O
%)	O
were	O
the	O
most	O
common	O
bacteria	O
detected	O
in	O
NP	O
samples	O
.	O

Subgroup	O
analysis	O
showed	O
that	O
OI	O
decreased	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
and	O
PaO	B-ENZY

The	O
capsid	O
and	O
replicase	O
proteins	O
of	O
PCV3	O
are	O
only	O
37	O
%	O
and	O
55	O
%	O
identical	O
to	O
PCV2	O
and	O
bat	B-ENZY
circoviruses	O
,	O
respectively	O
.	O

BAL	B-ENZY
fluid	O
from	O
mice	O
with	O
ARDS	O
dampens	O
the	O
TNF	O
-	O
	O
production	O
compared	O
to	O
cells	O
cultured	O
with	O
BAL	B-ENZY
lacking	O
sPD	O
-	O
1	O
(	O
2	O
.	O
7	O
pg	O
/	O
mL	O
(	O
SD	O
3	O
.	O
8	O
)	O
vs	O
.	O
52	O
.	O
38	O
pg	O
/	O
mL	O
(	O
SD	O
25	O
.	O
1	O
),	O
p	O
=	O
0	O
.	O
002	O
).	O

Extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
is	O
a	O
modified	O
cardiopulmonary	O
bypass	O
circuit	O
that	O
serves	O
as	O
an	O
artificial	O
membrane	O
lung	O
and	O
blood	O
pump	O
to	O
provide	O
gas	B-ENZY
exchange	O
and	O
systemic	O
perfusion	O
for	O
patients	O
when	O
their	O
own	O
heart	O
and	O
lungs	O
are	O
unable	O
to	O
function	O
adequately	O
.	O

TITLE	O
:	O
Extracorporeal	O
Gas	B-ENZY
Exchange	O
:	O
The	O
Expanding	O
Role	O
of	O
Extracorporeal	O
Support	O
in	O
Respiratory	O
Failure	O
.	O

However	O
,	O
patients	O
from	O
the	O
ECLS	O
group	O
had	O
preoperatively	O
higher	O
lactate	O
(	O
P	O
=	O
0	O
.	O
037	O
),	O
aspartate	B-ENZY
aminotransferase	I-ENZY
(	O
P	O
<	O
0	O
.	O
001	O
),	O
and	O
alanine	B-ENZY
aminotransferase	I-ENZY
(	O
P	O
<	O
0	O
.	O
001	O
)	O
levels	O
,	O
all	O
of	O
them	O
significantly	O
decreased	O
after	O
surgery	O
(	O
P	O
=	O
0	O
.	O
004	O
,	O
P	O
=	O
0	O
.	O
017	O
,	O
and	O
P	O
=	O
0	O
.	O
001	O
,	O
respectively	O
)	O
and	O
did	O
not	O
show	O
any	O
statistical	O
differences	O
to	O
the	O
corresponding	O
values	O
from	O
the	O
control	O
group	O
(	O
P	O
=	O
0	O
.	O
597	O
,	O
P	O
=	O
0	O
.	O
491	O
,	O
and	O
P	O
=	O
0	O
.	O
339	O
,	O
respectively	O
).	O

In	O
this	O
study	O
,	O
a	O
simple	O
way	O
to	O
conjugate	O
antigens	O
to	O
the	O
S	O
.	O
aureus	O
nanobioparticles	O
was	O
developed	O
by	O
utilizing	O
a	O
cell	O
wall	O
binding	O
domain	O
(	O
CBD	O
)	O
from	O
a	O
bacteriophage	O
lysin	B-ENZY
PlyV12	O
.	O

Our	O
results	O
show	O
that	O
bat	B-ENZY
astroviruses	O
form	O
a	O
group	O
that	O
is	O
genetically	O
distinct	O
from	O
astroviruses	O
infecting	O
other	O
mammals	O
.	O

Inclusion	O
criteria	O
were	O
patients	O
with	O
PaO	B-ENZY
Of	O
24	O
patients	O
at	O
risk	O
,	O
6	O
developed	O
mild	O
ARDS	O
and	O
4	O
of	O
each	O
moderate	O
or	O
severe	O
ARDS	O
,	O
respectively	O
,	O
3	O
	O
2	O
(	O
mean	O
	O
SD	O
)	O
days	O
after	O
inclusion	O
.	O

Specific	O
enzymatic	O
tests	O
,	O
together	O
with	O
a	O
time	O
-	O
of	O
-	O
addition	O
(	O
TOA	O
)	O
experiment	O
,	O
support	O
our	O
hypothesis	O
of	O
binding	O
both	O
to	O
IN	O
and	O
to	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
).	O

ABSTRACT	O
:	O
The	O
lipid	O
kinase	O
phosphatidylinositol	B-ENZY
4	I-ENZY
-	I-ENZY
kinase	I-ENZY
III	O
(	O
PI4KB	O
)	O
is	O
an	O
essential	O
host	O
factor	O
for	O
many	O
positive	O
-	O
sense	O
single	O
-	O
stranded	O
RNA	O
(+	O
RNA	O
)	O
viruses	O
including	O
human	O
pathogens	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
),	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
coxsackie	O
viruses	O
,	O
and	O
rhinoviruses	O
.	O

In	O
addition	O
,	O
binding	O
of	O
N	O
protein	O
to	O
NPM1	O
protects	O
it	O
from	O
proteolytic	O
degradation	O
by	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
,	O
leading	O
to	O
increased	O
cell	O
survival	O
.	O

TITLE	O
:	O
X	O
-	O
ray	O
Structure	O
and	O
Enzymatic	O
Activity	O
Profile	O
of	O
a	O
Core	O
Papain	B-ENZY
-	O
like	O
Protease	O
of	O
MERS	O
Coronavirus	O
with	O
utility	O
for	O
structure	O
-	O
based	O
drug	O
design	O
.	O

Accordingly	O
,	O
EndoU	O
-	O
deficient	O
viruses	O
can	O
retain	O
replication	O
only	O
in	O
cells	O
that	O
are	O
deficient	O
in	O
IFN	O
-	O
I	O
expression	O
or	O
sensing	O
,	O
and	O
in	O
cells	O
lacking	O
both	O
RNase	B-ENZY
L	O
and	O
PKR	O
.	O

Nevertheless	O
,	O
only	O
22	O
%	O
of	O
respondents	O
believed	O
that	O
camels	O
are	O
the	O
zoonotic	O
reservoir	O
of	O
MERS	O
-	O
CoV	O
.	O
Those	O
who	O
were	O
concerned	O
about	O
contracting	O
MERS	O
-	O
CoV	O
(	O
aOR	B-ENZY
:	O
1	O
.	O
6	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
2	O
-	O
2	O
.	O
1	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
those	O
who	O
thought	O
MERS	O
-	O
CoV	O
to	O
be	O
a	O
severe	O
disease	O
only	O
for	O
those	O
with	O
high	O
-	O
risk	O
conditions	O
(	O
aOR	B-ENZY
:	O
1	O
.	O
5	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
1	O
-	O
2	O
.	O
1	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
were	O
more	O
likely	O
to	O
believe	O
that	O
camels	O
are	O
the	O
zoonotic	O
source	O
.	O

Laboratory	O
diagnosis	O
of	O
MERS	O
-	O
CoV	O
infection	O
in	O
dromedaries	O
can	O
be	O
achieved	O
through	O
virus	O
isolation	O
using	O
Vero	O
cells	O
,	O
RNA	O
detection	O
by	O
real	O
-	O
time	O
quantitative	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
PCR	O
and	O
antigen	O
detection	O
using	O
respiratory	O
specimens	O
or	O
serum	O
.	O

Based	O
on	O
these	O
findings	O
,	O
whole	O
exome	O
sequencing	O
was	O
performed	O
,	O
leading	O
to	O
the	O
detection	O
of	O
two	O
novel	O
deleterious	O
variants	O
in	O
the	O
gene	O
coding	O
for	O
methionine	B-ENZY
synthase	I-ENZY
,	O
confirming	O
the	O
diagnosis	O
of	O
MSD	O
.	O

For	O
coronaviruses	O
(	O
CoVs	O
),	O
broad	O
diversity	O
exists	O
within	O
bat	B-ENZY
populations	O
and	O
uniquely	O
positions	O
them	O
to	O
seed	O
future	O
emergence	O
events	O
.	O

b	O
)	O
Case	O
-	O
control	O
study	O
matching	O
the	O
15	O
ECMO	O
cases	O
with	O
the	O
52	O
severe	O
ARDS	O
treated	O
between	O
2005	O
and	O
2011	O
in	O
which	O
alternative	O
rescue	O
treatments	O
(	O
prone	O
ventilation	O
,	O
tracheal	O
gas	B-ENZY
insufflation	O
(	O
TGI	O
)	O
and	O
/	O
or	O
the	O
administration	O
of	O
inhaled	O
nitric	O
oxide	O
(	O
iNO	O
))	O
were	O
used	O
.	O

ABSTRACT	O
:	O
Four	O
sampling	O
techniques	O
commonly	O
are	O
used	O
for	O
antemortem	O
identification	O
of	O
pathogens	O
from	O
cattle	O
with	O
bovine	O
respiratory	O
disease	O
(	O
BRD	O
):	O
the	O
nasal	O
swab	O
(	O
NS	O
),	O
guarded	O
nasopharyngeal	O
swab	O
(	O
NPS	O
),	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
),	O
and	O
transtracheal	O
wash	O
(	O
TTW	O
).	O

To	O
evaluate	O
agreement	O
among	O
TTW	O
and	O
NS	O
,	O
NPS	O
,	O
or	O
BAL	B-ENZY
for	O
identification	O
of	O
viral	O
and	O
bacterial	O
pathogens	O
in	O
dairy	O
calves	O
with	O
BRD	O
.	O

For	O
bovine	O
coronavirus	O
(	O
BCV	O
),	O
agreement	O
with	O
TTW	O
was	O
moderate	O
for	O
NS	O
and	O
NPS	O
,	O
and	O
good	O
for	O
BAL	B-ENZY
.	O

RESULTS	O
:	O
Agreement	O
among	O
TTW	O
and	O
NS	O
,	O
TTW	O
and	O
NPS	O
,	O
and	O
TTW	O
and	O
BAL	B-ENZY
,	O
was	O
very	O
good	O
for	O
identification	O
of	O
P	O
.	O
multocida	O
,	O
M	O
.	O
haemolytica	O
,	O
and	O
M	O
.	O
bovis	O
.	O

HCoV	O
strains	O
were	O
identified	O
in	O
BAL	B-ENZY
samples	O
using	O
strain	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
.	O

As	O
for	O
several	O
other	O
alphacoronaviruses	O
including	O
the	O
porcine	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
and	O
the	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
),	O
the	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
APN	O
)	O
protein	O
was	O
reported	O
to	O
be	O
a	O
functional	O
receptor	O
for	O
PEDV	O
.	O

Since	O
publication	O
of	O
the	O
ACR	O
criteria	O
for	O
vasculitis	O
,	O
the	O
sensitivity	O
for	O
each	O
type	O
of	O
vasculitis	O
,	O
except	O
GCA	B-ENZY
,	O
has	O
diminished	O
,	O
although	O
the	O
specificities	O
have	O
remained	O
high	O
,	O
highlighting	O
the	O
need	O
for	O
updated	O
classification	O
criteria	O
.	O

These	O
observations	O
provide	O
evidence	O
for	O
cross	O
-	O
species	O
transmission	O
of	O
MSLH14	O
-	O
like	O
bat	B-ENZY
RVAs	O
to	O
humans	O
,	O
highlighting	O
the	O
impact	O
of	O
bats	O
as	O
reservoirs	O
of	O
RVAs	O
on	O
public	O
health	O
.	O

Genotype	O
I16	O
has	O
previously	O
been	O
assigned	O
to	O
human	O
RVA	O
-	O
strain	O
B10	O
from	O
Kenya	O
only	O
,	O
which	O
raises	O
public	O
health	O
concern	O
,	O
particularly	O
considering	O
increased	O
human	O
-	O
bat	B-ENZY
interaction	O
.	O

HVS	B-ENZY
was	O
diagnosed	O
in	O
17	O
of	O
these	O
patients	O
(	O
77	O
.	O
3	O
%).	O

Specific	O
inhibitors	O
for	O
TGF	O
-	O
RI	O
,	O
p38	O
MAPK	B-ENZY
,	O
MEK	B-ENZY
,	O
and	O
STAT3	O
proved	O
that	O
SARS	O
-	O
CoV	O
PLpro	O
induced	O
TGF	O
-	O
1	O
-	O
dependent	O
up	O
-	O
regulation	O
of	O
Type	O
I	O
collagen	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Paramyxovirus	O
RNA	O
was	O
detected	O
in	O
4	O
of	O
248	O
(	O
1	O
%)	O
and	O
11	O
of	O
222	O
(	O
4	O
.	O
9	O
%)	O
bat	B-ENZY
faecal	O
and	O
urine	O
samples	O
,	O
respectively	O
.	O

Coronavirus	O
RNA	O
was	O
detected	O
in	O
55	O
of	O
248	O
(	O
22	O
%)	O
of	O
bat	B-ENZY
faecal	O
samples	O
;	O
filovirus	O
RNA	O
was	O
not	O
detected	O
in	O
any	O
of	O
the	O
bat	B-ENZY
samples	O
.	O

MERS	O
CoV	O
encodes	O
2	O
proteases	O
,	O
3C	O
-	O
like	O
protease	O
(	O
3CLpro	O
)	O
and	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
).	O

TITLE	O
:	O
Structure	O
of	O
the	O
S1	O
subunit	O
C	O
-	O
terminal	O
domain	O
from	O
bat	B-ENZY
-	O
derived	O
coronavirus	O
HKU5	O
spike	O
protein	O
.	O

ABSTRACT	O
:	O
Accumulating	O
evidence	O
indicates	O
that	O
MERS	O
-	O
CoV	O
originated	O
from	O
bat	B-ENZY
coronaviruses	O
(	O
BatCoVs	O
).	O

Additionally	O
,	O
ileum	O
gas	B-ENZY
was	O
detected	O
for	O
ten	O
of	O
the	O
sixteen	O
cases	O
in	O
the	O
upper	O
abdomen	O
during	O
assessment	O
with	O
chest	O
X	O
-	O
ray	O
.	O

Moreover	O
,	O
the	O
use	O
of	O
Vero	O
cells	O
expressing	O
TMPRSS2	O
and	O
MSPL	O
facilitated	O
PEDV	O
replication	O
in	O
the	O
absence	O
of	O
exogenous	O
trypsin	B-ENZY
.	O

ABSTRACT	O
:	O
In	O
the	O
contemporary	O
ICU	O
,	O
mechanically	O
ventilated	O
patients	O
may	O
not	O
have	O
arterial	O
blood	O
gas	B-ENZY
measurements	O
available	O
at	O
relevant	O
timepoints	O
.	O

ABSTRACT	O
:	O
Reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
)-	O
associated	O
DNA	O
polymerase	O
(	O
RDDP	O
)	O
and	O
ribonucleaser	O
H	O
(	O
RNase	B-ENZY
H	I-ENZY
)	O
functions	O
are	O
both	O
essential	O
for	O
HIV	O
-	O
1	O
genome	O
replication	O
,	O
and	O
the	O
identification	O
of	O
new	O
inhibitors	O
to	O
block	O
both	O
of	O
them	O
is	O
a	O
goal	O
actively	O
pursued	O
by	O
the	O
scientific	O
community	O
.	O

The	O
U	O
.	O
angolensis	O
stem	O
bark	O
methanol	O
extract	O
inhibit	O
both	O
HIV	O
-	O
1	O
RNase	B-ENZY
H	I-ENZY
function	O
and	O
RDDP	O
activity	O
with	O
IC	O

A	O
variety	O
of	O
viral	O
DUBs	O
(	O
vDUBs	O
),	O
including	O
the	O
MERS	O
-	O
CoV	O
papain	B-ENZY
-	O
like	O
protease	O
,	O
are	O
responsible	O
for	O
cleaving	O
the	O
viral	O
replicase	O
polyproteins	O
during	O
replication	O
,	O
and	O
are	O
thereby	O
critical	O
components	O
of	O
the	O
viral	O
replication	O
cycle	O
.	O

Because	O
both	O
ventilation	O
and	O
perfusion	O
heterogeneity	O
decrease	O
in	O
the	O
prone	O
posture	O
,	O
gas	B-ENZY
exchange	O
improves	O
.	O

TITLE	O
:	O
Severity	O
of	O
Inhalation	O
Injury	O
is	O
Predictive	O
of	O
Alterations	O
in	O
Gas	B-ENZY
Exchange	O
and	O
Worsened	O
Clinical	O
Outcomes	O
.	O

Overall	O
,	O
serum	O
cytokine	O
profiles	O
associated	O
with	O
HPS	B-ENZY
revealed	O
a	O
more	O
pro	O
-	O
inflammatory	O
milieu	O
as	O
compared	O
to	O
HFRS	O
.	O

Here	O
,	O
we	O
report	O
the	O
first	O
surveillance	O
of	O
bat	B-ENZY
viruses	O
in	O
Macau	O
.	O

In	O
this	O
study	O
,	O
we	O
collected	O
1004	O
samples	O
involving	O
10	O
bat	B-ENZY
species	O
from	O
7	O
sites	O
from	O
April	O
2015	O
to	O
May	O
2016	O
,	O
and	O
examined	O
the	O
presence	O
of	O
viruses	O
using	O
nucleic	O
acid	O
-	O
based	O
methods	O
.	O

The	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O
MERS	O
-	O
CoV	O
is	O
an	O
emerging	O
virus	O
that	O
is	O
closely	O
related	O
to	O
the	O
bat	B-ENZY
HKU4	O
-	O
CoV	O
.	O
3CL	O

The	O
cleavage	O
fragments	O
produced	O
by	O
trypsin	B-ENZY
and	O
TMPRSS2	O
differed	O
in	O
their	O
decoration	O
with	O
N	O
-	O
glycans	O
,	O
suggesting	O
that	O
these	O
proteases	O
cleave	O
different	O
SARS	O
S	O
glycoforms	O
.	O

In	O
fact	O
,	O
by	O
virtue	O
of	O
its	O
numerous	O
active	O
metabolites	O
,	O
H	O
.	O
indicus	O
was	O
able	O
to	O
inhibit	O
not	O
only	O
the	O
RT	O
-	O
associated	O
RNase	B-ENZY
H	I-ENZY
function	O
,	O
but	O
also	O
the	O
HIV	O
-	O
1	O
RT	O
-	O
associated	O
RNA	O
-	O
dependent	O
DNA	O
polymerase	O
activity	O
and	O
the	O
cellular	O
	O
-	O
glucosidase	O
.	O

ABSTRACT	O
:	O
We	O
identified	O
from	O
suckling	O
piglets	O
with	O
diarrhea	O
in	O
China	O
a	O
new	O
bat	B-ENZY
-	O
HKU2	O
-	O
like	O
porcine	O
coronavirus	O
(	O
porcine	O
enteric	O
alphacoronavirus	O
).	O

Angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
which	O
is	O
a	O
negative	O
regulator	O
of	O
angiotensin	O
II	O
in	O
the	O
renin	B-ENZY
-	O
angiotensin	O
system	O
,	O
has	O
been	O
reported	O
to	O
have	O
a	O
crucial	O
role	O
in	O
ALI	O
.	O

Bat	B-ENZY
flies	O
,	O
in	O
particular	O
,	O
are	O
highly	O
specialized	O
obligate	O
hematophagous	O
ectoparasites	O
that	O
incidentally	O
bite	O
humans	O
.	O

The	O
multivariable	O
linear	O
regression	O
analysis	O
of	O
the	O
relationship	O
between	O
peak	O
cTnI	O
value	O
and	O
patient	O
group	O
,	O
age	O
,	O
sex	O
,	O
and	O
type	O
of	O
ACS	B-ENZY
showed	O
that	O
the	O
presence	O
or	O
absence	O
of	O
OSA	O
significantly	O
contributed	O
to	O
the	O
peak	O
cTnI	O
level	O
,	O
which	O
was	O
54	O
%	O
lower	O
in	O
patients	O
with	O
OSA	O
than	O
in	O
those	O
without	O
OSA	O
.	O

ABSTRACT	O
:	O
One	O
of	O
the	O
most	O
severe	O
types	O
of	O
stroke	O
is	O
locked	O
-	O
in	O
syndrome	O
(	O
LIS	B-ENZY
)	O
due	O
to	O
the	O
loss	O
of	O
almost	O
all	O
voluntary	O
motor	O
functions	O
and	O
a	O
high	O
mortality	O
rate	O
.	O

TITLE	O
:	O
Sensitivity	O
and	O
specificity	O
of	O
a	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
detecting	O
feline	O
coronavirus	O
mutations	O
in	O
effusion	O
and	O
serum	O
/	O
plasma	O
of	O
cats	O
to	O
diagnose	O
feline	O
infectious	O
peritonitis	O
.	O

rotavirus	O
and	O
coronavirus	O
,	O
Salmonella	O
spp	B-ENZY
.,	O
Escherichia	O
coli	O
,	O
Clostridium	O
perfringens	O
and	O
Eimeria	O
spp	B-ENZY
.	O

The	O
detection	O
rate	O
of	O
the	O
other	O
enteropathogens	O
associated	O
with	O
C	O
.	O
parvum	O
was	O
45	O
	O
71	O
%	O
for	O
C	O
.	O
perfringens	O
followed	O
by	O
Salmonella	O
spp	B-ENZY
(	O
40	O
	O
0	O
%),	O
rotavirus	O
(	O
36	O
	O
0	O
%),	O
coronavirus	O
(	O
16	O
	O
0	O
%),	O
E	O
.	O
coli	O
(	O
12	O
	O
0	O
%)	O
and	O
Eimeria	O
spp	B-ENZY
(	O
4	O
	O
0	O
%)	O
The	O
sensitivity	O
for	O
detection	O
of	O
C	O
.	O
parvum	O
by	O
ELISA	O
and	O
mZN	O
staining	O
in	O
comparison	O
to	O
PCR	O
was	O
97	O
	O
14	O
%	O
and	O
72	O
	O
72	O
%,	O
respectively	O
.	O

Laboratory	O
results	O
show	O
increased	O
serum	O
creatinine	O
kinase	O
and	O
AST	B-ENZY
.	O

Also	O
,	O
the	O
arterial	O
blood	O
gas	B-ENZY
finding	O
of	O
severe	O
hypoxemia	O
,	O
hypercapnia	O
,	O
and	O
acidosis	O
may	O
not	O
be	O
apparent	O
until	O
respiratory	O
failure	O
is	O
profound	O
.	O

Based	O
on	O
the	O
sequence	O
of	O
its	O
genome	O
,	O
the	O
coronavirus	O
was	O
placed	O
in	O
the	O
Alphacoronavirus	O
genus	O
,	O
along	O
with	O
some	O
human	O
coronaviruses	O
,	O
bat	B-ENZY
viruses	O
and	O
the	O
porcine	O
epidemic	O
diarrhoea	O
virus	O
.	O

Herein	O
,	O
PEDV	O
isolate	O
85	O
-	O
7	O
could	O
proliferate	O
and	O
induce	O
cell	O
-	O
cell	O
fusion	O
in	O
a	O
trypsin	B-ENZY
independent	O
manner	O
on	O
Vero	O
cells	O
,	O
and	O
eight	O
homologous	O
mutation	O
strains	O
were	O
screened	O
by	O
continuous	O
proliferation	O
in	O
the	O
absence	O
of	O
trypsin	B-ENZY
on	O
Vero	O
cells	O
.	O

Further	O
analysis	O
confirmed	O
that	O
this	O
mutation	O
was	O
responsible	O
for	O
optimal	O
cell	O
-	O
adaptation	O
,	O
but	O
not	O
the	O
determinant	O
for	O
trypsin	B-ENZY
-	O
dependent	O
entry	O
of	O
PEDV	O
.	O

TITLE	O
:	O
Structurally	O
Guided	O
Removal	O
of	O
DeISGylase	O
Biochemical	O
Activity	O
from	O
Papain	B-ENZY
-	O
Like	O
Protease	O
Originating	O
from	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
.	O

Their	O
median	O
Sequential	O
Organ	O
Failure	O
Assessment	O
score	O
was	O
12	O
,	O
PaO	B-ENZY
Cytokine	O
levels	O
,	O
on	O
average	O
,	O
fall	O
rapidly	O
after	O
initiation	O
of	O
VV	O
ECMO	O
,	O
which	O
may	O
be	O
related	O
to	O
the	O
reduction	O
of	O
invasiveness	O
of	O
mechanical	O
ventilation	O
.	O

TITLE	O
:	O
Synthesis	O
and	O
biological	O
evaluation	O
of	O
NH	O
ABSTRACT	O
:	O
Neuraminidase	B-ENZY
inhibitors	O
can	O
deter	O
nascent	O
viruses	O
from	O
infecting	O
intact	O
cells	O
by	O
preventing	O
their	O
release	O
from	O
host	O
cells	O
.	O

miR	O
-	O
223	O
expression	O
is	O
increased	O
in	O
the	O
lungs	O
of	O
MTD	B-ENZY
-	O
induced	O
mice	O
or	O
ARDS	O
patients	O
following	O
trauma	O
/	O
transfusion	O
or	O
following	O
the	O
physiological	O
remission	O
of	O
ALI	O
/	O
ARDS	O
.	O

In	O
addition	O
,	O
MTD	B-ENZY
-	O
induced	O
miR	O
-	O
223	O
expression	O
activates	O
a	O
negative	O
feedback	O
pathway	O
that	O
targets	O
the	O
inhibition	O
of	O
NLRP3	O
expression	O
and	O
IL	O
-	O
1	O
release	O
;	O
therefore	O
,	O
miR	O
-	O
223	O
deficiency	O
can	O
lead	O
to	O
the	O
sustained	O
activation	O
of	O
NLRP3	O
-	O
IL	O
-	O
1	O
.	O

The	O
differences	O
in	O
gender	O
,	O
age	O
,	O
underlying	O
diseases	O
,	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHE	O
II	O
)	O
score	O
,	O
laboratory	O
parameters	O
on	O
the	O
day	O
when	O
ARDS	O
was	O
diagnosed	O
,	O
daily	O
immunosuppressive	O
dosage	O
,	O
NIV	O
support	O
condition	O
and	O
duration	O
,	O
arterial	O
blood	O
gas	B-ENZY
analysis	O
and	O
adverse	O
reactions	O
between	O
the	O
two	O
groups	O
were	O
compared	O
.	O

Consumption	O
of	O
antipyretic	O
medication	O
before	O
the	O
consultation	O
seemed	O
to	O
reduce	O
the	O
risk	O
of	O
developing	O
GI	O
symptoms	O
for	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
influenza	O
(	O
aOR	B-ENZY
=	O
0	O
.	O
3	O
;	O
[	O
0	O
.	O
1	O
-	O
0	O
.	O
6	O
];	O
p	O
=	O
0	O
.	O
002	O
).	O

Here	O
we	O
report	O
the	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
the	O
receptor	O
-	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
the	O
human	O
coronavirus	O
,	O
HCoV	O
-	O
229E	O
,	O
in	O
complex	O
with	O
the	O
ectodomain	O
of	O
its	O
receptor	O
,	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
APN	O
).	O

In	O
addition	O
,	O
we	O
report	O
the	O
first	O
discovery	O
of	O
bat	B-ENZY
SARSr	O
-	O
CoVs	O
highly	O
similar	O
to	O
human	O
SARS	O
-	O
CoV	O
in	O
ORF3b	O
and	O
in	O
the	O
split	O
ORF8a	O
and	O
8b	O
.	O

For	O
patients	O
with	O
ARDS	O
,	O
use	O
of	O
PP	O
,	O
gas	B-ENZY
exchange	O
,	O
ventilator	O
settings	O
and	O
plateau	O
pressure	O
(	O
Pplat	O
)	O
were	O
recorded	O
before	O
and	O
at	O
the	O
end	O
of	O
the	O
PP	O
session	O
.	O

The	O
optimal	O
cutoff	O
point	O
,	O
the	O
corresponding	O
limit	O
of	O
quantification	O
(	O
LoQ	O
)	O
and	O
the	O
limit	O
of	O
detection	O
(	O
LoD	B-ENZY
)	O
were	O
statistical	O
established	O
based	O
on	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curve	O
analysis	O
.	O

At	O
lower	O
pH	O
destabilisation	O
of	O
the	O
particle	O
structure	O
occurred	O
,	O
which	O
,	O
in	O
turn	O
,	O
rendered	O
the	O
polypeptides	O
extremely	O
sensitive	O
to	O
pepsin	B-ENZY
digestion	O
.	O

Of	O
the	O
two	O
known	O
upstream	O
MAPK	B-ENZY
kinases	O
(	O
MKK	B-ENZY
),	O
MKK7	O
,	O
but	O
not	O
MKK4	O
,	O
was	O
shown	O
to	O
be	O
responsible	O
for	O
IBV	O
-	O
induced	O
JNK	B-ENZY
activation	O
.	O

TITLE	O
:	O
Coronaviruses	O
and	O
arteriviruses	O
display	O
striking	O
differences	O
in	O
their	O
cyclophilin	B-ENZY
A	O
-	O
dependence	O
during	O
replication	O
in	O
cell	O
culture	O
.	O

ABSTRACT	O
:	O
Cyclophilin	B-ENZY
A	O
(	O
CypA	O
)	O
is	O
an	O
important	O
host	O
factor	O
in	O
the	O
replication	O
of	O
a	O
variety	O
of	O
RNA	O
viruses	O
.	O

Viruses	O
associated	O
to	O
synanthropic	O
bat	B-ENZY
genera	O
,	O
such	O
as	O
Myotis	O
or	O
Scotophilus	O
were	O
associated	O
to	O
highly	O
transformed	O
habitats	O
with	O
human	O
presence	O
while	O
viruses	O
associated	O
to	O
fruit	O
bat	B-ENZY
genera	O
were	O
correlated	O
with	O
natural	O
environments	O
with	O
dense	O
forest	O
,	O
grassland	O
areas	O
and	O
regions	O
of	O
high	O
elevation	O
.	O

ACS	B-ENZY
in	O
SCD	O
is	O
defined	O
as	O
the	O
presence	O
of	O
fever	O
and	O
/	O
or	O
new	O
respiratory	O
symptoms	O
accompanied	O
by	O
the	O
presence	O
of	O
a	O
new	O
pulmonary	O
infiltrate	O
on	O
chest	O
X	O
-	O
ray	O
.	O

TITLE	O
:	O
Disulfiram	O
can	O
inhibit	O
MERS	O
and	O
SARS	O
coronavirus	O
papain	B-ENZY
-	O
like	O
proteases	O
via	O
different	O
modes	O
.	O

TITLE	O
:	O
The	O
persistent	O
prevalence	O
and	O
evolution	O
of	O
cross	O
-	O
family	O
recombinant	O
coronavirus	O
GCCDC1	O
among	O
a	O
bat	B-ENZY
population	O
:	O
a	O
two	O
-	O
year	O
follow	O
-	O
up	O
.	O

Most	O
of	O
the	O
patients	O
(	O
88	O
.	O
1	O
%)	O
had	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	O
,	O
and	O
the	O
median	O
PaO	B-ENZY
The	O
outcome	O
of	O
ARDS	O
in	O
patients	O
with	O
hematological	O
malignancies	O
is	O
associated	O
with	O
the	O
severity	O
of	O
the	O
underlying	O
diseases	O
,	O
the	O
presence	O
of	O
multidrug	O
-	O
resistance	O
pathogens	O
,	O
and	O
the	O
amount	O
of	O
transfusion	O
;	O
however	O
,	O
strict	O
application	O
of	O
low	O
tidal	O
volume	O
ventilation	O
may	O
improve	O
the	O
outcome	O
of	O
these	O
patients	O
at	O
the	O
time	O
of	O
diagnosis	O
.	O

TITLE	O
:	O
Receptor	O
Usage	O
of	O
a	O
Novel	O
Bat	B-ENZY
Lineage	O
C	O
Betacoronavirus	O
Reveals	O
Evolution	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
-	O
Related	O
Coronavirus	O
Spike	O
Proteins	O
for	O
Human	O
Dipeptidyl	O
Peptidase	O
4	O
Binding	O
.	O

Decreasing	O
NETs	O
reduced	O
lung	O
injury	O
and	O
improved	O
survival	O
after	O
DNase	B-ENZY
I	O
treatment	O
or	O
with	O
partial	O
protein	O
arginine	B-ENZY
deiminase	I-ENZY
4	O
deficiency	O
(	O
PAD4	O
+/-).	O

ABSTRACT	O
:	O
A	O
50	O
-	O
year	O
-	O
old	O
man	O
with	O
acute	O
myelogenous	O
leukemia	O
underwent	O
allogeneic	O
bone	O
-	O
marrow	O
transplantation	O
(	O
BMT	B-ENZY
).	O

It	O
also	O
showed	O
a	O
significant	O
interaction	O
between	O
ACS	B-ENZY
history	O
and	O
age	O
(	O
P	O
=	O
0	O
.	O
0131	O
),	O
such	O
that	O
young	O
patients	O
with	O
their	O
first	O
ACS	B-ENZY
showed	O
significantly	O
lower	O
odds	O
of	O
CPAP	O
non	O
-	O
compliance	O
than	O
patients	O
with	O
recurrent	O
ACS	B-ENZY
and	O
significantly	O
lower	O
odds	O
of	O
CPAP	O
non	O
-	O
compliance	O
were	O
associated	O
with	O
ageing	O
only	O
in	O
patients	O
with	O
recurrent	O
ACS	B-ENZY
.	O

There	O
is	O
,	O
therefore	O
,	O
a	O
need	O
to	O
develop	O
additional	O
bat	B-ENZY
cell	O
lines	O
that	O
correspond	O
to	O
different	O
cell	O
types	O
,	O
including	O
less	O
represented	O
cell	O
types	O
such	O
as	O
immune	O
cells	O
,	O
and	O
culture	O
them	O
under	O
more	O
physiologically	O
relevant	O
conditions	O
to	O
study	O
virus	O
host	O
interactions	O
and	O
for	O
virus	O
isolation	O
.	O

The	O
authors	O
report	O
a	O
case	O
of	O
HVS	B-ENZY
following	O
general	O
anesthesia	O
,	O
where	O
a	O
continuous	O
intravenous	O
infusion	O
of	O
dexmedetomidine	O
was	O
effective	O
for	O
HVS	B-ENZY
.	O

An	O
arterial	O
blood	O
gas	B-ENZY
determination	O
showed	O
pH	O
7	O
.	O
63	O
,	O
PaCO	O
HVS	B-ENZY
can	O
occur	O
after	O
emergence	O
from	O
general	O
anesthesia	O
,	O
and	O
dexmedetomidine	O
infusion	O
was	O
effective	O
for	O
HVS	B-ENZY
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
activation	O
of	O
a	O
disintergrin	O
and	O
metalloprotease	O
17	O
(	O
ADAM17	O
)	O
induced	O
the	O
decrease	O
of	O
PEDV	O
infection	O
in	O
HEK293	O
and	O
IPEC	O
-	O
J2	O
cells	O
and	O
the	O
downregulation	O
of	O
cell	O
surface	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
APN	O
)	O
expression	O
,	O
an	O
important	O
entry	O
factor	O
for	O
PEDV	O
infection	O
.	O

The	O
diversity	O
and	O
prevalence	O
of	O
bat	B-ENZY
coronaviruses	O
presently	O
reported	O
from	O
western	O
Europe	O
is	O
much	O
higher	O
than	O
previously	O
described	O
and	O
includes	O
a	O
SARS	O
-	O
CoV	O
sister	O
group	O
.	O

This	O
study	O
highlights	O
the	O
importance	O
of	O
virus	O
surveillance	O
in	O
natural	O
reservoirs	O
and	O
emphasizes	O
the	O
need	O
for	O
preparedness	O
against	O
the	O
potential	O
spill	O
-	O
over	O
of	O
these	O
viruses	O
to	O
local	O
residents	O
living	O
near	O
bat	B-ENZY
caves	O
.	O

However	O
,	O
it	O
is	O
still	O
controversial	O
whether	O
the	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
pAPN	O
)	O
counterpart	O
on	O
Vero	O
cells	O
(	O
Vero	O
-	O
APN	O
)	O
confers	O
PEDV	O
entry	O
.	O

The	O
rapid	O
assay	O
was	O
tested	O
negative	O
in	O
all	O
51	O
alimentary	O
samples	O
RNA	O
-	O
positive	O
for	O
alphacoronaviruses	O
(	O
Rhinolophus	O
bat	B-ENZY
CoV	O
HKU2	O
,	O
Myotis	O
bat	B-ENZY
CoV	O
HKU6	O
,	O
Miniopterus	O
bat	B-ENZY
CoV	O
HKU8	O
and	O
Hipposideros	O
batCoV	O
HKU10	O
)	O
and	O
32	O
alimentary	O
samples	O
positive	O
for	O
lineage	O
B	O
(	O
SARS	O
-	O
related	O
Rhinolophus	O
bat	B-ENZY
CoV	O
HKU3	O
)	O
and	O
lineage	O
D	O
(	O
Rousettus	O
bat	B-ENZY
CoV	O
HKU9	O
)	O
betacoronaviruses	O
.	O

Severity	O
of	O
injury	O
was	O
determined	O
by	O
protein	O
content	O
and	O
MPO	O
activity	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
),	O
the	O
expression	O
of	O
inflammatory	O
cytokines	O
and	O
histopathology	O
.	O

All	O
six	O
isolated	O
compounds	O
have	O
been	O
evaluated	O
firstly	O
for	O
the	O
inhibition	O
of	O
both	O
Human	O
Immunodeficiency	O
Virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
Reverse	B-ENZY
Transcriptase	I-ENZY
(	O
RT	O
)-	O
associated	O
DNA	O
Polymerase	O
(	O
RDDP	O
)	O
and	O
Ribonuclease	B-ENZY
H	I-ENZY
(	O
RNase	B-ENZY
H	I-ENZY
)	O
activities	O
,	O
for	O
the	O
inhibition	O
of	O
HIV	O
-	O
1	O
integrase	O
(	O
IN	O
)	O
in	O
biochemical	O
assays	O
,	O
and	O
also	O
for	O
their	O
effect	O
on	O
viral	O
replication	O
.	O

The	O
same	O
active	O
compounds	O
affected	O
also	O
HIV	O
-	O
1	O
IN	O
strand	O
transfer	O
function	O
,	O
suggesting	O
the	O
involvement	O
of	O
the	O
RNase	B-ENZY
H	I-ENZY
active	O
site	O
.	O

Veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
can	O
be	O
utilized	O
for	O
severe	O
ACS	B-ENZY
in	O
adult	O
patients	O
with	O
sickle	O
cell	O
disease	O
.	O

TITLE	O
:	O
Contribution	O
of	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
to	O
porcine	O
deltacoronavirus	O
infection	O
.	O

Fecal	O
samples	O
were	O
tested	O
for	O
Cystoisospora	O
spp	B-ENZY
.	O

The	O
blood	O
samples	O
for	O
the	O
levels	O
of	O
steroid	O
hormones	O
and	O
insulin	O
-	O
like	O
growth	O
factor	O
I	O
(	O
IGF	O
-	O
I	O
)	O
were	O
assessed	O
using	O
immunoassays	O
and	O
the	O
levels	O
of	O
fatty	O
acids	O
were	O
assessed	O
using	O
gas	B-ENZY
chromatography	O
.	O

Fecal	O
pH	O
was	O
measured	O
at	O
enrollment	O
and	O
on	O
d	O
5	O
and	O
14	O
,	O
and	O
fecal	O
pathogen	O
(	O
C	O
.	O
parvum	O
,	O
coronavirus	O
,	O
rotavirus	O
,	O
and	O
Salmonella	O
spp	B-ENZY
.	O

The	O
spearman	O
'	O
s	O
test	O
showed	O
the	O
positive	O
correlation	O
between	O
knowledge	O
and	O
attitude	O
of	O
DHPs	B-ENZY
about	O
MERS	O
(	O
DHPs	B-ENZY
participated	O
in	O
this	O
study	O
showed	O
good	O
knowledge	O
and	O
positive	O
attitude	O
toward	O
MERS	O
.	O

Pirfenidone	O
substantially	O
reduced	O
NLRP3	O
and	O
ASC	O
expression	O
and	O
inhibited	O
caspase	B-ENZY
-	I-ENZY
1	I-ENZY
activation	O
and	O
IL	O
-	O
1	O
maturation	O
in	O
lung	O
tissues	O
.	O

In	O
an	O
international	O
clinical	O
trial	O
,	O
we	O
randomly	O
assigned	O
patients	O
with	O
very	O
severe	O
ARDS	O
,	O
as	O
indicated	O
by	O
one	O
of	O
three	O
criteria	O
-	O
a	O
ratio	O
of	O
partial	O
pressure	O
of	O
arterial	O
oxygen	O
(	O
Pao	B-ENZY
At	O
60	O
days	O
,	O
44	O
of	O
124	O
patients	O
(	O
35	O
%)	O
in	O
the	O
ECMO	O
group	O
and	O
57	O
of	O
125	O
(	O
46	O
%)	O
in	O
the	O
control	O
group	O
had	O
died	O
(	O
relative	O
risk	O
,	O
0	O
.	O
76	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
0	O
.	O
55	O
to	O
1	O
.	O
04	O
;	O
P	O
=	O
0	O
.	O
09	O
).	O

She	O
needed	O
immediate	O
oxygen	O
supply	O
,	O
while	O
ABGs	O
deteriorated	O
and	O
chest	O
imaging	O
and	O
PaO	B-ENZY

TITLE	O
:	O
Could	O
Heme	B-ENZY
Oxygenase	I-ENZY
-	O
1	O
Be	O
a	O
New	O
Target	O
for	O
Therapeutic	O
Intervention	O
in	O
Malaria	O
-	O
Associated	O
Acute	O
Lung	O
Injury	O
/	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
?	O

Patients	O
with	O
AKI	O
had	O
significantly	O
lower	O
PaO	B-ENZY
AKI	O
is	O
common	O
in	O
children	O
with	O
ARF	O
.	O

TITLE	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
and	O
bat	B-ENZY
coronavirus	O
HKU9	O
both	O
can	O
utilize	O
GRP78	O
for	O
attachment	O
onto	O
host	O
cells	O
.	O

The	O
results	O
showed	O
that	O
TGEV	O
N	O
protein	O
localised	O
in	O
the	O
cytoplasm	O
,	O
inhibited	O
IEC	O
growth	O
,	O
prolonged	O
the	O
S	O
-	O
phase	O
cell	O
cycle	O
by	O
down	O
-	O
regulating	O
cell	O
cycle	O
protein	O
cyclin	O
A	O
,	O
and	O
was	O
mainly	O
degraded	O
through	O
the	O
proteasome	B-ENZY
pathway	O
.	O

After	O
tracheal	O
intubation	O
,	O
her	O
oxygenation	O
index	O
(	O
OI	O
)	O
and	O
PaO	B-ENZY
We	O
successfully	O
treated	O
a	O
female	O
child	O
suffering	O
from	O
TB	O
pneumonia	O
-	O
induced	O
severe	O
ARDS	O
complicated	O
with	O
DIC	O
using	O
multimodal	O
interventions	O
.	O

The	O
majority	O
of	O
laboratories	O
demonstrated	O
satisfactory	O
performance	O
in	O
detecting	O
the	O
presence	O
of	O
MERS	O
-	O
CoV	O
using	O
NAT	B-ENZY
.	O

Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Spike	O
Protein	O
Is	O
Not	O
Activated	O
Directly	O
by	O
Cellular	O
Furin	B-ENZY
during	O
Viral	O
Entry	O
into	O
Target	O
Cells	O
.	O

We	O
found	O
that	O
the	O
furin	B-ENZY
inhibitor	O
dec	O
-	O
RVKR	O
-	O
CMK	B-ENZY
blocked	O
entry	O
of	O
MERS	O
-	O
CoV	O
harboring	O
an	O
S	O
protein	O
lacking	O
furin	B-ENZY
cleavage	O
sites	O
;	O
it	O
even	O
blocked	O
entry	O
into	O
furin	B-ENZY
-	O
deficient	O
LoVo	O
cells	O
.	O

Therefore	O
,	O
we	O
conclude	O
that	O
furin	B-ENZY
does	O
not	O
play	O
a	O
role	O
in	O
entry	O
of	O
MERS	O
-	O
CoV	O
into	O
cells	O
and	O
that	O
the	O
inhibitory	O
effect	O
of	O
dec	O
-	O
RVKR	O
-	O
CMK	B-ENZY
is	O
specific	O
for	O
TMPRSS2	O
and	O
cathepsin	B-ENZY
L	I-ENZY
rather	O
than	O
furin	B-ENZY
.	O

Balb	O
/	O
cJ	O
mice	O
died	O
in	O
3	O
to	O
6	O
days	O
post	O
MHV	O
-	O
3	O
infection	O
,	O
with	O
severe	O
hepatic	O
necrosis	O
and	O
significant	O
augmentation	O
of	O
serum	O
ALT	O
and	O
AST	B-ENZY
levels	O
.	O

TITLE	O
:	O
Protein	B-ENZY
kinase	I-ENZY
R	O
-	O
like	O
endoplasmatic	O
reticulum	O
kinase	O
is	O
a	O
mediator	O
of	O
stretch	O
in	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

In	O
terms	O
of	O
diseases	O
,	O
the	O
expert	O
panel	O
regarded	O
knowledge	O
of	O
Hendra	O
virus	O
,	O
Q	O
fever	O
,	O
Australian	O
bat	B-ENZY
lyssavirus	O
(	O
ABLV	O
),	O
anthrax	O
and	O

ABSTRACT	O
:	O
Bat	B-ENZY
populations	O
harbour	O
a	O
multitude	O
of	O
viruses	O
;	O
some	O
of	O
these	O
are	O
pathogenic	O
or	O
potentially	O
pathogenic	O
in	O
other	O
animals	O
or	O
humans	O
.	O

In	O
the	O
OLA	O
group	O
,	O
5	O
cmH	O
OLA	O
significantly	O
improved	O
lung	O
aeration	O
,	O
arterial	O
oxygenation	O
,	O
and	O
gas	B-ENZY
exchange	O
.	O

TITLE	O
:	O
Tannic	O
acid	O
protects	O
against	O
experimental	O
acute	O
lung	O
injury	O
through	O
downregulation	O
of	O
TLR4	O
and	O
MAPK	B-ENZY
.	O

Intriguingly	O
,	O
these	O
viruses	O
also	O
all	O
originate	O
from	O
bat	B-ENZY
reservoirs	O
.	O

As	O
compared	O
to	O
the	O
survival	O
group	O
,	O
the	O
white	O
blood	O
cell	O
count	O
,	O
serum	O
bilirubin	O
,	O
aspartate	B-ENZY
aminotransferase	I-ENZY
,	O
alanine	B-ENZY
aminotransferase	I-ENZY
,	O
creatine	B-ENZY
kinase	I-ENZY
,	O
and	O
lactate	O
dehydrogenase	O
were	O
significantly	O
higher	O
,	O
and	O
serum	O
albumin	O
levels	O
were	O
significantly	O
lower	O
in	O
patients	O
who	O
died	O
.	O

Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
(	O
KEGG	O
)	O
analysis	O
showed	O
differentially	O
expressed	O
mRNAs	O
were	O
linked	O
to	O
inflammation	O
-	O
related	O
pathways	O
,	O
including	O
NF	O
-	O
B	O
,	O
Toll	O
-	O
like	O
receptor	O
,	O
NOD	B-ENZY
-	O
like	O
receptor	O
,	O
Jak	O
-	O
STAT	O
,	O
TNF	O
,	O
and	O
RIG	O
-	O
I	O
-	O
like	O
receptor	O
pathways	O
.	O

Dual	O
-	O
luciferase	B-ENZY
reporter	O
assay	O
confirmed	O
that	O
miR	O
-	O
22	O
directly	O
bound	O
to	O
ssc_circ_009380	O
.	O

Prolyl	B-ENZY
hydroxylase	I-ENZY
domain	O
(	O
PHD	O
)-	O
2	O
protein	O
,	O
a	O
major	O
PHD	O
in	O
ECs	O
,	O
plays	O
a	O
critical	O
role	O
in	O
intracellular	O
oxygen	O
homeostasis	O
,	O
angiogenesis	O
,	O
and	O
pulmonary	O
hypertension	O
.	O

TITLE	O
:	O
Novel	O
natural	O
non	O
-	O
nucleoside	O
inhibitors	O
of	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
identified	O
by	O
shape	O
-	O
and	O
structure	O
-	O
based	O
virtual	O
screening	O
techniques	O
.	O

Here	O
,	O
we	O
present	O
cryo	O
-	O
EM	O
analyses	O
of	O
a	O
stabilized	O
trimeric	O
SARS	O
-	O
CoV	O
S	O
,	O
as	O
well	O
as	O
the	O
trypsin	B-ENZY
-	O
cleaved	O
,	O
stabilized	O
S	O
,	O
and	O
its	O
interactions	O
with	O
ACE2	O
.	O

Data	O
were	O
collected	O
on	O
the	O
PICU	O
characteristics	O
,	O
patient	O
demographics	O
,	O
and	O
elements	O
of	O
PARDS	O
(	O
ie	O
,	O
PARDS	O
risk	O
factors	O
,	O
hypoxaemia	O
severity	O
metrics	O
,	O
type	O
of	O
ventilation	O
),	O
comorbidities	O
,	O
chest	O
imaging	O
,	O
arterial	O
blood	O
gas	B-ENZY
measurements	O
,	O
and	O
pulse	O
oximetry	O
.	O

TITLE	O
:	O
From	O
cycloheptathiophene	O
-	O
3	O
-	O
carboxamide	O
to	O
oxazinone	O
-	O
based	O
derivatives	O
as	O
allosteric	O
HIV	O
-	O
1	O
ribonuclease	B-ENZY
H	I-ENZY
inhibitors	O
.	O

In	O
infected	O
cells	O
,	O
PEDV	O
-	O
induced	O
apoptosis	O
is	O
accompanied	O
by	O
nuclear	O
concentration	O
and	O
fragmentation	O
as	O
a	O
result	O
of	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
and	O
caspase	B-ENZY
-	I-ENZY
8	I-ENZY
activation	O
and	O
AIFM1	O
and	O
PARP	O
cleavage	O
.	O

In	O
keeping	O
with	O
a	O
previous	O
study	O
,	O
pre	O
-	O
cleavage	O
at	O
the	O
S1	O
/	O
S2	O
motif	O
(	O
RSVR	O
)	O
was	O
important	O
although	O
not	O
essential	O
for	O
subsequent	O
MERS	O
-	O
S	O
activation	O
by	O
TMPRSS2	O
,	O
and	O
indirect	O
evidence	O
was	O
obtained	O
that	O
this	O
motif	O
is	O
processed	O
by	O
a	O
protease	O
depending	O
on	O
an	O
intact	O
RXXR	O
motif	O
,	O
most	O
likely	O
furin	B-ENZY
.	O

The	O
differences	O
of	O
demographic	O
indexes	O
(	O
gender	O
,	O
age	O
),	O
time	O
of	O
admission	O
,	O
type	O
of	O
injury	O
,	O
atrial	O
fibrillation	O
,	O
trachea	O
cannula	O
,	O
multiple	O
injury	O
,	O
open	O
injury	O
,	O
shock	O
,	O
surgery	O
,	O
blood	O
transfusion	O
,	O
central	O
venous	O
indwelling	O
catheter	O
,	O
infection	O
,	O
and	O
blood	O
routine	O
indexes	O
[	O
white	O
blood	O
cell	O
count	O
(	O
WBC	O
),	O
red	O
blood	O
cell	O
count	O
(	O
RBC	O
),	O
platelet	O
count	O
(	O
PLT	O
),	O
plateletcytocrit	O
(	O
PCT	O
),	O
hematocrit	O
(	O
Hct	O
)],	O
biochemical	O
indexes	O
[	O
total	O
bilirubin	O
(	O
TBil	O
),	O
albumin	O
(	O
Alb	O
),	O
serum	O
creatinine	O
(	O
SCr	O
),	O
blood	O
sodium	O
,	O
blood	O
calcium	O
,	O
blood	O
potassium	O
,	O
blood	O
glucose	O
],	O
arterial	O
blood	O
gas	B-ENZY
analysis	O
indexes	O
[	O
partial	O
pressure	O
of	O
carbon	O
dioxide	O
(	O
PaCO	O
A	O
total	O
of	O
303	O
patients	O
with	O
severe	O
trauma	O
,	O
including	O
223	O
males	O
and	O
80	O
females	O
,	O
were	O
enrolled	O
.	O

Half	O
an	O
hour	O
later	O
,	O
the	O
boy	O
experienced	O
convulsions	O
and	O
cardiopulmonary	O
arrest	O
,	O
and	O
emergency	O
examination	O
found	O
hypoketotic	O
hypoglycemia	O
,	O
metabolic	O
acidosis	O
,	O
significant	O
increases	O
in	O
serum	O
aminotransferases	O
and	O
creatine	B-ENZY
kinase	I-ENZY
,	O
and	O
renal	O
damage	O
.	O

The	O
boy	O
had	O
a	O
significant	O
reduction	O
in	O
free	O
carnitine	O
in	O
blood	O
and	O
significant	O
increases	O
in	O
medium	O
-	O
and	O
long	O
-	O
chain	O
fatty	O
acyl	O
carnitine	O
,	O
urinary	O
glutaric	O
acid	O
,	O
3	O
-	O
hydroxy	O
glutaric	O
acid	O
,	O
isovalerylglycine	O
,	O
and	O
ethylmalonic	O
acid	O
,	O
suggesting	O
the	O
possibility	O
of	O
multiple	O
acyl	B-ENZY
-	I-ENZY
CoA	I-ENZY
dehydrogenase	I-ENZY
deficiency	O
.	O

TITLE	O
:	O
Regulation	O
of	O
in	O
vivo	O
behavior	O
of	O
TAT	B-ENZY
-	O
modified	O
liposome	O
by	O
associated	O
protein	O
corona	O
and	O
avidity	O
to	O
tumor	O
cells	O
.	O

We	O
conclude	O
that	O
by	O
optimizing	O
TAT	B-ENZY
-	O
modified	O
PLDs	O
,	O
the	O
occurring	O
PC	O
balances	O
pharmacokinetics	O
and	O
tumor	O
penetration	O
through	O
interference	O
with	O
avidity	O
.	O

Tracer	O
gas	B-ENZY
experiments	O
conducted	O
on	O
the	O
eighth	O
floor	O
,	O
where	O
the	O
initial	O
patient	O
was	O
hospitalized	O
,	O
confirmed	O
that	O
the	O
tracer	O
gas	B-ENZY
spread	O
to	O
adjacent	O
patient	O
rooms	O
and	O
rooms	O
across	O
corridors	O
.	O

Pre	O
-	O
existing	O
medical	O
conditions	O
(	O
adjusted	O
Odds	O
ratio	O
(	O
aOR	B-ENZY
)=	O
2	O
.	O
43	O
,	O
95	O
%	O
confidence	O
interval	O
:	O
(	O
CI	O
)	O
[	O
1	O
.	O
11	O
-	O
5	O
.	O
33	O
])	O
and	O
hospitalized	O
patients	O
(	O
aOR	O
=	O
29	O
.	O
99	O
,	O
95	O
%	O
CI	O
[	O
1	O
.	O
80	O
-	O
48	O
.	O
65	O
])	O
were	O
the	O
strongest	O
risk	O
predictors	O
of	O
death	O
from	O
MERS	O
.	O

It	O
is	O
also	O
vital	O
to	O
assume	O
a	O
diagnosis	O
of	O
G6PD	B-ENZY
deficiency	O
until	O
proven	O
otherwise	O
in	O
a	O
patient	O
who	O
presents	O
with	O
rasburicase	O
induced	O
hemolysis	O
and	O
avoid	O
administration	O
of	O
methylene	O
blue	O
even	O
if	O
the	O
patient	O
is	O
from	O
a	O
low	O
risk	O
ethnicity	O
for	O
G6PD	B-ENZY
as	O
in	O
our	O
patient	O
.	O

However	O
,	O
our	O
knowledge	O
into	O
basic	O
bat	B-ENZY
biology	O
and	O
immunology	O
is	O
very	O
limited	O
and	O
we	O
have	O
little	O
understanding	O
of	O
major	O
factors	O
contributing	O
to	O
the	O
risk	O
of	O
bat	B-ENZY
virus	O
spillover	O
events	O
.	O

Here	O
we	O
provide	O
a	O
brief	O
review	O
of	O
the	O
latest	O
findings	O
in	O
bat	B-ENZY
viruses	O
and	O
their	O
potential	O
risk	O
of	O
cross	O
-	O
species	O
transmission	O
.	O

Neutrophil	O
extracellular	O
trap	O
concentrations	O
were	O
quantified	O
(	O
as	O
DNA	O
-	O
myeloperoxidase	B-ENZY
complexes	O
)	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
and	O
serum	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

[	O
1	O
]	O
A	O
""""	O
blood	O
gas	B-ENZY
analysis	O
""""	O
can	O
be	O
performed	O
on	O
blood	O
obtained	O
from	O
anywhere	O
in	O
the	O
circulatory	O
system	O
(	O
artery	O
,	O
vein	O
,	O
or	O
capillary	O
).	O

TITLE	O
:	O
Geographical	O
structure	O
of	O
bat	B-ENZY
SARS	O
-	O
related	O
coronaviruses	O
.	O

We	O
also	O
analyze	O
the	O
viral	O
geographical	O
structure	O
that	O
may	O
improve	O
our	O
understanding	O
of	O
the	O
evolution	O
of	O
bat	B-ENZY
SARSr	O
-	O
CoVs	O
.	O

TITLE	O
:	O
Interferon	O
Regulatory	O
Factor	O
3	O
-	O
Mediated	O
Signaling	O
Limits	O
Middle	O
-	O
East	O
Respiratory	O
Syndrome	O
(	O
MERS	O
)	O
Coronavirus	O
Propagation	O
in	O
Cells	O
from	O
an	O
Insectivorous	O
Bat	B-ENZY
.	O

The	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
according	O
to	O
pre	O
-	O
ECMO	O
arterial	O
blood	O
gas	B-ENZY
:	O
an	O
extended	O
group	O
(	O
n	O
=	O
14	O
)	O
and	O
a	O
conventional	O
group	O
(	O
n	O
=	O
48	O
).	O

Our	O
current	O
model	O
on	O
the	O
origin	O
of	O
SARS	O
is	O
that	O
the	O
human	O
SARS	O
-	O
CoV	O
that	O
caused	O
the	O
epidemic	O
in	O
2002	O
/	O
2003	O
was	O
probably	O
a	O
result	O
of	O
multiple	O
recombination	O
events	O
from	O
a	O
number	O
of	O
SARSr	O
-	O
CoV	O
ancestors	O
in	O
different	O
horseshoe	O
bat	B-ENZY
species	O
.	O

TITLE	O
:	O
Analysis	O
of	O
Coronavirus	O
Temperature	O
-	O
Sensitive	O
Mutants	O
Reveals	O
an	O
Interplay	O
between	O
the	O
Macrodomain	O
and	O
Papain	B-ENZY
-	O
Like	O
Protease	O
Impacting	O
Replication	O
and	O
Pathogenesis	O
.	O

TITLE	O
:	O
Identification	O
and	O
design	O
of	O
novel	O
small	O
molecule	O
inhibitors	O
against	O
MERS	O
-	O
CoV	O
papain	B-ENZY
-	O
like	O
protease	O
via	O
high	O
-	O
throughput	O
screening	O
and	O
molecular	O
modeling	O
.	O

ABSTRACT	O
:	O
Cholesterol	B-ENZY
25	I-ENZY
-	I-ENZY
hydroxylase	I-ENZY
(	O
CH25H	O
)	O
has	O
been	O
shown	O
lately	O
to	O
be	O
a	O
host	O
restriction	O
factor	O
that	O
encodes	O
an	O
enzyme	O
,	O
which	O
catalyzes	O
the	O
oxidized	O
form	O
of	O
cholesterol	O
to	O
25	O
-	O
hydroxycholesterol	O
(	O
25HC	O
).	O

ABSTRACT	O
:	O
Nucleic	O
acid	O
amplification	O
technology	O
(	O
NAT	B-ENZY
)	O
has	O
been	O
the	O
most	O
used	O
one	O
for	O
rapid	O
detection	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
since	O
MERS	O
-	O
CoV	O
was	O
first	O
detected	O
in	O
2012	O
.	O

Trace	O
element	O
and	O
PAH	B-ENZY
analysis	O
demonstrated	O
the	O
almost	O
similar	O
chemical	O
composition	O
of	O
both	O
particle	O
fractions	O
.	O

TITLE	O
:	O
Discovery	O
and	O
Characterization	O
of	O
Novel	O
Bat	B-ENZY
Coronavirus	O
Lineages	O
from	O
Kazakhstan	O
.	O

In	O
this	O
study	O
,	O
bat	B-ENZY
guano	O
was	O
collected	O
from	O
bat	B-ENZY
caves	O
in	O
three	O
different	O
sites	O
of	O
southern	O
Kazakhstan	O
that	O
tested	O
positive	O
for	O
coronaviruses	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
VIP	O
inhibited	O
the	O
expression	O
of	O
IL	O
-	O
17R	O
in	O
the	O
lungs	O
of	O
mice	O
with	O
ARDS	O
and	O
NIH3T3	O
cells	O
stimulated	O
with	O
LPS	O
,	O
which	O
was	O
partly	O
inhibited	O
by	O
antagonists	O
of	O
protein	B-ENZY
kinase	I-ENZY
A	I-ENZY
and	O
protein	B-ENZY
kinase	I-ENZY
C	I-ENZY
.	O
Taken	O
together	O
,	O
our	O
results	O
demonstrated	O
that	O
VIP	O
inhibited	O
the	O
activation	O
of	O
fibroblast	O
via	O
downregulation	O
of	O
IL	O
-	O
17RC	O
,	O
which	O
may	O
contribute	O
to	O
the	O
protective	O
effects	O
of	O
VIP	O
against	O
ARDS	O
in	O
mice	O
.	O

In	O
addition	O
,	O
we	O
also	O
found	O
that	O
p38	O
MAPK	B-ENZY
and	O
SAPK	B-ENZY
/	O
JNK	B-ENZY
were	O
activated	O
in	O
PEDV	O
-	O
infected	O
Vero	O
cells	O
.	O

The	O
expression	O
levels	O
of	O
citrate	B-ENZY
synthase	I-ENZY
(	O
CS	O
),	O
cytochrome	O
C	O
,	O
somatic	O
(	O
CYC	O
,	O
S	O
)	O
and	O
sodium	O
-	O
potassium	O
adenosine	O
triphosphatase	B-ENZY
(	O
Na	O
It	O
was	O
concluded	O
that	O
IBV	O
T	O
strain	O
infection	O
in	O
laying	O
hens	O
reduced	O
mitochondrial	O
counts	O
only	O
in	O
the	O
shell	O
gland	O
region	O
of	O
the	O
oviduct	O
.	O

Although	O
we	O
perhaps	O
most	O
frequently	O
think	O
of	O
viruses	O
when	O
discussing	O
emerging	O
respiratory	O
infections	O
,	O
bacteria	O
have	O
not	O
been	O
left	O
out	O
of	O
the	O
mix	O
,	O
as	O
we	O
have	O
witnessed	O
an	O
increase	O
in	O
the	O
number	O
of	O
infections	O
from	O
Legionella	O
spp	B-ENZY
.	O

We	O
present	O
the	O
case	O
of	O
a	O
patient	O
who	O
presented	O
with	O
symptoms	O
consistent	O
with	O
viral	O
myocarditis	O
but	O
ultimately	O
was	O
found	O
to	O
have	O
severe	O
coronary	O
artery	O
disease	O
(	O
CAD	B-ENZY
).	O

We	O
highlight	O
this	O
case	O
to	O
discuss	O
the	O
importance	O
of	O
maintaining	O
a	O
broad	O
differential	O
and	O
pursuing	O
complete	O
work	O
-	O
up	O
when	O
treating	O
younger	O
patients	O
with	O
chest	O
pain	O
and	O
elevated	O
serum	O
troponin	O
who	O
lack	O
typical	O
risk	O
factors	O
for	O
CAD	B-ENZY
.	O

In	O
patients	O
with	O
ARDS	O
,	O
venovenous	O
(	O
VV	O
)	O
ECLS	O
is	O
commonly	O
used	O
,	O
where	O
venous	O
blood	O
is	O
drained	O
into	O
a	O
circuit	O
that	O
passes	O
through	O
a	O
membrane	O
lung	O
,	O
which	O
provides	O
gas	B-ENZY
exchange	O
,	O
and	O
then	O
returned	O
to	O
the	O
venous	O
system	O
.	O

In	O
conclusion	O
,	O
we	O
firstly	O
carried	O
out	O
whole	O
genome	O
characterization	O
of	O
the	O
SARS	O
-	O
like	O
bat	B-ENZY
coronavirus	O
discovered	O
in	O
the	O
Republic	O
of	O
Korea	O
;	O
however	O
,	O
it	O
presumably	O
has	O
no	O
human	O
infectivity	O
.	O

In	O
this	O
study	O
,	O
a	O
total	O
of	O
190	O
faecal	O
samples	O
from	O
dairy	O
calves	O
with	O
diarrhoea	O
were	O
collected	O
from	O
14	O
farms	O
in	O
six	O
Chinese	O
provinces	O
,	O
and	O
BCoV	O
was	O
detected	O
in	O
18	O
.	O
95	O
%	O
(	O
36	O
/	O
190	O
)	O
of	O
the	O
samples	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
.	O

Viral	O
RNA	O
was	O
extracted	O
from	O
pooled	O
tissue	O
samples	O
(	O
trachea	O
,	O
lungs	O
,	O
spleen	O
,	O
and	O
liver	O
)	O
and	O
tested	O
for	O
Avian	O
influenza	O
virus	O
(	O
AIV	O
),	O
Newcastle	O
disease	O
virus	O
(	O
NDV	O
),	O
and	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

TITLE	O
:	O
Synthesis	O
and	O
biological	O
evaluation	O
of	O
dihydroquinazoline	O
-	O
2	O
-	O
amines	O
as	O
potent	O
non	O
-	O
nucleoside	O
reverse	B-ENZY
transcriptase	I-ENZY
inhibitors	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
HIV	O
-	O
1	O
strains	O
.	O

Binary	O
Logistic	O
regression	O
analysis	O
showed	O
that	O
neutral	O
red	O
phagocytosis	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
0	O
.	O
596	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
95	O
%	O
CI	O
)	O
=	O
0	O
.	O
212	O
-	O
0	O
.	O
997	O
]	O
and	O
alkaline	B-ENZY
phosphatase	I-ENZY
activity	O
(	O
OR	O
=	O
0	O
.	O
573	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
339	O
-	O
0	O
.	O
968	O
)	O
were	O
the	O
influencing	O
factors	O
of	O
prognosis	O
(	O
both	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
AUC	O
of	O
alkaline	B-ENZY
phosphatase	I-ENZY
for	O
the	O
prognosis	O
of	O
ARDS	O
patients	O
caused	O
by	O
abdominal	O
infection	O
was	O
0	O
.	O
813	O
;	O
when	O
the	O
cut	O
-	O
off	O
value	O
was	O
19	O
.	O
72	O
mol	O
/	O
L	O
,	O
the	O
sensitivity	O
was	O
75	O
.	O
0	O
%,	O
and	O
the	O
specificity	O
was	O
87	O
.	O
5	O
%.	O

S	O
RBD	O
-	O
HBD	O
2	O
treatment	O
also	O
enhanced	O
phosphorylation	O
and	O
activation	O
of	O
receptor	O
-	O
interacting	O
serine	O
/	O
threonine	O
-	O
protein	B-ENZY
kinase	I-ENZY
2	O
and	O
IFN	O
regulatory	O
factor	O
3	O
compared	O
to	O
S	O
RBD	O
alone	O
.	O

We	O
tested	O
16	O
different	O
respiratory	O
virus	O
infections	O
in	O
post	O
-	O
surgery	O
mild	O
symptomatic	O
PSP	O
group	O
and	O
asymptomatic	O
PSP	O
group	O
using	O
a	O
quantitative	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
)	O
assay	O
panel	O
.	O

A	O
control	O
group	O
without	O
injury	O
received	O
volume	O
controlled	O
MV	O
(	O
CTRL	O
,	O
n	O
=	O
6	O
),	O
The	O
multiple	O
inert	O
gas	B-ENZY
elimination	O
technique	O
and	O
CT	O
were	O
performed	O
at	O
baseline	O
(	O
BL	O
),	O
0	O
.	O
5	O
hours	O
,	O
1	O
hours	O
,	O
2	O
hours	O
,	O
24	O
hours	O
,	O
and	O
48	O
hours	O
after	O
injury	O
.	O

Fraxin	O
might	O
increase	O
the	O
superoxide	B-ENZY
dismutase	I-ENZY
(	O
SOD	O
)	O
activity	O
to	O
avoid	O
oxidative	O
damage	O
.	O

The	O
inability	O
of	O
the	O
lung	O
to	O
perform	O
its	O
primary	O
function	O
of	O
gas	B-ENZY
exchange	O
can	O
result	O
from	O
multiple	O
mechanisms	O
,	O
including	O
obstruction	O
of	O
the	O
airways	O
,	O
loss	O
of	O
alveolar	O
structure	O
,	O
loss	O
of	O
lung	O
epithelial	O
integrity	O
from	O
direct	O
epithelial	O
cell	O
killing	O
,	O
and	O
degradation	O
of	O
the	O
critical	O
extracellular	O
matrix	O
.	O

It	O
is	O
unknown	O
whether	O
positive	O
airway	O
pressure	O
treatment	O
may	O
influence	O
adverse	O
events	O
and	O
consequences	O
of	O
ACS	B-ENZY
.	O

In	O
vivo	O
,	O
miR	O
-	O
150	O
decreased	O
total	O
cell	O
and	O
neutrophil	O
counts	O
,	O
and	O
production	O
of	O
inflammatory	O
cytokines	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
),	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
and	O
tumor	O
necrosis	O
factor	O
-	O
	O
(	O
TNF	O
-	O
	O
)	O
as	O
well	O
as	O
levels	O
of	O
total	O
protein	O
,	O
albumin	O
and	O
IgM	O
in	O
the	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
fluid	O
in	O
LPS	O
-	O
induced	O
ALI	O
mice	O
.	O

Data	O
on	O
patients	O
'	O
general	O
and	O
clinical	O
conditions	O
,	O
radiographic	O
findings	O
,	O
ventilator	O
settings	O
,	O
gas	B-ENZY
exchange	O
,	O
and	O
treatment	O
methods	O
were	O
collected	O
and	O
compared	O
between	O
survivors	O
and	O
non	O
-	O
survivors	O
.	O

In	O
addition	O
,	O
ORF8b	O
also	O
strongly	O
inhibits	O
Tank	B-ENZY
-	I-ENZY
binding	I-ENZY
kinase	I-ENZY
1	I-ENZY
(	O
TBK1	B-ENZY
)-	O
mediated	O
induction	O
of	O
NF	O
-	O
B	O
signaling	O
.	O

Serum	O
lactate	O
,	O
aspartate	B-ENZY
transaminase	I-ENZY
(	O
AST	B-ENZY
)	O
and	O
alanine	B-ENZY
transaminase	I-ENZY
(	O
ALT	O
)	O
were	O
significantly	O
elevated	O
among	O
non	O
survivors	O
.	O

Our	O
results	O
provide	O
a	O
basis	O
for	O
the	O
identification	O
of	O
dual	O
HIV	O
-	O
1	O
IN	O
and	O
RT	O
RNase	B-ENZY
H	I-ENZY
inhibitors	O
compounds	O
.	O

We	O
identified	O
11	O
CoV	O
strains	O
from	O
22	O
individual	O
samples	O
of	O
four	O
bat	B-ENZY
species	O
.	O

The	O
structures	O
of	O
Ptal	B-ENZY
-	O
N	O
*	O
01	O
:	O
01	O
display	O
unusual	O
peptide	O
presentation	O
features	O
in	O
that	O
the	O
bat	B-ENZY
-	O
specific	O
3	O
-	O
amino	O
acid	O
(	O
aa	O
)	O
insertion	O
enables	O
the	O
tight	O
""""	O
surface	O
anchoring	O
""""	O
of	O
the	O
P1	O
-	O
Asp	O
in	O
pocket	O
A	O
of	O
bat	B-ENZY
MHC	O
I	O
.	O
As	O
the	O
classical	O
primary	O
anchoring	O
positions	O
,	O
the	O
B	O
and	O
F	O
pockets	O
of	O
Ptal	B-ENZY
-	O
N	O
*	O
01	O
:	O
01	O
also	O
show	O
unconventional	O
conformations	O
,	O
which	O
contribute	O
to	O
unusual	O
peptide	O
motifs	O
and	O
distinct	O
peptide	O
presentation	O
.	O

Our	O
study	O
sheds	O
light	O
on	O
bat	B-ENZY
adaptive	O
immunity	O
and	O
may	O
benefit	O
future	O
vaccine	O
development	O
against	O
bat	B-ENZY
-	O
borne	O
viruses	O
of	O
high	O
impact	O
on	O
humans	O
.	O

Although	O
RNase	B-ENZY
H	I-ENZY
inhibitors	O
have	O
not	O
been	O
developed	O
into	O
licensed	O
drugs	O
,	O
recent	O
progress	O
has	O
led	O
to	O
the	O
identification	O
of	O
a	O
number	O
of	O
small	O
molecules	O
with	O
inhibitory	O
activity	O
at	O
low	O
micromolar	O
or	O
even	O
nanomolar	O
concentrations	O
.	O

We	O
also	O
found	O
that	O
the	O
induction	O
of	O
GILT	O
expression	O
reduced	O
the	O
level	O
and	O
activity	O
of	O
cathepsin	B-ENZY
L	I-ENZY
,	O
which	O
is	O
required	O
for	O
the	O
entry	O
of	O
these	O
RNA	O
viruses	O
in	O
lysosomes	O
.	O

In	O
addition	O
,	O
amoxicillin	O
is	O
commonly	O
used	O
in	O
combination	O
with	O
the	O
beta	B-ENZY
-	I-ENZY
lactamase	I-ENZY
inhibitor	O
clavulanic	O
acid	O
.	O

Pets	O
,	O
livestock	O
and	O
humans	O
can	O
be	O
carriers	O
of	O
Cryptosporidium	O
spp	B-ENZY
.	O

Here	O
,	O
at	O
the	O
molecular	O
level	O
,	O
we	O
found	O
that	O
all	O
purified	O
bat	B-ENZY
CD26s	O
(	O
bCD26s	O
)	O
from	O
a	O
diverse	O
range	O
of	O
species	O
interact	O
with	O
the	O
receptor	O
binding	O
domain	O
(	O
RBD	O
)	O
of	O
MERS	O
-	O
CoV	O
,	O
with	O
equilibrium	O
dissociation	O
constant	O
values	O
ranging	O
from	O
several	O
to	O
hundreds	O
at	O
the	O
micromolar	O
level	O
.	O

Compared	O
with	O
controls	O
,	O
the	O
experimental	O
group	O
had	O
a	O
significantly	O
higher	O
proportion	O
of	O
antibiotics	O
discontinuation	O
or	O
de	O
-	O
escalation	O
in	O
the	O
ED	O
(	O
26	O
.	O
0	O
%	O
vs	O
16	O
.	O
1	O
%,	O
P	O
=	O
.	O
007	O
),	O
neuraminidase	B-ENZY
inhibitor	O
uses	O
(	O
8	O
.	O
9	O
%	O
vs	O
0	O
.	O
6	O
%,	O
P	O
<	O
.	O
001	O
),	O
and	O
shorter	O
duration	O
of	O
intravenous	O
antibiotics	O
(	O
10	O
.	O
0	O
vs	O
14	O
.	O
5	O
days	O
,	O
P	O
<	O
.	O
001	O
).	O

These	O
results	O
suggested	O
that	O
additional	O
barriers	O
limit	O
the	O
emergence	O
of	O
zoonotic	O
CoV	O
.	O
In	O
this	O
work	O
,	O
we	O
describe	O
overcoming	O
host	O
restriction	O
of	O
two	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)-	O
like	O
bat	B-ENZY
CoVs	O
using	O
exogenous	O
protease	O
treatment	O
.	O

Finally	O
,	O
we	O
found	O
that	O
the	O
addition	O
of	O
exogenous	O
trypsin	B-ENZY
also	O
rescues	O
HKU5	O
-	O
CoV	O
,	O
a	O
second	O
bat	B-ENZY
group	O
2c	O
CoV	O
.	O
Together	O
,	O
these	O
results	O
indicate	O
that	O
proteolytic	O
cleavage	O
of	O
the	O
spike	O
,	O
not	O
receptor	O
binding	O
,	O
is	O
the	O
primary	O
infection	O
barrier	O
for	O
these	O
two	O
group	O
2c	O
CoVs	O
.	O

TITLE	O
:	O
Discovery	O
of	O
dihydroxyindole	O
-	O
2	O
-	O
carboxylic	O
acid	O
derivatives	O
as	O
dual	O
allosteric	O
HIV	O
-	O
1	O
Integrase	O
and	O
Reverse	B-ENZY
Transcriptase	I-ENZY
associated	O
Ribonuclease	B-ENZY
H	I-ENZY
inhibitors	O
.	O

Using	O
a	O
dual	O
-	O
luciferase	B-ENZY
reporter	O
assay	O
,	O
miR	O
-	O
142a	O
-	O
3p	O
was	O
found	O
to	O
bind	O
directly	O
bound	O
to	O
the	O
3	O
'	O
untranslated	O
region	O
(	O
3	O
'	O
UTR	O
)	O
of	O
Rab3a	O
mRNA	O
and	O
downregulate	O
its	O
expression	O
.	O

The	O
interaction	O
between	O
MALAT1	O
and	O
miR	O
-	O
425	O
was	O
predicted	O
using	O
a	O
bioinformatics	O
tool	O
and	O
verified	O
by	O
dual	O
luciferase	B-ENZY
assay	O
.	O

SADS	O
-	O
CoV	O
also	O
blocked	O
poly	O
(	O
I	O
:	O
C	O
)-	O
induced	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
IRF	O
-	O
3	O
and	O
NF	O
-	O
B	O
.	O
Furthermore	O
,	O
SADS	O
-	O
CoV	O
did	O
not	O
interfere	O
with	O
the	O
activity	O
of	O
IFN	O
-	O
	O
promoter	O
stimulated	O
by	O
IRF3	O
,	O
TBK1	B-ENZY
and	O
IKK	O
,	O
but	O
counteracted	O
its	O
activation	O
induced	O
by	O
IPS	O
-	O
1	O
and	O
RIG	O
-	O
I	O
.	O
Collectively	O
,	O
this	O
study	O
is	O
the	O
first	O
investigation	O
that	O
shows	O
interactions	O
between	O
SADS	O
-	O
CoV	O
and	O
the	O
host	O
innate	O
immunity	O
,	O
which	O
provides	O
information	O
of	O
the	O
molecular	O
mechanisms	O
underlying	O
SASD	O
-	O
CoV	O
infection	O
.	O

Disease	O
severity	O
was	O
evaluated	O
as	O
mild	O
,	O
moderate	O
and	O
severe	O
disease	O
based	O
on	O
lowest	O
PaO	B-ENZY

When	O
transmitted	O
to	O
humans	O
,	O
they	O
cause	O
hemorrhagic	O
fever	O
with	O
renal	O
syndrome	O
(	O
HFRS	O
)	O
in	O
Asia	O
and	O
Europe	O
and	O
hantavirus	O
(	O
cardio	O
)	O
pulmonary	O
syndrome	O
(	O
HPS	B-ENZY
)	O
in	O
the	O
Americas	O
.	O

We	O
discovered	O
nine	O
full	O
genomes	O
of	O
bat	B-ENZY
CoVs	O
in	O
this	O
study	O
and	O
revealed	O
great	O
genetic	O
diversity	O
for	O
eight	O
of	O
them	O
.	O

Lopinavir	O
/	O
Ritonavir	O
,	O
Nucleoside	O
analogues	O
,	O
Neuraminidase	B-ENZY
inhibitors	O
,	O
Remdesivir	O
,	O
peptide	O
(	O
EK1	O
),	O
abidol	O
,	O
RNA	O
synthesis	O
inhibitors	O
(	O
such	O
as	O
TDF	O
,	O
3TC	O
),	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
such	O
as	O
hormones	O
and	O
other	O
molecules	O
),	O
Chinese	O
traditional	O
medicine	O
,	O
such	O
ShuFengJieDu	O
Capsules	O
and	O
Lianhuaqingwen	O
Capsule	O
,	O
could	O
be	O
the	O
drug	O
treatment	O
options	O
for	O
2019	O
-	O
nCoV	O
.	O
However	O
,	O
the	O
efficacy	O
and	O
safety	O
of	O
these	O
drugs	O
for	O
2019	O
-	O
nCoV	O
still	O
need	O
to	O
be	O
further	O
confirmed	O
by	O
clinical	O
experiments	O
.	O

Here	O
,	O
we	O
report	O
a	O
novel	O
bat	B-ENZY
-	O
origin	O
CoV	O
causing	O
severe	O
and	O
fatal	O
pneumonia	O
in	O
humans	O
.	O

The	O
virus	O
is	O
phylogenetically	O
closest	O
to	O
a	O
bat	B-ENZY
SARS	O
-	O
like	O
CoV	O
(	O
SL	O
-	O
ZC45	O
,	O
GenBank	O
MG772933	O
)	O
with	O
87	O
.	O
6	O
%	O
to	O
87	O
.	O
7	O
%	O
nucleotide	O
identity	O
,	O
but	O
is	O
in	O
a	O
separate	O
clade	O
.	O

Moreover	O
,	O
these	O
viruses	O
have	O
a	O
single	O
intact	O
open	O
reading	O
frame	O
gene	O
8	O
,	O
as	O
a	O
further	O
indicator	O
of	O
bat	B-ENZY
-	O
origin	O
CoVs	O
.	O

The	O
primary	O
endpoint	O
was	O
the	O
prognostic	O
capacity	O
of	O
the	O
PP	O
-	O
induced	O
changes	O
in	O
PaO	B-ENZY
Ninety	O
patients	O
were	O
included	O
;	O
28	O
-	O
day	O
mortality	O
was	O
46	O
%.	O

Exosomes	O
containing	O
self	O
-	O
antigens	O
,	O
20S	O
proteasome	B-ENZY
,	O
and	O
viral	O
antigens	O
were	O
detected	O
at	O
significantly	O
higher	O
levels	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
serum	O
of	O
recipients	O
with	O
symptomatic	O
respiratory	O
viral	O
infections	O
(	O
n	O
=	O
35	O
)	O
as	O
compared	O
with	O
stable	O
controls	O
(	O
n	O
=	O
32	O
).	O

Chinese	O
bat	B-ENZY
species	O
with	O
commercial	O
value	O
were	O
identified	O
as	O
natural	O
reservoirs	O
of	O
coronaviruses	O
and	O
are	O
used	O
in	O
Traditional	O
Chinese	O
Medicine	O
.	O

Most	O
importantly	O
,	O
our	O
study	O
illustrates	O
two	O
distinct	O
spreading	O
patterns	O
from	O
infected	O
cells	O
to	O
uninfected	O
cells	O
during	O
PDCoV	O
transmission	O
,	O
and	O
the	O
role	O
of	O
trypsin	B-ENZY
in	O
PDCoV	O
replication	O
in	O
cells	O
with	O
different	O
virus	O
spreading	O
types	O
.	O

Vehicle	O
,	O
nafithromycin	O
(	O
100	O
mg	O
/	O
kg	O
),	O
azithromycin	O
(	O
600	O
mg	O
/	O
kg	O
)	O
and	O
dexamethasone	O
(	O
20	O
mg	O
/	O
kg	O
)	O
were	O
administered	O
orally	O
,	O
1	O
h	O
prior	O
to	O
LPS	O
challenge	O
and	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
fluid	O
was	O
collected	O
thereafter	O
at	O
18	O
,	O
24	O
and	O
48	O
h	O
to	O
determine	O
the	O
total	O
cell	O
count	O
,	O
total	O
protein	O
,	O
myeloperoxidase	B-ENZY
(	O
MPO	O
),	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)-	O
	O
and	O
interleukin	O
(	O
IL	O
)-	O
6	O
.	O

Only	O
patients	O
who	O
met	O
all	O
of	O
the	O
following	O
criteria	O
were	O
included	O
in	O
this	O
analysis	O
:	O
sustained	O
blunt	O
injuries	O
,	O
presented	O
with	O
severe	O
traumatic	O
brain	O
injury	O
,	O
sustained	O
an	O
associated	O
SDH	B-ENZY
,	O
presented	O
with	O
an	O
initial	O
Glasgow	O
Coma	O
Scale	O
(	O
GCS	O
)	O
score	O
	O
8	O
and	O
an	O
Abbreviated	O
Injury	O
Scale	O
score	O
of	O
head	O
	O
3	O
,	O
and	O
underwent	O
a	O
CO	O
or	O
DC	O
within	O
4	O
hours	O
of	O
hospital	O
arrival	O
.	O

Some	O
differences	O
were	O
found	O
between	O
the	O
CO	O
and	O
DC	O
groups	O
regarding	O
age	O
(	O
mean	O
[	O
standard	O
deviation	O
(	O
SD	O
)]:	O
47	O
.	O
9	O
years	O
[	O
22	O
.	O
8	O
]	O
versus	O
39	O
.	O
6	O
years	O
[	O
20	O
.	O
1	O
];	O
Although	O
most	O
of	O
the	O
patients	O
underwent	O
CO	O
for	O
acute	O
SDH	B-ENZY
,	O
no	O
significant	O
differences	O
were	O
observed	O
in	O
the	O
incidence	O
of	O
ARDS	O
,	O
pneumonia	O
,	O
PE	O
,	O
or	O
systemic	O
sepsis	O
when	O
compared	O
with	O
patients	O
who	O
underwent	O
DC	O
.	O

The	O
natural	O
host	O
of	O
2019	O
-	O
nCoV	O
may	O
be	O
the	O
bat	B-ENZY
Rhinolophus	O
affinis	O
as	O
2019	O
-	O
nCoV	O
showed	O
96	O
.	O
2	O
%	O
of	O
whole	O
-	O
genome	O
identity	O
to	O
BatCoV	O
RaTG13	O
.	O

We	O
found	O
that	O
the	O
virus	O
replicates	O
to	O
high	O
titer	O
in	O
Vero	O
-	O
CCL81	O
cells	O
and	O
Vero	O
E6	O
cells	O
in	O
the	O
absence	O
of	O
trypsin	B-ENZY
.	O

Thrombin	B-ENZY
time	O
in	O
critical	O
SARS	O
-	O
CoV	O
-	O
2	O
patients	O
was	O
also	O
shorter	O
than	O
that	O
in	O
controls	O
.	O

ABSTRACT	O
:	O
Coronaviruses	O
express	O
a	O
multifunctional	O
papain	B-ENZY
-	O
like	O
protease	O
,	O
termed	O
PLP2	O
.	O

TITLE	O
:	O
""""	O
Awake	O
""""	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
combined	O
with	O
continuous	O
renal	O
replacement	O
therapy	O
(	O
CRRT	O
)	O
for	O
the	O
treatment	O
of	O
severe	O
chemical	O
gas	B-ENZY
inhalation	O
lung	O
injury	O
.	O

Herein	O
,	O
we	O
describe	O
the	O
case	O
of	O
a	O
patient	O
with	O
severe	O
chemical	O
gas	B-ENZY
inhalation	O
lung	O
injury	O
who	O
failed	O
to	O
respond	O
to	O
traditional	O
mechanical	O
ventilation	O
and	O
was	O
subsequently	O
treated	O
with	O
awake	O
ECMO	O
combined	O
with	O
CRRT	O
.	O

Higher	O
rate	O
of	O
fever	O
,	O
cough	O
,	O
expectoration	O
,	O
and	O
headache	O
,	O
lower	O
lymphocytes	O
,	O
albumin	O
,	O
serum	O
sodium	O
levels	O
and	O
higher	O
total	O
bilirubin	O
,	O
creatine	B-ENZY
kinase	I-ENZY
,	O
lactate	O
dehydrogenase	O
and	O
C	O
-	O
reactive	O
protein	O
levels	O
and	O
lower	O
oxygenation	O
index	O
were	O
observed	O
in	O
pneumonia	O
patients	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

ACE	B-ENZY
(	O
angiotensin	O
-	O
converting	O
enzyme	O
)	O
inhibitors	O
do	O
not	O
inhibit	O
ACE2	O
because	O
ACE	B-ENZY
and	O
ACE2	O
are	O
different	O
enzymes	O
.	O

